Anti-TCR antibody molecules and uses thereof

Abstract

The disclosure provides antibody molecules that bind to TCR Vβ regions and multispecific molecules comprising said antibody molecules. Additionally, disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, pharmaceutical compositions comprising aforesaid molecules, and methods of treating a cancer using the aforesaid molecules.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Application 62 / 693,653 filed on July 3, 2018, U.S. Provisional Application 62 / 737,829 filed on September 27, 2018, U.S. Provisional Application 62 / 788,674 filed on January 4, 2019, and U.S. Provisional Application 62 / 808,700 filed on February 21, 2019, the entire contents of each of which are hereby incorporated by reference. BACKGROUND Current molecules designed to redirect T cells to promote tumor cell lysis for cancer immunotherapy typically target the CD3 epsilon (CD3e) subunit of the T cell receptor (TCR). However, there are limitations to this approach. Previous studies have shown that, e.g., low doses of anti-CD3e monoclonal antibody (mAb) can cause T cell dysfunction and exert immunosuppressive effects. In addition, anti-CD3e mAbs bind to all T cells and thus activate a large number of T cells. Such non-physiological massive activation of T cells by these anti-CD3e mAbs can result in the production of proinflammatory cytokines such as IFN-gamma, IL-1-beta, IL-6, IL-10 and TNF-alpha, causing a “cytokine storm” known as the cytokine release syndrome (CRS), which is also associated with neurotoxicity (NT). Thus, it might be advantageous to develop antibodies that avoid or reduce CRS and / or NT. Any discussion of the prior art throughout the specification should not be considered as an express or implied admission that such prior art is widely known or forms part of the common general knowledge in the field. It is an object of the present invention to overcome or ameliorate one or more of the disadvantages of the prior art, or at least to provide a useful alternative. SUMMARY OF THE INVENTION 1.     The present disclosure provides a composition comprising a multispecific molecule comprising: (i) a first domain comprising an antibody molecule or antigen binding domain that binds to a T cell receptor beta variable (TCRpV) region of a T cell receptor beta (TCRP) on a T cell in a T cell population, 2019297451   16 Sep 2026 wherein the antibody molecule or antigen binding domain is a TCR agonist that binds to an outward facing region of the TCRpV region that is structurally conserved and sequence-wise variable; and wherein the first domain binds to human TCRPV5, human TCRPV6, human TCRPV12, or human TCRpV20; and (ii) a second domain that binds to a second target molecule, wherein the second domain comprises a cytokine, wherein: (a) the cytokine is a human IL-2 having a sequence with at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 2191, 2270, and 2280; (b) the cytokine is a human IL-12 having a sequence with at least 90% sequence identity to SEQ ID NO: 2290; (c) the cytokine is a human IL-15 having a sequence with at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 2170 and 2320; or (d) the cytokine is a human IL-21 having a sequence with at least 90% sequence identity to SEQ ID NO: 2193; and wherein the second target molecule is expressed by the same T cell expressing the TCRP comprising the TCRPV to which the first domain of the multispecific molecule binds, wherein when contacted to the T cell population, the multispecific molecule activates and / or expands the T cell. The present disclosure provides a recombinant polynucleotide comprising a sequence encoding the multispecific molecule of the composition as described herein. The present disclosure provides a method of making the multispecific molecule of the composition as described herein: culturing the host cell comprising the recombinant polynucleotide or a vector comprising the recombinant polynucleotide as described herein under conditions suitable for gene expression and / or homo- or heterodimerization. 2019297451   16 Sep 2026 The present disclosure provides a pharmaceutical composition comprising the composition as described herein, and a pharmaceutically acceptable carrier, excipient, or diluent. The present disclosure provides a method of treating cancer in a subject in need thereof comprising: administering a therapeutically effective amount of the composition or the pharmaceutical composition as described herein to the subject, thereby treating the cancer in the subject, wherein the subject is human. The present disclosure provides a method of treating a solid cancer in a human subject in need thereof comprising: administering a therapeutically effective amount of the composition or the pharmaceutical composition as described herein to the human subject, thereby treating the solid cancer in the human subject, wherein the first domain binds to human TCRPV5, human TCRPV6, human TCRPV12, or human TCRPV20; wherein the second domain comprises a cytokine that binds to a second target molecule expressed by T cells of the human subject; wherein: (i)(a) the cytokine is a human IL-2 having a sequence with at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 2191, 2270, and 2280, or (b) the cytokine is a human IL-2 having a sequence with at least 95% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 2191, 2270, and 2280; (ii)(a) the cytokine is a human IL-12 having a sequence with at least 90% sequence identity to SEQ ID NO: 2290, or (b) the cytokine is a human IL-12 having a sequence with at least 95% sequence identity to SEQ ID NO: 2290; (iii)(A)(a) the cytokine is a human IL-15 having a sequence with at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 2170 and 2320, or (b) the cytokine is a human IL-15 having a sequence with at least 95% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 2170 and 2320; or 2019297451   16 Sep 2026 (B)(a) the cytokine is a human IL-15 having a sequence with at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 2170 and 2320, and the cytokine further comprises an IL15Ralpha dimerizing domain, or (b) the cytokine is a human IL-15 having a sequence with at least 95% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 2170 and 2320, and the cytokine further comprises an IL15Ralpha dimerizing domain; or (iv)(a) the cytokine is a human IL-21 having a sequence with at least 90% sequence identity to SEQ ID NO: 2193, or (b) the cytokine is a human IL-21 having a sequence with at least 95% sequence identity to SEQ ID NO: 2193; wherein binding of the first domain to the TCRPV region and binding of the second domain to the second target molecule promote the subset of T cells to kill cancer cells. The present disclosure provides a method of expanding and / or activating T cells in a T cell population comprising: contacting the T cell population with an effective amount of the composition as described herein, thereby expanding and / or activating the T cells in the T cell population, wherein the T cells express a T cell receptor (TCR) comprising the T cell receptor beta (TCRP); wherein the expansion is selective expansion of a subset of T cells that express a TCR comprising a TCRP that comprises a TCRPV region subfamily member to which the first domain binds in the T cell population; and wherein the T cell expansion and / or activation occurs in vivo or ex vivo. The present disclosure provides use of the composition or the pharmaceutical composition as described herein in the manufacture of a medicament for treating a solid cancer in a human subject in need thereof, wherein the first domain binds to a human T cell receptor beta chain variable (TCRPV) region of a human TCRP of a human TCRP subfamily member expressed by a subset of T cells of the human subject; 2019297451   16 Sep 2026 wherein the first domain binds to human TCRPV5, human TCRPV6, human TCRPV12, or human TCRPV20; wherein the second domain comprises a cytokine that binds to a second target molecule expressed by T cells of the human subject; wherein: (i)(a)  the cytokine is a human IL-2 having a sequence with at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 2191, 2270, and 2280, or (b) the cytokine is a human IL-2 having a sequence with at least 95% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 2191, 2270, and 2280; (ii)(a) the cytokine is a human IL-12 having a sequence with at least 90% sequence identity to SEQ ID NO: 2290, or (b) the cytokine is a human IL-12 having a sequence with at least 95% sequence identity to SEQ ID NO: 2290; (iii)(A)(a) the cytokine is a human IL-15 having a sequence with at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 2170 and 2320, or (b) the cytokine is a human IL-15 having a sequence with at least 95% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 2170 and 2320; or (B)(a) the cytokine is a human IL-15 having a sequence with at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 2170 and 2320, and the cytokine further comprises an IL15Ralpha dimerizing domain, or (b) the cytokine is a human IL-15 having a sequence with at least 95% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 2170 and 2320, and the cytokine further comprises an IL15Ralpha dimerizing domain; or (iv)(a) the cytokine is a human IL-21 having a sequence with at least 90% sequence identity to SEQ ID NO: 2193, or (b) the cytokine is a human IL-21 having a sequence with at least 95% sequence identity to SEQ ID NO: 2193; 2019297451   16 Sep 2026 wherein binding of the first domain to the TCRPV region and binding of the second domain to the second target molecule promote the subset of T cells to kill cancer cells. Disclosed herein are, inter alia, antibody molecules directed to the variable chain of the beta subunit of TCR (TCRPV) which bind and, e.g., activate or expand, T cells, e.g., a subset of T cells (“anti-TCRpV antibody molecules”). In some embodiments, the anti-TCRPV antibody molecules disclosed herein result in a cytokine profile, e.g., a cytokine secretion profile, that differs from that of a T cell engager that binds to a receptor or molecule other than a TCRPV region (“a non-TCRPV-binding T cell engager”). In some embodiments, the anti-TCRPV antibody molecules disclosed herein result in lesser, minimal, or no production of cytokines associated with cytokine release syndrome (CRS), e.g., IL-6, IL-1beta, IL-10 and TNF alpha; and enhanced and / or delayed production of IL-2 and IFN-gamma. In some embodiments, the [Text continues on Page 2] anti-TCRpV antibodies disclosed herein result in expansion of an immune cell, e.g., a T cell, a tumor infiltrating lymphocyte (TIL), an NK cell, or other immune cells (e.g., as described herein). Also provided herein are methods of making said anti-TCRpV antibody molecules, and methods of using said anti-TCRpV antibody molecules including, methods of using an anti-TCRpV antibody molecule for expanding an immune cell or an immune cell population, and method of using an anti-TCRpV antibody molecule for treating cancer, including the use as combination therapy with TIL and immune checkpoint therapeutics. This disclosure further provides multispecific molecules, e.g., bispecific molecules, comprising said anti-TCRpV antibody molecules. In some embodiments, compositions comprising anti-TCRpV antibody molecules of the present disclosure, can be used, e.g., to activate and / or redirect T cells to promote tumor cell lysis for cancer immunotherapy. In some embodiments, compositions comprising anti-TCRpV antibody molecules as disclosed herein limit the unwanted side-effects of CRS and / or NT, e.g., CRS and / or NT associated with anti-CD3e targeting. In some embodiments, the anti-TCRpV antibody molecules disclosed herein result in lesser, minimal, or no production of cytokines associated with cytokine release syndrome (CRS), e.g., IL-6, IL-lbeta, IL-10 and TNF alpha; and enhanced and / or delayed production of IL-2 and IFN-gamma, compared with an anti-CD3 antibody molecule (e.g., a low affinity anti-CD3 antibody molecule). In some embodiments, administration of the anti-TCRpV antibody molecules disclosed herein in a subject results in reduced cytokine release syndrome (CRS) (e.g., lesser duration of CRS or no CRS), a reduced severity of CRS (e.g., absence of severe CRS, e.g., CRS grade 4 or 5), reduced neurotoxicity (NT), or a reduced severity of NT, compared with similar administration of an anti-CD3 antibody molecule (e.g., a low affinity anti-CD3 antibody molecule). Accordingly, provided herein are, anti-TCRpV antibody molecules, multispecific or multifunctional molecules (e.g., multispecific or multifunctional antibody molecules) (also referred to herein as a “composition”) that comprise anti-TCRpV antibody molecules, nucleic acids encoding the same, methods of producing the aforesaid molecules, pharmaceutical compositions comprising aforesaid molecules, and methods of treating a disease or disorder, e.g., cancer, using the aforesaid molecules. The antibody molecules and pharmaceutical compositions disclosed herein can be used (alone or in combination with other agents or therapeutic modalities) to treat, prevent and / or diagnose disorders and conditions, e.g., cancer, e.g., as described herein. In one aspect, the disclosure provides an antibody molecule, e.g., a non-murine, e.g., a human-like (e.g., a human, or humanized antibody molecule), which binds, e.g., specifically binds, to a T cell receptor beta variable (TCRpV) region. In some embodiments, the anti-TCRBV antibody molecule comprises an antigen binding domain of an antibody disclosed in any of Tables 1-2, or 10-12, or a sequence with at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity thereto. In some embodiments, the anti-TCRBV antibody molecule comprises a leader sequence comprising the amino acid sequence of SEQ ID NO: 3288. In some embodiments, the anti-TCRBV antibody molecule does not comprise a leader sequence comprising the amino acid sequence of SEQ ID NO: 3288. In some embodiments, binding of the anti-TCRpV antibody molecule to a TCRpV region results in a cytokine profile, e.g., a cytokine secretion profile, (e.g., comprising one or more cytokines and / or one or more chemokines), that differs from that of a T cell engager that binds to a receptor or molecule other than a TCRpV region (“a non-TCRpV-binding T cell engager”). In some embodiments, the cytokine profile, e.g., cytokine secretion profile, comprises one, two, three, four, five, six, seven, or all of the following: (i) increased level, e.g., expression level, and / or activity of IL-2; (ii) reduced level, e.g., expression level, and / or activity of IL-1P; (iii) reduced level, e.g., expression level, and / or activity of IL-6; (iv) reduced level, e.g., expression level, and / or activity of TNFa; (v) reduced level, e.g., expression level, and / or activity of IL-10; (vi) a delay, e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more hours delay, in increased level, e.g., expression level, and / or activity of IL-2; (vii) a delay, e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 hours delay, in increased level, e.g., expression level, and / or activity of IFN-gamma; or (viii) increased level, e.g., expression level, and / or activity of IL-15, e.g., wherein (i)-(viii) are relative to the cytokine profile, e.g., cytokine secretion profile, of the non-TCRpV-binding T cell engager. In some embodiments, binding of the anti-TCRBV antibody to a TCRpV region results in reduced cytokine storm, e.g., reduced cytokine release syndrome (CRS) and / or neurotoxicity (NT), as measured by an assay of Example 3, e.g., relative to the cytokine storm induced by the non-TCRpV-binding T cell engager. In some embodiments, binding of the anti-TCRBV antibody to a TCRpV region results in one, two, three or all of: (ix) reduced T cell proliferation kinetics; (x) cell killing, e.g., target cell killing, e.g. cancer cell killing, e.g., as measured by an assay of Example 4; (xi) increased Natural Killer (NK) cell proliferation, e.g., expansion; or (xii) expansion, e.g., at least about 1.1-10 fold expansion (e.g., at least about 1.1, 1.2, 1.3, 1.4, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, or 10 fold expansion), of a population of memory T cells, e.g., wherein (ix)-(xii) are relative to the non-TCRpV-binding T cell engager. In some embodiments, an anti-TCRpV antibody molecule disclosed herein recognizes (e.g., binds to), a structurally conserved domain on the TCRpV protein (e.g., as denoted by the circled area in FIG. 24A). In some embodiments, an anti-TCRpV antibody molecule disclosed herein does not recognize, e.g., bind to, an interface of a TCRpV:TCRalpha complex. In some embodiments, an anti-TCRpV antibody molecule disclosed herein does not recognize, e.g., bind to, a constant region of a TCRpV protein. An exemplary antibody that binds to a constant region of a TCRBV region is JOVI.l as described in Viney et al., (Hybridoma. 1992 Dec;l 1(6):701-13). In some embodiments, an anti-TCRpV antibody molecule disclosed herein does not recognize, e.g., bind to, one or more (e.g., all) of a complementarity determining region (e.g., CDR1, CDR2 and / or CDR3) of a TCRpV protein. In some embodiments, binding of the anti-TCRpV antibody molecule to a TCRpV region results in one, two, three, four, five, six, seven, eight, nine, ten or more (e.g., all) of the following: (i) reduced level, e.g., expression level, and / or activity of IL-1P; (ii) reduced level, e.g., expression level, and / or activity of IL-6; (iii) reduced level, e.g., expression level, and / or activity of TNFa; (iv) increased level, e.g., expression level, and / or activity of IL-2; (v) a delay, e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more hours delay, in increased level, e.g., expression level, and / or activity of IL-2; (vi) a delay, e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 hours delay, in increased level, e.g., expression level, and / or activity of IFN-gamma; (vii) reduced T cell proliferation kinetics; (viii) reduced cytokine storm, e.g., cytokine release syndrome (CRS) and / or neurotoxicity (NT), e.g., as measured by an assay of Example 3; (ix) cell killing, e.g., target cell killing, e.g. cancer cell killing, e.g., as measured by an assay of Example 4; (x) increased level, e.g., expression level, and / or activity of IL-15; or (xi) increased Natural Killer (NK) cell proliferation, e.g., expansion. In some embodiments, any one or all of (i)-(xi) or any combination thereof resulting from an anti-TCRpV antibody molecule disclosed herein is compared to an antibody that binds to: a CD3 molecule, e.g., CD3 epsilon (CD3e) molecule; or a TCR alpha (TCRa) molecule. In some embodiments, binding of the anti-TCRpV antibody molecule to a TCRpV region results in secretion, e.g., production of perforin and / or Granzyme B. In an aspect, the disclosure provides an antibody molecule which binds, e.g., specifically binds, to a T cell receptor beta variable chain (TCRpV) region, wherein the anti-TCRpV antibody molecule comprises an antigen binding domain comprising: (a) a light chain variable region (VL) comprising: (i) one, two or all of (e.g., three) a light chain complementarity determining region 1 (LC CDR1), a light chain complementarity determining region 2 (LC CDR2), and a light chain complementarity determining region 3 (LC CDR3) of SEQ ID NO: 10 or SEQ ID NO: 11; and (ii) a framework region (FR) having at least 95% identity with one, two, three, or all of (e.g., four) a non-murine germline framework 1 (FR1), a non-murine germline framework region 2 (FR2), a non-murine germline framework region 3 (FR3), and a nonmurine germline framework region 4 (FR4); and / or (b) a heavy chain variable region (VH) comprising: (i) one, two or all of (e.g., three) a heavy chain complementarity determining region 1 (HC CDR1), a heavy chain complementarity determining region 2 (HC CDR2) and a heavy chain complementarity determining region 3 (HC CDR3) of SEQ ID NO: 9; and (ii) a framework region (FR) having at least 95% identity with one, two, three, or all of (e.g., four) a non-murine germline framework 1 (FR1), a non-murine germline framework region 2 (FR2), a non-murine germline framework region 3 (FR3), and a nonmurine germline framework region 4 (FR4). In some embodiments, the VL comprises a sequence having a consensus sequence of SEQ ID NO: 230 or 3289. In some embodiments, the VH comprises a sequence having a consensus sequence of SEQ ID NO: 231 or 3290. In some embodiments, the anti-TCRpV antibody molecule binds to TCRP V6, e.g., one or more of TCRp V6-4*01, TCRp V6-4*02, TCRp V6-9*01, TCRp V6-8*01, TCRp V6-5*01, TCRp V6-6*02, TCRp V6-6*01, TCRp V6-2*01, TCRp V6-3*01 or TCRp V6-l*01, or a variant thereof. In some embodiment, the anti-TCRpV antibody molecule comprises an antigen binding domain comprising: (i) a HC CDR1, a HC CDR2 and a HC CDR3 of SEQ ID NO: 1 or SEQ ID NO: 9, or an amino acid sequence listed in Table 1; or (ii) a LC CDR1, a LC CDR2, and a LC CDR3 of SEQ ID NO: 2, SEQ ID NO: 10 or SEQ ID NO: 11, or an amino acid sequence listed in Table 1. In some embodiments, the anti-TCRpV antibody molecule comprises an antigen binding domain comprising a light chain variable region (VL) comprising one, two or all (e.g., three) of a LC CDR1, a LC CDR2 and a LC CDR3 of SEQ ID NO: 2, SEQ ID NO: 10 or SEQ ID NO: 11, or an amino acid sequence listed in Table 1. In some embodiments, the anti-TCRpV antibody molecule comprises an antigen binding domain comprising a heavy chain variable region (VH) comprising one, two or all (e.g., three) of a HC CDR1, a HC CDR2 and a HC CDR3 of SEQ ID NO: 1 or SEQ ID NO: 9, or an amino acid sequence listed in Table 1. In some embodiments, the anti-TCRpV antibody molecule comprises an antigen binding domain comprising: (i) a VL comprising: a LC CDR1 amino acid sequence of SEQ ID NO: 6 (or an amino acid sequence with not more than 1, 2, 3 or 4 modifications, e.g., substitutions, additions or deletions thereof), a LC CDR2 amino acid sequence of SEQ ID NO:7 (or an amino acid sequence with not more than 1, 2, 3 or 4 modifications, e.g., substitutions, additions or deletions thereof), and / or a LC CDR3 amino acid sequence of SEQ ID NO:8 (or an amino acid sequence with not more than 1, 2, 3 or 4 modifications, e.g., substitutions, additions or deletions thereof); and / or (ii) a VH comprising: a HC CDR1 amino acid sequence of SEQ ID NO: 3 (or an amino acid sequence with not more than 1, 2, 3 or 4 modifications, e.g., substitutions, additions or deletions thereof), a HC CDR2 amino acid sequence of SEQ ID NO:4 (or an amino acid sequence with not more than 1, 2, 3 or 4 modifications, e.g., substitutions, additions or deletions thereof), and / or a HC CDR3 amino acid sequence of SEQ ID NO:5 (or an amino acid sequence with not more than 1, 2, 3 or 4 modifications, e.g., substitutions, additions or deletions thereof). In some embodiments, the anti-TCRpV antibody molecule comprises an antigen binding domain comprising: a variable heavy chain (VH) of an amino acid sequence listed in Table 1, e.g., SEQ ID NO: 9, or a sequence having at least about 85%, 90%, 95%, or 99% sequence identity to an amino acid sequence listed in Table 1, e.g., SEQ ID NO: 9; and / or a variable light chain (VL) of an amino acid sequence listed in Table 1, e.g., SEQ ID NO: 10 or SEQ ID NO: 11, or a sequence having at least about 85%, 90%, 95%, or 99% sequence identity to an amino acid sequence listed in Table 1, e.g., SEQ ID NO: 10 or SEQ ID NO: 11. In some embodiments, the anti-TCRpV antibody molecule comprises an antigen binding domain comprising: (i) the VH amino acid sequence of SEQ ID NO: 9; (ii) an amino acid sequence having at least about 85%, 90%, 95%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 9; (iii) the VL amino acid sequence of SEQ ID NO: 10; and / or (iv) an amino acid sequence having at least about 85%, 90%, 95%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 10. In an aspect, provided herein is an antibody molecule which binds, e.g., specifically binds, to a T cell receptor beta variable chain (TCRpV) region, wherein the anti-TCRpV antibody molecule comprises an antigen binding domain comprising: (a) a light chain variable region (VL) comprising: (i) one, two or all of (e.g., three) a light chain complementarity determining region 1 (LC CDR1), a light chain complementarity determining region 2 (LC CDR2), and a light chain complementarity determining region 3 (LC CDR3) of a humanized B-H light chain (LC) of Table 2; and (ii) a framework region (FR) having at least 95% identity with one, two, three or all (e.g., four) of a framework region 1 (FR1), a framework region 2 (FR2), a framework region 3 (FR3), and a framework region 4 (FR4) of a humanized B-H LC of Table 2; and / or (b) a heavy chain variable region (VH) comprising: (i) one, two or all of (e.g., three) a heavy chain complementarity determining region 1 (HC CDR1), a heavy chain complementarity determining region 2 (HC CDR2) and a heavy chain complementarity determining region 3 (HC CDR3) of a humanized B-H heavy chain (HC) of Table 2; and (ii) a framework region (FR) having at least 95% identity with one, two, three or all (e.g., four) of a framework region 1 (FR1), a framework region 2 (FR2), a framework region 3 (FR3), and a framework region 4 (FR4) of a humanized B-H HC of Table 2. In some embodiments, the anti-TCRBV binds to TCRP V12, e.g., TCRP V12-4*01, TCRP V12-3*01, or TCRP V12-5*01, or a variant thereof. In some embodiment, the anti-TCRpV antibody molecule comprises an antigen binding domain comprising: (i) a HC CDR1, a HC CDR2 and a HC CDR3 of Antibody B listed in Table 2; or (ii) a LC CDR1, a LC CDR2, and a LC CDR3 of Antibody B listed in Table 2. In some embodiments, the anti-TCRpV antibody molecule comprises an antigen binding domain comprising a light chain variable region (VL) comprising one, two or all (e.g., three) of a LC CDR1, a LC CDR2 and a LC CDR3 of SEQ ID NO: 2, SEQ ID NO: 10 or SEQ ID NO: 11, or an amino acid sequence listed in Table 1. In some embodiments, the anti-TCRpV antibody molecule comprises an antigen binding domain comprising a heavy chain variable region (VH) comprising one, two or all (e.g., three) of a HC CDR1, a HC CDR2 and a HC CDR3 of a humanized B-H antibody listed in Table 2. In some embodiments, the anti-TCRpV antibody molecule comprises an antigen binding domain comprising a light chain variable region (VL) comprising one, two or all (e.g., three) of a LC CDR1, a LC CDR2 and a LC CDR3 of a humanized B-H antibody listed in Table 2. In some embodiments, the anti-TCRpV antibody molecule comprises: a VH sequence of a humanized B-H antibody listed in Table 2, or a sequence having at least about 85%, 90%, 95%, or 99% sequence identity to a VH of a humanized B-H antibody listed in Table 2; and / or a VL sequence of a humanized B-H antibody listed in Table 2, or a sequence having at least about 85%, 90%, 95%, or 99% sequence identity to a VL of a humanized B-H antibody listed in Table 2. In some embodiments, the anti-TCRpV antibody molecule comprises a framework region (FR) having at least 95% identity with one of: a FR1, a FR2, a FR3, and a FR4 of a humanized B-H LC of Table 2. In some embodiments, the anti-TCRpV antibody molecule comprises a framework region (FR) having at least 95% identity with any two of: a FR1, a FR2, a FR3, and a FR4 of a humanized B-H LC of Table 2. In some embodiments, the anti-TCRpV antibody molecule comprises a framework region (FR) having at least 95% identity with any three of: a FR1, a FR2, a FR3, and a FR4 of a humanized B-H LC of Table 2. In some embodiments, the anti-TCRpV antibody molecule comprises a framework region (FR) having at least 95% identity with all of: a FR1, a FR2, a FR3, and a FR4 of a humanized B-HLC of Table 2. In some embodiments, the anti-TCRpV antibody molecule comprises a framework region (FR) having at least 95% identity with one of: a FR1, a FR2, a FR3, and a FR4 of a humanized B-H HC of Table 2. In some embodiments, the anti-TCRpV antibody molecule comprises a framework region (FR) having at least 95% identity with any two of: a FR1, a FR2, a FR3, and a FR4 of a humanized B-H HC of Table 2. In some embodiments, the anti-TCRpV antibody molecule comprises a framework region (FR) having at least 95% identity with any three of: a FR1, a FR2, a FR3, and a FR4 of a humanized B-H HC of Table 2. In some embodiments, the anti-TCRpV antibody molecule comprises a framework region (FR) having at least 95% identity with all of: a FR1, a FR2, a FR3, and a FR4 of a humanized B-HHC of Table 2. In another aspect, the disclosure provides a non-murine, e.g., a human-like antibody molecule (e.g., a human or humanized antibody molecule), which binds, e.g., specifically binds, to a T cell receptor beta variable (TCRpV) region. In some embodiments, binding of the anti-TCRpV antibody molecule results in expansion, e.g., at least about 1.1-50 fold expansion (e.g., at least about 1.5-40 fold, 2-35 fold, 3-30 fold, 5-25 fold, 8-20 fold, or 10-15 fold expansion), of a population of memory T cells, e.g., T effector memory (Tem) cells, e.g., Tem cells expressing CD45RA (Temra) cells, e.g., CD4+ or CD8+ Temra cells. In some embodiments, the expansion is at least about 1.1-10 fold expansion (e.g., at least about 1.1, 1.2, 1.3, 1.4, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, or 10 fold expansion). In some embodiments, expansion of the population of memory effector T cells, e.g., Tem cells, e.g., Temra cells, e.g., CD4+ or CD8+ Temra cells, is compared to expansion of a similar population of cells with an antibody that binds to: a CD3 molecule, e.g., CD3 epsilon (CD3e) molecule; or a TCR alpha (TCRa) molecule. In some embodiments, the population of expanded T effector memory cells comprises cells T cells, e.g., CD3+, CD8+ or CD4+ T cells. In some embodiments, the population of expanded T effector memory cells comprises CD3+ and CD8+ T cells. In some embodiments, the population of expanded T effector memory cells comprises CD3+ and CD4+ T cells. In some embodiments, the population of expanded T effector memory (Tem) cells comprises cells T cells, e.g., CD3+, CD8+ or CD4+ T cells, which express or re-express, CD45RA, e.g., CD45RA+. In some embodiments, the population comprises Tem cells expressing CD45RA, e.g., Temra cells. In some embodiments, expression of CD45RA on Temra cells, e.g., CD4+ or CD8+ Temra cells, can be detected by a method disclosed herein, e.g., flow cytometry. In some embodiments, Temra cells have low or no expression of CCR7, e.g., CCR7- or CCR7 low. In some embodiments, expression of CCR7 on Temra cells cannot be detected by a method disclosed herein, e.g., flow cytometry. In some embodiments, Temra cells express CD95, e.g., CD95+. In some embodiments, expression of CD95 on Temra cells can be detected by a method disclosed herein, e.g., flow cytometry. In some embodiments, Temra cells express CD45RA, e.g., CD45RA+, have low or no expression of CCR7, e.g., CCR7- or CCR7 low, and express CD95, e.g., CD95+. In some embodiments Temra cells can be identified as CD45RA+, CCR7- and CD95+ cells. In some embodiments, Temra cells comprise CD3+, CD4+ or CD8+ T cells (e.g., CD3+ T cells, CD3+ CD8+ T cells, or CD3+ CD4+ T cells). In some embodiments, binding of the anti-TCRpV antibody molecule results in expansion, e.g., at least about 1.1-50 fold expansion (e.g., at least about 1.5-40 fold, 2-35 fold, 330 fold, 5-25 fold, 8-20 fold, or 10-15 fold expansion), of a subpopulation of T cells. In some embodiments, the anti-TCRpV antibody molecule-activated (e.g., expanded) subpopulation of T cells resemble Temra cells in high expression of CD45RA and / or low expression of CCR7. In some embodiments, the anti-TCRpV antibody molecule-activated (e.g., expanded) subpopulation of T cells do not display upregulation of the senescence markers CD57 and / or KLRG1. In some embodiments, the anti-TCRpV antibody molecule-activated (e.g., expanded) subpopulation of T cells do not display upregulation of co-stimulatory molecules CD27 and / or CD28. In some embodiments, the anti-TCRpV antibody molecule-activated (e.g., expanded) subpopulation of T cells are highly proliferative. In some embodiments, the anti-TCRpV antibody molecule-activated (e.g., expanded) subpopulation of T cells secrete IL-2. In some embodiments, expression of surface markers on T cells can be detected by a method disclosed herein, e.g., flow cytometry. In some embodiments, the proliferative capability of T cells can be detected by a method disclosed herein, e.g., a method described in Example 4. In some embodiments, cytokine expression of T cells can be detected by a method disclosed herein, e.g., a method described in Examples 10 and 21. In some embodiments, the expansion is at least about 1.1-10 fold expansion (e.g., at least about 1.1, 1.2, 1.3, 1.4, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, or 10 fold expansion). In some embodiments, the expansion is compared to expansion of a similar population of cells with an antibody that binds to a CD3 molecule, e.g., CD3 epsilon (CD3e) molecule; or a TCR alpha (TCRa) molecule. In some embodiments, binding of the anti-TCRpV antibody molecule to a TCRPV region results in one, two, three, four, five, six, seven, eight, nine, ten or more (e.g., all) of the following: (i) reduced level, e.g., expression level, and / or activity of IL-1P; (ii) reduced level, e.g., expression level, and / or activity of IL-6; (iii) reduced level, e.g., expression level, and / or activity of TNFa; (iv) increased level, e.g., expression level, and / or activity of IL-2; (v) a delay, e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more hours delay, in increased level, e.g., expression level, and / or activity of IL-2; (vi) a delay, e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 hours delay, in increased level, e.g., expression level, and / or activity of IFNg; (vii) reduced T cell proliferation kinetics; (viii) reduced cytokine storm, e.g., cytokine release syndrome (CRS) and / or neurotoxicity (NT), e.g., as measured by an assay of Example 3; (ix) cell killing, e.g., target cell killing, e.g. cancer cell killing, e.g., as measured by an assay of Example 4; (x) increased level, e.g., expression level, and / or activity of IL-15; or (xi) increased Natural Killer (NK) cell proliferation, e.g., expansion, compared to an antibody that binds to: a CD3 molecule, e.g., CD3 epsilon (CD3e) molecule; or a TCR alpha (TCRa) molecule. In some embodiments of any of the compositions disclosed herein, binding of the anti-TCRpV antibody molecule to a TCRPV region results in a reduction of at least 2, 5, 10, 20, 50, 100, or 200 fold, or at least 2-200 fold (e.g., 5-150, 10-100, 20-50 fold) in the expression level and or activity of IL-ip as measured by an assay of Example 3. In some embodiments of any of the compositions disclosed herein, binding of the anti-TCRpV antibody molecule to a TCRpV region results in a reduction of at least 2, 5, 10, 20, 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 fold, or at least 2-1000 fold (e.g., 5-900, 10800, 20-700, 50-600, 100-500, or 200-400 fold) in the expression level and or activity of IL-6 as measured by an assay of Example 3. In some embodiments of any of the compositions disclosed herein, binding of the anti-TCRpV antibody molecule to a TCRpV region results in a reduction of at least 2, 5, 10, 20, 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, or 2000 fold, or at least 2-2000 fold (e.g., 51000, 10-900, 20-800, 50-700, 100-600, 200-500, or 300-400 fold) in the expression level and or activity of TNFa as measured by an assay of Example 3. In some embodiments of any of the compositions disclosed herein, binding of the anti-TCRpV antibody molecule to a TCRpV region results in an increase of at least 2, 5, 10, 20, 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, or 2000 fold, or at least 2-2000 fold (e.g., 51000, 10-900, 20-800, 50-700, 100-600, 200-500, or 300-400 fold) in the expression level and or activity of IL-2 as measured by an assay of Example 3. In some embodiments of any of the compositions disclosed herein, binding of the anti-TCRpV antibody molecule to a TCRpV region results in an increase of at least 2, 5, 10, 20, 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, or 2000 fold, or at least 2-2000 fold (e.g., 51000, 10-900, 20-800, 50-700, 100-600, 200-500, or 300-400 fold) in the expression level and or activity of IL-15 as measured by an assay of Example 4. In some embodiments of any of the compositions disclosed herein, binding of the anti-TCRpV antibody molecule results in proliferation, e.g., expansion, e.g., at least about 1.1-50 fold expansion (e.g., at least about 1.5-40 fold, 2-35 fold, 3-30 fold, 5-25 fold, 8-20 fold, or 10-15 fold expansion), of a population of Natural Killer (NK) cells. In some embodiments, the expansion of NK cells is at least about 1.1-30 fold expansion (e.g., at least about 1.1, 1.2, 1.3, 1.4, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, or at least about 1.1-5, 5-10, 10-15, 15-20, 20-25, or 25-30 fold expansion). In some embodiments, the expansion of NK cells is measure by an assay of Example 4. In some embodiments, the expansion of NK cells by, e.g., binding of, the anti-TCRpV antibody molecule is compared to expansion of an otherwise similar population not contacted with the anti-TCRpV antibody molecule. In some embodiments of any of the compositions disclosed herein, binding of the anti-TCRpV antibody molecule results in cell killing, e.g., target cell killing, e.g. cancer cell killing. In some embodiments, the cancer cell is a hematological cancer cell or a solid tumor cell. In some embodiments, the cancer cell is a multiple myeloma cell. In some embodiments, binding of the anti-TCRpV antibody molecule results in cell killing in vitro or in vivo. In some embodiments, cell killing is measured by an assay of Example 4. In some embodiments of any of the compositions disclosed herein, binding of the anti-TCRpV antibody molecule to a TCRpV region results in an increase or decrease of at least 2, 5, 10, 20, 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, or 2000 fold, or at least 2-2000 fold (e.g., 5-1000, 10-900, 20-800, 50-700, 100-600, 200-500, or 300-400 fold) of any of the activities described herein compared the activity of 16G8 or TM23 murine antibody, or a humanized version thereof as described in US Patent 5,861,155. In an aspect, provided herein is an antibody molecule which binds, e.g., specifically binds, to a T cell receptor beta variable chain (TCRpV) region (an anti-TCRpV antibody molecule), wherein the anti-TCRpV antibody molecule: (i) binds specifically to an epitope on TCRpV, e.g., the same or similar epitope as the epitope recognized by an anti-TCRpV antibody molecule as described herein, e.g., a second anti-TCRpV antibody molecule; (ii) shows the same or similar binding affinity or specificity, or both, as an anti-TCRpV antibody molecule as described herein, e.g., a second anti-TCRpV antibody molecule; (iii) inhibits, e.g., competitively inhibits, the binding of an anti-TCRpV antibody molecule as described herein, e.g., a second anti-TCRpV antibody molecule; (iv) binds the same or an overlapping epitope with an anti-TCRpV antibody molecule as described herein, e.g., a second anti-TCRpV antibody molecule; or (v) competes for binding, and / or binds the same epitope, with an anti-TCRpV antibody molecule as described herein, e.g., a second anti-TCRpV antibody molecule, In some embodiments, the second anti-TCRpV antibody molecule comprises an antigen binding domain chosen from Table 1 or Table 2, or a sequence substantially identical thereto. In some embodiments, the second anti-TCRpV antibody molecule comprises an antigen binding domain, comprising: a heavy chain complementarity determining region 1 (HC CDR1), a heavy chain complementarity determining region 2 (HC CDR2) and / or a heavy chain complementarity determining region 3 (HC CDR3) of SEQ ID NO: 1 or SEQ ID NO: 9; and / or a light chain complementarity determining region 1 (LC CDR1), a light chain complementarity determining region 2 (LC CDR2), and / or a light chain complementarity determining region 3 (LC CDR3) of SEQ ID NO: 2, SEQ ID NO: 10 or SEQ ID NO: 11. In some embodiments of any of the compositions disclosed herein, binding of the anti-TCRpV antibody molecule to a TCRpV region results in a change in any (e.g., one, two, three, four or all) of (i)-(v) that is different, e.g., an increase or decrease, of at least 2, 5, 10, 20, 50, 100-fold, compared the activity of 16G8 or TM23 murine antibody or a humanized version thereof as described in US Patent 5,861,155. In some embodiments of any of the compositions disclosed herein, the anti-TCRpV antibody molecule binds to a TCRBV family (e.g., gene family), e.g., a TCRBV gene family comprising subfamilies, e.g., as described herein. In some embodiments, the TCRBV family, e.g., gene family, comprises: a TCRP V6 subfamily, a TCRP V10 subfamily, a TCRP V12 subfamily, a TCRp V5 subfamily, a TCRp V7 subfamily, a TCRp Vil subfamily, a TCRp V14 subfamily, a TCRP V16 subfamily, a TCRP V18 subfamily, a TCRP V9 subfamily, a TCRP V13 subfamily, a TCRp V4 subfamily, a TCRp V3 subfamily, a TCRp V2 subfamily, a TCRp V15 v, a TCRp V30 subfamily, a TCRp V19 subfamily, a TCRp V27 subfamily, a TCRp V28 subfamily, a TCRp V24 subfamily, a TCRp V20 subfamily, TCRp V25 subfamily, a TCRp V29 subfamily, a TCRp V23 subfamily, a TCRp V21 subfamily, a TCRp VI subfamily, a TCRp V17 subfamily, or a TCRP V26 subfamily. In some embodiments, the anti-TCRpV antibody binds to a TCRP V6 subfamily chosen from: TCRp V6-4*01, TCRp V6-4*02, TCRp V6-9*01, TCRp V6-8*01, TCRp V6-5*01, TCRp V6-6*02, TCRp V6-6*01, TCRp V6-2*01, TCRp V6-3*01 or TCRp V6-l*01. In some embodiments the TCRP V6 subfamily comprises TCRP V6-5*01. In some embodiments, the anti-TCRpV antibody binds to a TCRP V10 subfamily chosen from: TCRp V10-l*01, TCRp V10-l*02, TCRp V10-3*01 or TCRp V10-2*01. In some embodiments, the anti-TCRpV antibody binds to a TCRP V12 subfamily chosen from: TCRp V12-4*01, TCRp V12-3*01 or TCRp V12-5*01. In some embodiments of any of the compositions disclosed herein, the anti-TCRpV antibody molecule does not bind to TCRP V12, or binds to TCRP V12 with an affinity and / or binding specificity that is less than (e.g., less than about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or about 2-, 5-, or 10- fold) the affinity and / or binding specificity of the 16G8 murine antibody or a humanized version thereof as described in US Patent 5,861,155. In some embodiments of any of the compositions disclosed herein, the anti-TCRpV antibody molecule binds to TCRP V12 with an affinity and / or binding specificity that is greater than (e.g., greater than about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or about 2-, 5-, or 10- fold) the affinity and / or binding specificity of the 16G8 murine antibody or a humanized version thereof as described in US Patent 5,861,155. In some embodiments of any of the compositions disclosed herein, the anti-TCRpV antibody molecule binds to a TCRpV region other than TCRP V12 (e.g., TCRpV region as described herein, e.g., TCRP V6 subfamily (e.g., TCRP V6-5*01) with an affinity and / or binding specificity that is greater than (e.g., greater than about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or about 2-, 5-, or 10- fold) the affinity and / or binding specificity of the 16G8 murine antibody or a humanized version thereof as described in US Patent 5,861,155. In some embodiments of any of the compositions disclosed herein, the anti-TCRpV antibody molecule does not comprise at least one CDR of Antibody B. In some embodiments of any of the compositions disclosed herein, the anti-TCRpV antibody molecule does not comprise the CDRs of Antibody B. In some embodiments of any of the compositions disclosed herein, the anti-TCRpV antibody binds to a TCRP V5 subfamily chosen from: TCRP V5-5*01, TCRP V5-6*01, TCRP V5-4*01, TCRp V5-8*01, TCRp V5-l*01. In some embodiments of any of the compositions disclosed herein, the anti-TCRpV antibody binds to a TCRP V5 subfamily chosen from: TCRP V5-5*01, TCRP V5-6*01, TCRP V5-4*01, TCRp V5-8*01, TCRp V5-l*01. In some embodiments of any of the compositions disclosed herein, the anti-TCRpV antibody molecule does not bind to TCRP V5-5*01 or TCRP V5-l*01, or binds to TCRP V5-5*01 or TCRP V5-l*01 with an affinity and / or binding specificity that is less than (e.g., less than about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or about 2-, 5-, or 10- fold) the affinity and / or binding specificity of the TM23 murine antibody or a humanized version thereof as described in US Patent 5,861,155. In some embodiments of any of the compositions disclosed herein, the anti-TCRpV antibody molecule binds to TCRP V5-5*01 or TCRP V5-l*01with an affinity and / or binding specificity that is greater than (e.g., greater than about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or about 2-, 5-, or 10- fold) the affinity and / or binding specificity of the TM23 murine antibody or a humanized version thereof as described in US Patent 5,861,155. In some embodiments of any of the compositions disclosed herein, the anti-TCRpV antibody molecule binds to a TCRpV region other than TCRP V5-5*01 or TCRP V5-l*01 (e.g., TCRpV region as described herein, e.g., TCRP V6 subfamily (e.g., TCRP V6-5*01) with an affinity and / or binding specificity that is greater than (e.g., greater than about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or about 2-, 5-, or 10- fold) the affinity and / or binding specificity of the TM23 murine antibody or a humanized version thereof as described in US Patent 5,861,155. In some embodiments of any of the compositions disclosed herein, the anti-TCRpV antibody molecule does not comprise at least one CDR of the TM23 murine antibody. In some embodiments of any of the compositions disclosed herein, the anti-TCRpV antibody molecule does not comprise the CDRs of the TM23 murine antibody. In some embodiments of any of the compositions disclosed herein, an anti-TCRpV antibody molecule disclosed herein does not comprise the sequence of a murine anti-rat TCR antibody R73, e.g., as disclosed in J Exp Med. 1989 Jan 1; 169(1): 73-86, herein incorporated by reference in its entirety. In some embodiments of any of the compositions disclosed herein, a multispecific antibody molecule disclosed herein does not comprise the sequence of a murine anti-rat TCR antibody R73, e.g., as disclosed in J Immunol. 1993 Mar 15;150(6):2305-15, herein incorporated by reference in its entirety. In some embodiments of any of the compositions disclosed herein, an anti-TCRpV antibody molecule disclosed herein does not comprise a viral peptide-MHC complex, e.g., as disclosed in Oncoimmunology. 2016; 5(1): el052930, herein incorporated by reference in its entirety. In some embodiments of any of the compositions disclosed herein, a multispecific antibody molecule disclosed herein does not comprise a viral peptide-MHC complex, e.g., as disclosed in Oncoimmunology. 2016; 5(1): el052930, herein incorporated by reference in its entirety. In some embodiments of any of the compositions disclosed herein, the anti-TCRpV 5 antibody molecule binds to one or more (e.g., all) of the following TCRpV subfamilies: (i) TCRP V6 subfamily comprising, e.g., one or more of TCRP V6-4*01, TCRP V6-4*02, TCRp V6-9*01, TCRp V6-8*01, TCRp V6-5*01, TCRp V6-6*02, TCRp V6-6*01, TCRp V6-2*01, TCRp V6-3*01 or TCRp V6-l*01; (ii) TCRP V10 subfamily comprising, e.g., one or more of TCRP V10-l*01, TCRP V10-1*02, TCRp V10-3*01 or TCRp V10-2*01; (iii) TCRP V5 subfamily comprising, e.g., one or more of TCRP V5-6*01, TCRP V5-4*01, or TCRp V5-8*01; (iv) TCRP V12 subfamily comprising e.g., one or more of TCRP V12-4*01, TCRP V12-3*01, or TCRp V12-5*01; (v) TCRP V7 subfamily comprising e.g., one or more of TCRP V7-7*01, TCRP V7-6*01, TCRp V7 -8*02, TCRp V7 -4*01, TCRp V7-2*02, TCRp V7-2*03, TCRp V7-2*01, TCRp V7-3*01, TCRp V7-9*03, or TCRp V7-9*01; (vi) TCRP Vil subfamily comprising e.g., one or more of TCRP VI 1-1*01, TCRP VI1-2*01 or TCRp VI 1-3*01; (vii) TCRP V14 subfamily comprising TCRP V14*01; (viii) TCRP V16 subfamily comprising TCRP VI6*01; (ix) TCRP VI8 subfamily comprising TCRP VI8*01; (x) TCRP V9 subfamily comprising T e.g., one or more of CRP V9*01 or TCRP V9*02; (xi) TCRP V13 subfamily comprising TCRP V13*01; (xii) TCRP V4 subfamily comprising e.g., one or more of e.g., one or more of TCRP V4-2*01, TCRp V4-3*01, or TCRp V4-l*01; (xiii) TCRP V3 subfamily comprising TCRP V3-l*01; (xiv) TCRP V2 subfamily comprising TCRP V2*01; (xv) TCRP V15 subfamily comprising TCRP V15*01; (xvi) TCRP V30 subfamily comprising e.g., one or more of TCRP V30*01, or TCRP V30*02; (xvii) TCRP V19 subfamily comprising e.g., one or more of TCRP VI9*01, or TCRP V19*02; (xviii) TCRP V27 subfamily comprising TCRP V27*01; (xix) TCRP V28 subfamily comprising TCRP V28*01; (xx) TCRP V24 subfamily comprising TCRP V24-l*01; (xxi) TCRP V20 subfamily comprising e.g., one or more of TCRP V20-l*01, or TCRP V20-l*02; (xxii) TCRP V25 subfamily comprising TCRP V25-l*01; or (xxiii) TCRP V29 subfamily comprising TCRP V29-l*01; (xxiv) TCRp V21 subfamily; (xxv) TCRp VI subfamily; (xxvi) TCRp V17 subfamily; (xvii) TCRP V23 subfamily; or (xviii) TCRP V26 subfamily. In some embodiments of any of the compositions disclosed herein, the anti-TCRpV antibody molecule binds to one or more (e.g., all) of the following TCRpV subfamilies: (i) TCRp V6, e.g., one or more of TCRp V6-4*01, TCRp V6-4*02, TCRp V6-9*01, 5 TCRp V6-8*01, TCRp V6-5*01, TCRp V6-6*02, TCRp V6-6*01, TCRp V6-2*01, TCRp V6-3*01 or TCRp V6-l*01; (ii) TCRp V10, e.g., one or more of TCRp V10-l*01, TCRp V10-l*02, TCRp V10-3*01 or TCRp V10-2*01; (iii) TCRp V12, e.g., one or more of TCRp V12-4*01, TCRp V12-3*01, or TCRp V12-10   5*01; or (iv) TCRp V5, e.g., one or more of TCRp V5-5*01, TCRp V5-6*01, TCRp V5-4*01, TCRp V5-8*01, TCRp V5-l*01. In some embodiments, the anti-TCRpV antibody molecule binds to TCRP V6, e.g., one or more of TCRp V6-4*01, TCRp V6-4*02, TCRp V6-9*01, TCRp V6-8*01, TCRp V6-5*01, 15 TCRp V6-6*02, TCRp V6-6*01, TCRp V6-2*01, TCRp V6-3*01 or TCRp V6-l*01. In some embodiments, the anti-TCRpV antibody molecule binds to TCRP V6-5*01. In some embodiments, the anti-TCRpV antibody molecule does not bind to TCRP V12. In some embodiments, the anti-TCRpV antibody molecule does not bind to TCRP V5-5*01 or TCRp V5-l*01. In an aspect, provided herein is a multispecific molecule (e.g., a bispecific molecule), comprising a first moiety (e.g., a first immune cell engager) comprising an antibody molecule which binds (e.g., specifically binds) to a T cell receptor beta variable region (TCRPV) (“anti-TCRpV antibody molecule”). In some embodiments, the multispecific molecule comprises a second moiety which comprises one or more of: a tumor-targeting moiety, a cytokine molecule, a stromal modifying moiety, or an anti-TCRpV antibody molecule other than the first moiety. In some embodiments, binding of the first moiety to the TCRPV region results in a cytokine profile, e.g., cytokine secretion profile, that differs from that of a T cell engager that binds to a receptor or molecule other than a TCRPV region (“a non-TCRpV-binding T cell engager”). In another aspect, the disclosure provides a multispecific molecule, e.g., a bispecific molecule, comprising the anti-TCRpV antibody molecule disclosed herein. In some embodiments, the multispecific molecule further comprises: a tumor-targeting moiety, a cytokine molecule, an immune cell engager, e.g., a second immune cell engager, and / or a stromal modifying moiety. In yet another aspect, disclosed herein is a multispecific molecule, e.g., a bispecific molecule, comprising: (i) a first moiety comprising a first immune cell engager comprising an anti-TCRpV antibody molecule disclosed herein; and (ii) a second moiety comprising one or more of: a tumor-targeting moiety; a second immune cell engager; a cytokine molecule or a stromal modifying moiety. In another aspect, the disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding an anti-TCRpV antibody molecule disclosed herein, or a nucleotide sequence having at least 75%, 80%, 85%, 90%, 95%, or 99% identity thereto. In another aspect, the disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a multispecific molecule disclosed herein, or a nucleotide sequence having at least 75%, 80%, 85%, 90%, 95%, or 99% identity thereto. In yet another aspect, the disclosure provides a vector, e.g., an expression vector, comprising a nucleotide sequence encoding an anti-TCRpV antibody molecule disclosed herein, or a nucleotide sequence having at least 75%, 80%, 85%, 90%, 95%, or 99% identity thereto. In another aspect, the disclosure provides a vector, e.g., an expression vector, comprising a nucleotide sequence encoding a multispecific molecule disclosed herein, or a nucleotide sequence having at least 75%, 80%, 85%, 90%, 95%, or 99% identity thereto. In one aspect, the disclosure provides a cell, e.g., host cell, e.g., a population of cells, comprising a nucleic acid molecule encoding an anti-TCRpV antibody molecule disclosed herein, or a nucleotide sequence having at least 75%, 80%, 85%, 90%, 95%, or 99% identity thereto. In some embodiments, the cell or population of cells comprising a nucleic acid molecule encoding anti-TCRpV antibody molecule, comprises: (i) a heavy chain comprising: a variable region (VH), e.g., a VH listed in Table 1 or 2, or a sequence having at least 75%, 80%, 85%, 90%, 95%, or 99% identity thereto; and one or more heavy chain constant regions, e.g., as described herein; and / or (ii) a light chain comprising: a variable region (VL) e.g., a VL listed in Table 1 or 2, or a sequence having at least 75%, 80%, 85%, 90%, 95%, or 99% identity thereto; and a light chain constant region, e.g., as described herein, e.g., a kappa chain constant region comprising the sequence of SEQ ID NO: 39, or a sequence with at least 85%, 90%, 95%, or 99% sequence identity thereto. In some embodiments, the cell or population of cells further comprises an IgJ heavy chain constant region or a fragment thereof. In some embodiments, the IgJ heavy chain constant region comprises the sequence of SEQ ID NO: 76 or a sequence with at least 85%, 90%, 95%, or 99% sequence identity thereto. In some embodiments, the IgJ is comprised in, e.g., expressed in, the same cell or population of cells comprising, e.g., expressing, the anti-TCRpV antibody molecule, e.g., the heavy chain and / or the light chain of the anti-TCRpV antibody molecule. In some embodiments, the IgJ is expressed in a different cell or population of cells than the cell or population of cells comprising, e.g., expressing, the anti-TCRpV antibody molecule, e.g., the heavy chain and / or the light chain of the anti-TCRpV antibody molecule. In one aspect, the disclosure provides a cell, e.g., host cell, e.g., a population of cells, comprising a nucleic acid molecule encoding a multispecific molecule disclosed herein, or a nucleotide sequence having at least 75%, 80%, 85%, 90%, 95%, or 99% identity thereto. In one aspect, disclosed herein is an anti-TCRpV antibody molecule for use in the manufacture of a medicament for treating a disease, e.g., cancer, in a subject. In one aspect, disclosed herein is a multispecific molecule comprising an anti-TCRpV antibody molecule for use in the manufacture of a medicament for treating a disease, e.g., cancer, in a subject. In another aspect, the disclosure provides a method of making, e.g., producing, an anti-TCRpV antibody molecule, a multispecific molecule described herein, comprising culturing a host cell described herein, under suitable conditions. In some embodiments of a method of making a multispecific molecule, the conditions comprise, e.g., conditions suitable for gene expression and / or homo- or heterodimerization. In another aspect, the disclosure provides a pharmaceutical composition comprising an anti-TCRpV antibody molecule, or a multispecific molecule described herein, and a pharmaceutically acceptable carrier, excipient, or stabilizer. In an aspect, the disclosure provides a method of modulating, e.g., enhancing, an immune response in a subject comprising administering to the subject an effective amount of an antibody molecule which binds (e.g., specifically binds) to a T cell receptor beta variable region (TCRpV) (“anti-TCRpV antibody molecule”). In an aspect, the disclosure provides a method of modulating, e.g., enhancing, an immune response in a subject comprising administering to the subject an effective amount of a multispecific molecule disclosed herein. In some embodiments, the method comprises expanding, e.g., increasing the number of, an immune cell population in the subject. In an aspect, the disclosure provides a method of expanding, e.g., increasing the number of, an immune cell population comprising, contacting the immune cell population with an effective amount of an antibody molecule which binds (e.g., specifically binds) to a T cell receptor beta variable region (TCRpV) (“anti-TCRpV antibody molecule”). In an aspect, the disclosure provides a method of expanding, e.g., increasing the number of, an immune cell population comprising, contacting the immune cell population with an effective amount of a multispecific molecule disclosed herein. In some embodiments, the expansion occurs in vivo or ex vivo (e.g., in vitro). In some embodiments, the immune cell population comprises a TCRpV expressing cell, e.g., a TCRpV+ cell. In some embodiments, the TCRpV expressing cell is a T cell, e.g., a CD8+ T cell, a CD3+ T cell or a CD4+ T cell. In some embodiments, the immune cell population comprises a T cell (e.g., a CD4 T cell, a CD8 T cell, (e.g., an effector T cell or a memory T cell (e.g., a memory effector T cell (e.g., TEM cell, e.g., TEMRA cell), or a tumor infiltrating lymphocyte (TIL). In some embodiments, the immune cell population comprises a T cell, a Natural Killer cell, a B cell, or a myeloid cell. In some embodiments, the immune cell population is obtained from a healthy subject. In an aspect, provided herein is a method of treating a disease e.g., cancer, in a subject comprising administering to the subject an effective amount, e.g., a therapeutically effective amount, of an anti-TCRpV antibody molecule or a multispecific molecule comprising an anti-TCRpV antibody molecule disclosed herein, thereby treating the disease. In a related aspect, provided herein is a composition comprising an anti-TCRpV antibody molecule or a multispecific molecule comprising an anti-TCRpV antibody molecule disclosed herein, for use in the treatment of a disease, e.g., cancer, in a subject. In some embodiments, the disease is a cancer, e.g., a solid tumor or a hematological cancer, or a metastatic lesion. In some embodiments, the method further comprises administering a second agent, e.g., therapeutic agent, e.g., as described herein. In some embodiments, second agent comprises a therapeutic agent (e.g., a chemotherapeutic agent, a biologic agent, hormonal therapy), radiation, or surgery. In some embodiments, therapeutic agent is selected from: a chemotherapeutic agent, or a biologic agent. In another aspect, provided herein is a method of targeting, e.g., directing or re-directing, a therapy, e.g., treatment, to a T cell, e.g., in a subject, e.g., having a disease, e.g., cancer, comprising administering an effective amount of: (i) an anti-TCRpV antibody disclosed herein; and (ii) the therapy, e.g., a tumor targeting therapy (e.g., an antibody that binds to a cancer antigen), e.g., as described herein, thereby targeting the T cell. In some embodiments, (i) and (ii) are conjugated, e.g., linked. In some embodiments, (i) and (ii) are administered simultaneously or concurrently. In some embodiments, the method results in: reduced cytokine release syndrome (CRS) (e.g., lesser duration of CRS or no CRS), or a reduced severity of CRS (e.g., absence of severe CRS, e.g., CRS grade 4 or 5) compared to administration of (ii) alone. In some embodiments, CRS is assessed by an assay of Example 3. In some embodiments, the method results in: reduced neurotoxicity (NT) (e.g., lesser duration of NT or no NT), or a reduced severity of NT (e.g., absence of severe NT) compared to administration of (ii) alone. In yet another aspect, the disclosure provides, a method of targeting a T cell, e.g., in a subject having a disease, e.g., cancer, with an anti-TCRpV antibody disclosed herein or a multispecific molecule comprising an anti-TCRpV antibody disclosed herein. In another aspect, the disclosure provides a method of treating, e.g., preventing or reducing, cytokine release syndrome (CRS) and / or neurotoxicity (NT) in a subject, e.g., CRS and / or NT associated with a treatment, e.g., a previously administered treatment, comprising administering to the subject an effective amount of an anti-TCRpV antibody disclosed herein or a multispecific molecule comprising an anti-TCRpV antibody disclosed herein, wherein, the subject has a disease, e.g., a cancer, thereby treating, e.g., preventing or reducing, CRS and / or NT in the subject. In a related aspect, the disclosure provides a composition comprising an anti-TCRpV antibody disclosed herein or a multispecific molecule comprising an anti-TCRpV antibody disclosed herein, for use in the treatment, e.g., prevention or reduction, of cytokine release syndrome (CRS) and / or neurotoxicity (NT) in a subject, e.g., CRS and / or NT associated with a treatment, e.g., a previously administered treatment, comprising administering to the subject an effective amount of the anti-TCRpV antibody, wherein the subject has a disease, e.g., a cancer. In some embodiments of a method or composition for use disclosed herein, the anti-TCRpV antibody is administered concurrently with or after the administration of the treatment associated with CRS and / or NT. In another aspect, provided herein is a method of expanding, e.g., increasing the number of, an immune cell population comprising, contacting the immune cell population with an antibody molecule, e.g., humanized antibody molecule, which binds, e.g., specifically binds, to a T cell receptor beta variable chain (TCRpV) region (e.g., anti-TCRpV antibody molecule described herein or a multispecific molecule comprising an anti-TCRpV antibody molecule described herein), thereby expanding the immune cell population. In some embodiments, the expansion occurs in vivo or ex vivo (e.g., in vitro). In an aspect, provided herein is a method of evaluating a subject having a cancer, comprising acquiring a value of the status of a TCRpV molecule for the subject, wherein said value comprises a measure of the presence of, e.g., level or activity of, a TCRpV molecule in a sample from the subject, wherein the value of the status of a TCRpV molecule is higher, e.g., increased, in a sample from the subject compared to a reference value, e.g., a value from a healthy subject, e.g., a subject that does not have cancer. In another aspect, the disclosure provides a method of treating a subject having a cancer, the method comprising (i) acquiring a value of the status of a TCRpV molecule for the subject, wherein said value comprises a measure of the presence of, e.g., level or activity of, a TCRpV molecule in a sample from the subject, and (ii) responsive to said value, administering an effective amount of an anti- TCRpV antibody molecule described herein (e.g., a TCRpV agonist) to the subject, thereby treating the cancer. In some embodiments, the value is higher, e.g., increased, in a sample from the subject compared to a reference value, e.g., a value from a healthy subject, e.g., a subject that does not have cancer. In a related aspect, the disclosure provides a composition comprising an anti- TCRpV antibody molecule for use in the treatment of a subject having a cancer, comprising (i) acquiring a value of the status of a TCRpV molecule for the subject, wherein said value comprises a measure of the presence of, e.g., level or activity of, a TCRpV molecule in a sample from the subject, and (ii) responsive to said value, administering an effective amount of an anti- TCRpV antibody molecule described herein (e.g., a TCRpV agonist) to the subject. In an aspect, provided herein is method of evaluating a subject for the presence of a cancer, the method comprising: (i) acquiring a value of the status of one or more TCRpV molecules for the subject, e.g., in a biological sample from the subject, wherein said value comprises a measure of the presence of, e.g., level or activity of, a TCRpV molecule in a sample from the subject, and (ii) determining whether the value for the one or more TCRpV molecules is higher, e.g., increased, in a sample from the subject compared to a reference value, e.g., a value from a healthy subject, e.g., a subject that does not have cancer, wherein a value that is higher, e.g., increased, in the subject relative to the reference, e.g., healthy subject, is indicative of the presence of cancer in the subject. In another aspect, the disclosure provides, a method of treating a subject having cancer, the method comprising: (i) acquiring a value of the status of one or more TCRpV molecules for the subject, e.g., in a biological sample from the subject, wherein said value comprises a measure of the presence of, e.g., level or activity of, a TCRpV molecule in a sample from the subject; (ii) determining whether the value for the one or more TCRpV molecules is higher, e.g., increased, in a sample from the subject compared to a reference value, e.g., a value from a healthy subject, e.g., a subject that does not have cancer, and (iii) if a value that is higher, e.g., increased, in the subject relative to the reference value is determined, administering an effective amount of an anti- TCRpV antibody molecule, e.g., as described herein (e.g., a TCRPV agonist), to the subject, thereby treating the cancer. In a related aspect, provided herein is a composition comprising anti- TCRpV antibody molecule for use in a method of treating a subject having a cancer, comprising (i) acquiring a value of the status of one or more TCRpV molecules for the subject, e.g., in a biological sample from the subject, wherein said value comprises a measure of the presence of, e.g., level or activity of, a TCRpV molecule in a sample from the subject; (ii) determining whether the value for the one or more TCRpV molecules is higher, e.g., increased, in a sample from the subject compared to a reference value, e.g., a value from a healthy subject, e.g., a subject that does not have cancer, and (iii) if a value that is higher, e.g., increased, in the subject relative to the reference value is determined, administering an effective amount of an anti- TCRpV antibody molecule, e.g., as described herein (e.g., a TCRpV agonist), to the subject. In some embodiments of any of the methods of treatment, or composition for use disclosed herein, the status is indicative of the subject having cancer, or a symptom thereof. In some embodiments of any of the methods of treatment or composition for use disclosed herein, the status is indicative of responsiveness to a therapy, e.g., a therapy comprising an anti-TCRpV antibody molecule, e.g., as described herein. In some embodiments of any of the methods of treatment or composition for use disclosed herein, the value of the status is determined, e.g., measured, by an assay described herein. In yet another aspect, provided herein is a method of treating a subject having a cancer, comprising administering to the subject an effective amount of an anti-TCRBV antibody molecule described herein, wherein the subject has a higher, e.g., increased, level or activity of one or more TCRBV molecules, e.g., as described herein, compared to a reference level or activity of one or more TCRBV molecules, e.g., in a healthy subject, e.g., a subject not having a cancer In an aspect, the disclosure provides, method of treating a subject having a cancer, comprising (i) isolating a biological sample from the subject; e.g., a peripheral blood sample, biopsy sample, or bone marrow sample; and (ii) acquiring a value of the status of one or more TCRpV molecules for the subject, e.g., in the biological sample from the subject, wherein said value comprises a measure of the presence of, e.g., level or activity of, a TCRpV molecule in a sample from the subject compared to a reference value, e.g., a sample from a health subject, wherein a value that is higher, e.g., increased, in the subject relative to the reference, e.g., healthy subject, is indicative of the presence of cancer in the subject, (iii) contacting the biological sample with an anti-TCRpV antibody molecule, e.g., in vitro; and (iv) administering the biological sample or a portion thereof from step (iii) to the subject. In another aspect, provided herein is method of expanding a population of immune effector cells from a subject having a cancer, the method comprising: (i) isolating a biological sample comprising a population of immune effector cells from the subject; e.g., a peripheral blood sample, biopsy sample, or bone marrow sample; (ii) acquiring a value of the status of one or more TCRpV molecules for the subject, e.g., in the biological sample from the subject, wherein said value comprises a measure of the presence of, e.g., level or activity of, a TCRpV molecule in a sample from the subject compared to a reference value, e.g., a sample from a health subject, wherein a value that is higher, e.g., increased, in the subject relative to the reference, e.g., healthy subject, is indicative of the presence of cancer in the subject, and (iii) contacting the biological sample comprising a population of immune effector cells with an anti- TCRpV antibody molecule. In some embodiments, the method further comprises administering the population of immune effector cells contacted with the anti-TCRpV antibody molecule to the subject. In some embodiments, a method of expansion, or method of treatment, or composition for use disclosed herein comprises measuring T cell function (e.g., cytotoxic activity, cytokine secretion, or degranulation) in the population of immune effector cells, e.g., compared to a reference population, e.g., an otherwise similar population not contacted with the anti-TCRpV antibody molecule or a population of immune effector cells obtained from a healthy subject (e.g., a subject that does not have a cancer). In some embodiments of any of the methods or composition for use disclosed herein, the biological sample comprising the population of immune effector cells is contacted with an anti-TCRpV antibody molecule that binds to the one or more TCRpV molecules (e.g., the same TCRpV molecule) identified as being higher, e.g., increased, in the biological sample. In some embodiments of any of the methods or composition for use disclosed herein, the biological sample comprising the population of immune effector cells is contacted with an anti-TCRpV antibody molecule that does not bind to the one or more TCRpV molecules (e.g., a different TCRpV molecule) identified as being higher, e.g., increased, in the biological sample. In another aspect, provided herein is a method of identifying one or more TCRpV molecules associated with a cancer, the method comprising: (i) acquiring a status for a plurality of TCRpV molecules in a biological sample from a first subject having the disease and in a biological sample from a second subject not having the disease; and (ii) determining whether the level or activity of one or more of the TCRpV molecules is higher, e.g., increased, in the first subject relative to the second subject; thereby identifying one or more TCRpV molecules associated with the cancer. In some embodiments of any of the methods or composition for use disclosed herein, the one or more of the TCRpV molecules comprises one or more, (e.g., all) of the following TCRpV subfamilies: (i) TCRP V6 subfamily comprising, e.g., one or more of TCRP V6-4*01, TCRP V6-4*02, TCRp V6-9*01, TCRp V6-8*01, TCRp V6-5*01, TCRp V6-6*02, TCRp V6-6*01, TCRp V6-2*01, TCRp V6-3*01 or TCRp V6-l*01; (ii) TCRP V10 subfamily comprising, e.g., one or more of TCRP V10-l*01, TCRP V10-1*02, TCRp V10-3*01 or TCRp V10-2*01; (iii) TCRP V5 subfamily comprising, e.g., one or more of TCRP V5-6*01, TCRP V5-4*01, or TCRp V5-8*01; (iv) TCRP V12 subfamily comprising e.g., one or more of TCRP V12-4*01, TCRP V12-3*01, or TCRp V12-5*01; (v) TCRP V7 subfamily comprising e.g., one or more of TCRP V7-7*01, TCRP V7-6*01, TCRp V7 -8*02, TCRp V7 -4*01, TCRp V7-2*02, TCRp V7-2*03, TCRp V7-2*01, TCRp V7-3*01, TCRp V7-9*03, or TCRp V7-9*01; (vi) TCRP Vil subfamily comprising e.g., one or more of TCRP VI 1-1*01, TCRP VI1-2*01 or TCRp VI 1-3*01; (vii) TCRP V14 subfamily comprising TCRP V14*01; (viii) TCRP V16 subfamily comprising TCRP VI6*01; (ix) TCRP VI8 subfamily comprising TCRP VI8*01; (x) TCRP V9 subfamily comprising T e.g., one or more of CRP V9*01 or TCRP V9*02; (xi) TCRP V13 subfamily comprising TCRP V13*01; (xii) TCRP V4 subfamily comprising e.g., one or more of e.g., one or more of TCRP V4-2*01, TCRp V4-3*01, or TCRp V4-l*01; (xiii) TCRP V3 subfamily comprising TCRP V3-l*01; (xiv) TCRP V2 subfamily comprising TCRP V2*01; (xv) TCRP V15 subfamily comprising TCRP V15*01; (xvi) TCRP V30 subfamily comprising e.g., one or more of TCRP V30*01, or TCRP V30*02; (xvii) TCRP V19 subfamily comprising e.g., one or more of TCRP V19*01, or TCRP V19*02; (xviii) TCRP V27 subfamily comprising TCRP V27*01; (xix) TCRP V28 subfamily comprising TCRP V28*01; (xx) TCRP V24 subfamily comprising TCRP V24-l*01; (xxi) TCRP V20 subfamily comprising e.g., one or more of TCRP V20-l*01, or TCRP V20-l*02; (xxii) TCRP V25 subfamily comprising TCRP V25-l*01; or (xxiii) TCRP V29 subfamily comprising TCRP V29-l*01; (xxiv) TCRp V21 subfamily; (xxv) TCRp VI subfamily; (xxvi) TCRp V17 subfamily; (xvii) TCRP V23 subfamily; or (xviii) TCRP V26 subfamily. In some embodiments of any of the methods or composition for use disclosed herein, the cancer is a solid tumor including but not limited to: melanoma, pancreatic (e.g., pancreatic adenocarcinoma) cancer, breast cancer, colorectal cancer (CRC), lung cancer (e.g., small or nonsmall cell lung cancer), skin cancer, ovarian cancer, or liver cancer. In some embodiments of any of the methods or composition for use disclosed herein, the cancer is a hematological cancer including, but not limited to: a B-cell or T cell malignancy, e.g., Hodgkin’s lymphoma, Non-Hodgkin’s lymphoma (e.g., B cell lymphoma, diffuse large B cell lymphoma (DLBCL), follicular lymphoma, chronic lymphocytic leukemia (B-CLL), mantle cell lymphoma, marginal zone B-cell lymphoma, Burkitt lymphoma, lymphoplasmacytic lymphoma, hairy cell leukemia), acute myeloid leukemia (AML), chronic myeloid leukemia, myelodysplastic syndrome, multiple myeloma, and acute lymphocytic leukemia. In some embodiments of a method of expansion, or method of treatment, or composition for use disclosed herein, a higher, e.g., increased, level or activity of one or more TCRpV molecules in a subject, e.g., in a sample from a subject, is indicative of a bias, e.g., a preferential expansion, e.g., clonal expansion, of T cells expressing said one or more TCRpV molecules in the subject. In some embodiments, a subject having a cancer, e.g., as disclosed herein, has a higher, e.g., increased, level or activity of one or more TCRpV molecules associated with the cancer. In some embodiments, the TCRpV molecule is associated with, e.g., recognizes, a cancer antigen, e.g., a cancer associated antigen or a neoantigen. In some embodiments of any of the methods or composition for use disclosed herein, the subject has B-CLL. In some embodiments, a subject having B-CLL has a higher, e.g., increased, level or activity of one or more TCRpV molecules, e.g., one or more TCRpV molecules comprising: (i) TCRP V6 subfamily comprising, e.g., TCRP V6-4*01, TCRP V6-4*02, TCRP V6-9*01, TCRp V6-8*01, TCRp V6-5*01, TCRp V6-6*02, TCRp V6-6*0I, TCRp V6-2*01, TCRp V6-3*01 or TCRp V6-l*01; (ii) TCRp V5 subfamily comprising TCRp V5-6*01, TCRp V5-4*01, or TCRp V5-8*01; (iii) TCRp V3 subfamily comprising TCRp V3-l*01; (iv) TCRp V2 subfamily comprising TCRP V2*01; or (v) TCRP V19 subfamily comprising TCRP V19*01, or TCRp VI9*02. In some embodiments, a subject having B-CLL has a higher, e.g., increased, level or activity of a TCRP V6 subfamily comprising, e.g., TCRP V6-4*01, TCRP V6-4*02, TCRP V6-9*01, TCRp V6-8*01, TCRp V6-5*01, TCRp V6-6*02, TCRp V6-6*01, TCRp V6-2*01, TCRp V6-3*01 or TCRP V6-l*01. In some embodiments, the subject is administered an anti-TCRpV molecule (e.g., an agonistic anti- TCRpV molecule as described herein) that binds to one or more members of the TCRP V6 subfamily. In some embodiments, administration of the an anti-TCRpV molecule results in expansion of immune cells expressing one or more members of the TCRP V6 subfamily. In some embodiments, a subject having B-CLL has a higher, e.g., increased, level or activity of a TCRP V5 subfamily comprising TCRP V5-6*01, TCRP V5-4*01, or TCRP V5-8*01. In some embodiments, the subject is administered an anti-TCRpV molecule (e.g., an agonistic anti- TCRpV molecule as described herein) that binds to one or more members of the TCRP V5 subfamily. In some embodiments, administration of the an anti-TCRpV molecule results in expansion of immune cells expressing one or more members of the TCRP V5 subfamily. In some embodiments, a subject having B-CLL has a higher, e.g., increased, level or activity of a TCRP V3 subfamily comprising TCRP V3-l*01. In some embodiments, the subject is administered an anti-TCRpV molecule (e.g., an agonistic anti- TCRpV molecule as described herein) that binds to one or more members of the TCRP V3 subfamily. In some embodiments, administration of the an anti-TCRpV molecule results in expansion of immune cells expressing one or more members of the TCRP V3 subfamily. In some embodiments, a subject having B-CLL has a higher, e.g., increased, level or activity of a TCRP V2 subfamily comprising TCRP V2*01. In some embodiments, the subject is administered an anti-TCRpV molecule (e.g., an agonistic anti- TCRpV molecule as described herein) that binds to one or more members of the TCRP V2 subfamily. In some embodiments, administration of the an anti-TCRpV molecule results in expansion of immune cells expressing one or more members of the TCRP V2 subfamily. In some embodiments, a subject having B-CLL has a higher, e.g., increased, level or activity of a TCRP V19 subfamily comprising TCRP V19*01, or TCRP V19*02. In some embodiments, the subject is administered an anti-TCRpV molecule (e.g., an agonistic anti-TCRBV molecule as described herein) that binds to one or more members of the TCRP V19 subfamily. In some embodiments, administration of the an anti-TCRpV molecule results in expansion of immune cells expressing one or more members of the TCRP V19 subfamily. In some embodiments of any of the methods or composition for use disclosed herein, the subject has melanoma. In some embodiments, a subject having melanoma has a higher, e.g., increased, level or activity of one or more TCRpV molecules, e.g., one or more TCRpV molecules comprising the TCRP V6 subfamily comprising, e.g., TCRP V6-4*01, TCRP V6-4*02, TCRp V6-9*01, TCRp V6-8*01, TCRp V6-5*01, TCRp V6-6*02, TCRp V6-6*01, TCRp V6-2*01, TCRP V6-3*01 or TCRP V6-1*01. In some embodiments, the subject is administered an anti-TCRpV molecule (e.g., an agonistic anti-TCRpV molecule as described herein) that binds to one or more members of the TCRP V6 subfamily. In some embodiments, administration of the an anti-TCRpV molecule results in expansion of immune cells expressing one or more members of the TCRP V6 subfamily. In some embodiments of any of the methods or composition for use disclosed herein, the subject has DLBCL. In some embodiments, a subject having melanoma has a higher, e.g., increased, level or activity of one or more TCRpV molecules, e.g., one or more TCRpV molecules comprising: (i) TCRP V13 subfamily comprising TCRP V13*01; (ii) TCRP V3 subfamily comprising TCRP V3-l*01; or (iii) TCRP V23 subfamily. In some embodiments, a subject having DLBCL has a higher, e.g., increased, level or activity of a TCRP V13 subfamily comprising TCRP V13*01. In some embodiments, the subject is administered an anti-TCRpV molecule (e.g., an agonistic anti- TCRpV molecule as described herein) that binds to one or more members of the TCRP V13 subfamily. In some embodiments, administration of the an anti-TCRpV molecule results in expansion of immune cells expressing one or more members of the TCRP V13 subfamily. In some embodiments, a subject having DLBCL has a higher, e.g., increased, level or activity of a TCRP V3 subfamily comprising TCRP V3-l*01. In some embodiments, the subject is administered an anti-TCRpV molecule (e.g., an agonistic anti- TCRPV molecule as described herein) that binds to one or more members of the TCRP V3 subfamily. In some embodiments, administration of the an anti-TCRpV molecule results in expansion of immune cells expressing one or more members of the TCRP V3 subfamily. In some embodiments, a subject having DLBCL has a higher, e.g., increased, level or activity of a TCRP V23 subfamily. In some embodiments, the subject is administered an anti-TCRpV molecule (e.g., an agonistic anti- TCRPV molecule as described herein) that binds to one or more members of the TCRP V23 subfamily. In some embodiments, administration of the an anti-TCRpV molecule results in expansion of immune cells expressing one or more members of the TCRP V23 subfamily. In some embodiments of any of the methods or composition for use disclosed herein, the subject has CRC. In some embodiments, a subject having melanoma has a higher, e.g., increased, level or activity of one or more TCRPV molecules, e.g., one or more TCRPV molecules comprising: (i) TCRP V19 subfamily comprising TCRP V19*01, or TCRP V19*02; (ii) TCRp V12 subfamily comprising TCRp V12-4*01, TCRp V12-3*01, or TCRp V12-5*01; (iii) TCRP V16 subfamily comprising TCRP V16*01; or (iv) TCRP V21 subfamily. In some embodiments, a subject having CRC has a higher, e.g., increased, level or activity of a TCRP V19 subfamily comprising TCRP V19*01, or TCRP V19*02. In some embodiments, the subject is administered an anti-TCRpV molecule (e.g., an agonistic anti-TCRpV molecule as described herein) that binds to one or more members of the TCRP V19 subfamily. In some embodiments, administration of the an anti-TCRpV molecule results in expansion of immune cells expressing one or more members of the TCRP V19 subfamily. In some embodiments, a subject having CRC has a higher, e.g., increased, level or activity of a TCRP V12 subfamily comprising TCRP V12-4*01, TCRP V12-3*01, or TCRP V12-5*01. In some embodiments, the subject is administered an anti-TCRpV molecule (e.g., an agonistic anti- TCRpV molecule as described herein) that binds to one or more members of the TCRP V12 subfamily. In some embodiments, administration of the an anti-TCRpV molecule results in expansion of immune cells expressing one or more members of the TCRP V12 subfamily. In some embodiments, a subject having CRC has a higher, e.g., increased, level or activity of a TCRP V16 subfamily comprising TCRP V16*0I. In some embodiments, the subject is administered an anti-TCRpV molecule (e.g., an agonistic anti- TCRpV molecule as described herein) that binds to one or more members of the TCRP V16 subfamily. In some embodiments, administration of the an anti-TCRpV molecule results in expansion of immune cells expressing one or more members of the TCRP V16 subfamily. In some embodiments, a subject having CRC has a higher, e.g., increased, level or activity of a TCRP V21 subfamily. In some embodiments, the subject is administered an anti-TCRpV molecule (e.g., an agonistic anti- TCRpV molecule as described herein) that binds to one or more members of the TCRP V21 subfamily. In some embodiments, administration of the an anti-TCRpV molecule results in expansion of immune cells expressing one or more members of the TCRP V21 subfamily. Alternatively or in combination with any of the embodiments disclosed herein, provided herein is an anti-TCRpV antibody molecule which: (i) binds specifically to an epitope on TCRpV, e.g., the same or similar epitope as the epitope recognized by an anti-TCRpV antibody molecule as described herein, e.g., a second anti-TCRpV antibody molecule; (ii) shows the same or similar binding affinity or specificity, or both, as an anti-TCRpV antibody molecule as described herein, e.g., a second anti-TCRpV antibody molecule; (iii) inhibits, e.g., competitively inhibits, the binding of an anti-TCRpV antibody molecule as described herein, e.g., a second anti-TCRpV antibody molecule; (iv) binds the same or an overlapping epitope with an anti-TCRpV antibody molecule as described herein, e.g., a second anti-TCRpV antibody molecule; or (v) competes for binding, and / or binds the same epitope, with an anti-TCRpV antibody molecule as described herein, e.g., a second anti-TCRpV antibody molecule, In some embodiments, the second anti-TCRpV antibody molecule comprises an antigen binding domain chosen from Table 1 or Table 2, or a sequence substantially identical thereto. In some embodiments, the second anti-TCRpV antibody molecule comprises an antigen binding domain, comprising: a heavy chain complementarity determining region 1 (HC CDR1), a heavy chain complementarity determining region 2 (HC CDR2) and / or a heavy chain complementarity determining region 3 (HC CDR3) of SEQ ID NO: 1 or SEQ ID NO: 9; and / or a light chain complementarity determining region 1 (LC CDR1), a light chain complementarity determining region 2 (LC CDR2), and / or a light chain complementarity determining region 3 (LC CDR3) of SEQ ID NO: 2, SEQ ID NO: 10 or SEQ ID NO: 11. In some embodiments of any of the compositions or methods disclosed herein, the anti-TCRpV antibody molecule comprises an antigen binding domain comprising: (i) a heavy chain complementarity determining region 1 (HC CDR1), a heavy chain complementarity determining region 2 (HC CDR2) and / or a heavy chain complementarity determining region 3 (HC CDR3) of SEQ ID NO: 1 or SEQ ID NO: 9, or a sequence disclosed in Table 1; or (ii) a light chain complementarity determining region 1 (LC CDR1), a light chain complementarity determining region 2 (LC CDR2), and / or a light chain complementarity determining region 3 (LC CDR3) of SEQ ID NO: 2, SEQ ID NO: 10 or SEQ ID NO: 11, or a sequence disclosed in Table 1. In some embodiments of any of the compositions or methods disclosed herein, the anti-TCRpV antibody molecule comprises an antigen binding domain comprising a light chain variable region (VL) comprising one, two or all (e.g., three) of a LC CDR1, a LC CDR2 and a LC CDR3 of SEQ ID NO: 2, SEQ ID NO: 10 or SEQ ID NO: 11. In some embodiments of any of the compositions or methods disclosed herein, the anti-TCRpV antibody molecule comprises an antigen binding domain comprising a heavy chain variable region (VH) comprising one, two or all (e.g., three) of a HC CDR1, a HC CDR2 and a HC CDR3 of SEQ ID NO: 1 or SEQ ID NO: 9. In some embodiments of any of the compositions or methods disclosed herein, the anti-TCRpV antibody molecule comprises an antigen binding domain comprising: (i) a VL comprising: a LC CDR1 amino acid sequence of SEQ ID NO: 6 (or an amino acid sequence with not more than 1, 2, 3 or 4 modifications, e.g., substitutions, additions or deletions thereof), a LC CDR2 amino acid sequence of SEQ ID NO:7 (or an amino acid sequence with not more than 1, 2, 3 or 4 modifications, e.g., substitutions, additions or deletions thereof), and / or a LC CDR3 amino acid sequence of SEQ ID NO:8 (or an amino acid sequence with not more than 1, 2, 3 or 4 modifications, e.g., substitutions, additions or deletions thereof); and / or (ii) a VH comprising: a HC CDR1 amino acid sequence of SEQ ID NO: 3 (or an amino acid sequence with not more than 1, 2, 3 or 4 modifications, e.g., substitutions, additions or deletions thereof), a HC CDR2 amino acid sequence of SEQ ID NO:4 (or an amino acid sequence with not more than 1, 2, 3 or 4 modifications, e.g., substitutions, additions or deletions thereof), and / or a HC CDR3 amino acid sequence of SEQ ID NO:5 (or an amino acid sequence with not more than 1, 2, 3 or 4 modifications, e.g., substitutions, additions or deletions thereof). In some embodiments of any of the compositions or methods disclosed herein, the anti-TCRpV antibody molecule comprises an antigen binding domain comprising: a variable heavy chain (VH) of SEQ ID NO: 9, or a sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity thereto; and / or a variable light chain (VL) of SEQ ID NO: 10 or SEQ ID NO: 11, or a sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity thereto. In some embodiments of any of the compositions or methods disclosed herein, the anti-TCRpV antibody molecule comprises an antigen binding domain comprising the VH amino acid sequence of SEQ ID NO: 9 and the VL amino acid sequence of SEQ ID NO: 10. In some embodiments of any of the compositions or methods disclosed herein, the anti-TCRpV antibody molecule comprises an antigen binding domain comprising the VH amino acid sequence of SEQ ID NO: 9 and the VL amino acid sequence of SEQ ID NO: 11. In some embodiments of any of the compositions or methods disclosed herein, the anti-TCRpV antibody molecule comprises a heavy chain comprising a framework region, e.g., framework region 3 (FR3), comprising one or both of: (i) a Threonine at position 73, e.g., a substitution at position 73 according to Kabat numbering, e.g., a Glutamic Acid to Threonine substitution; or (ii) a Glycine at position, e.g., a substitution at position 94 according to Kabat numbering, e.g., a Arginine to Glycine substitution. In some embodiments, the substitution is relative to a human germline heavy chain framework region sequence. In some embodiments of any of the compositions or methods disclosed herein, the anti-TCRPV antibody molecule comprises a light chain comprising a framework region, e.g., framework region 1 (FR1), comprising a Phenylalanine at position 10, e.g., a substitution at position 10 according to Kabat numbering, e.g., a Serine to Phenyalanine substitution. In some embodiments, the substitution is relative to a human germline light chain framework region sequence. In some embodiments of any of the compositions or methods disclosed herein, the anti-TCRpV antibody molecule comprises a light chain comprising a framework region, e.g., framework region 2 (FR2), comprising one or both of: (i) a Histidine at position 36, e.g., a substitution at position 36 according to Kabat numbering, e.g., a Tyrosine to Histidine substitution; or (ii) an Alanine at position 46, e.g., a substitution at position 46 according to Kabat numbering, e.g., a Arginine to Alanine substitution. In some embodiments, the substitution is relative to a human germline light chain framework region sequence. In some embodiments of any of the compositions or methods disclosed herein, the anti-TCRpV antibody molecule comprises a light chain comprising a framework region, e.g., framework region 3 (FR3), comprising a Phenylalanine at position 87, e.g., a substitution at position 87 according to Kabat numbering, e.g., a Tyrosine to Phenyalanine substitution. In some embodiments, the substitution is relative to a human germline light chain framework region sequence. In some embodiments of any of the compositions or methods disclosed herein, the anti-TCRpV antibody molecule binds to TCRp V6, e.g., TCRp V6-4*01, TCRp V6-4*02, TCRp V6-9*01, TCRp V6-8*01, TCRp V6-5*01, TCRp V6-6*02, TCRp V6-6*01, TCRp V6-2*01, TCRp V6-3*01 or TCRP V6-l*01. In some embodiments the anti-TCRpV antibody molecule binds to TCRp V6-5*01. In some embodiments, TCRp V6, e.g., TCRp V6-4*01, TCRp V6-4*02, TCRp V6-9*01, TCRp V6-8*01, TCRp V6-5*01, TCRp V6-6*02, TCRp V6-6*01, TCRp V6-2*01, TCRp V6-3*01 or TCRP V6-l*01, is recognized, e.g., bound, by SEQ ID NO: 1 and / or SEQ ID NO: 2. In some embodiments, TCRp V6, e.g., TCRp V6-4*01, TCRp V6-4*02, TCRp V6-9*01, TCRp V6-8*01, TCRp V6-5*01, TCRp V6-6*02, TCRp V6-6*01, TCRp V6-2*01, TCRp V6-3*01 or TCRP V6-l*01, is recognized, e.g., bound, by SEQ ID NO: 9 and / or SEQ ID NO: 10. In some embodiments, TCRp V6, e.g., TCRp V6-4*01, TCRp V6-4*02, TCRp V6-9*01, TCRp V6-8*01, TCRp V6-5*01, TCRp V6-6*02, TCRp V6-6*01, TCRp V6-2*01, TCRp V6-3*01 or TCRP V6-l*01, is recognized, e.g., bound, by SEQ ID NO: 9 and / or SEQ ID NO: 11. In some embodiments, TCRP V6-5*01 is recognized, e.g., bound by SEQ ID NO: 9 and / or SEQ ID NO: 10, or a sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity thereto. In some embodiments, TCRP V6-5*01 is recognized, e.g., bound by SEQ ID NO: 9 and / or SEQ ID NO: 11, or a sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity thereto. In some embodiments of any of the compositions or methods disclosed herein, the anti-TCRpV antibody molecule comprises an antigen binding domain comprising: (i) a heavy chain complementarity determining region (HC CDR1), a HC CDR2 and / or a HC CDR3 of SEQ ID NO: 15, SEQ ID NO: 23, SEQ ID NO: 24 or SEQ IC NO: 25, or a sequence disclosed in Table 2; and / or (ii) a light chain complementarity determining region 1 (LC CDR1), a LC CDR2, and / or a LC CDR3 of SEQ ID NO: 16, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29 or SEQ ID NO:30, or a sequence disclosed in Table 2. In some embodiments of any of the compositions or methods disclosed herein, the anti-TCRpV antibody molecule comprises an antigen binding domain comprising a light chain variable region (VL) comprising one, two or all of a LC CDR1, a LC CDR2 and a LC CDR3 of SEQ ID NO: 16, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29 or SEQ ID NO:30. In some embodiments of any of the compositions or methods disclosed herein, the anti-TCRpV antibody molecule comprises an antigen binding domain comprising a heavy chain variable region (VH) comprising one, two or all of a HC CDR1, a HC CDR2 and a HC CDR3 of SEQ ID NO: 15, SEQ ID NO: 23, SEQ ID NO: 24 or SEQ ID NO: 25. In some embodiments of any of the compositions or methods disclosed herein, the anti-TCRpV antibody molecule comprises an antigen binding domain comprising: (i) a VL comprising: a LC CDR1 amino acid sequence of SEQ ID NO: 20 (or an amino acid sequence with not more than 1, 2, 3 or 4 modifications, e.g., substitutions, additions or deletions thereof), a LC CDR2 amino acid sequence of SEQ ID NO:21 (or an amino acid sequence with not more than 1, 2, 3 or 4 modifications, e.g., substitutions, additions or deletions thereof), and / or a LC CDR3 amino acid sequence of SEQ ID NO:22 (or an amino acid sequence with not more than 1, 2, 3 or 4 modifications, e.g., substitutions, additions or deletions thereof); and / or (ii) a VH comprising: a HC CDR1 amino acid sequence of SEQ ID NO: 17 (or an amino acid sequence with not more than 1, 2, 3 or 4 modifications, e.g., substitutions, additions or deletions thereof), a HC CDR2 amino acid sequence of SEQ ID NO: 18 (or an amino acid sequence with not more than 1, 2, 3 or 4 modifications, e.g., substitutions, additions or deletions thereof), and / or a HC CDR3 amino acid sequence of SEQ ID NO: 19 (or an amino acid sequence with not more than 1, 2, 3 or 4 modifications, e.g., substitutions, additions or deletions thereof). In some embodiments of any of the compositions or methods disclosed herein, the anti-TCRpV antibody molecule comprises an antigen binding domain comprising: a variable heavy chain (VH) of SEQ ID NO: 23, SEQ ID NO: 24 or SEQ ID NO: 25, or a sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity thereto; and / or a variable light chain (VL) of SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29 or SEQ ID NO:30, or a sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity thereto. In some embodiments of any of the compositions or methods disclosed herein, the anti-TCRpV antibody molecule comprises a light chain comprising a framework region, e.g., framework region 1 (FR1), comprising one, two or all (e.g., three) of: (i) an Aspartic Acid at position 1, e.g., a substitution at position 1 according to Kabat numbering, e.g., a Alanine to Aspartic Acid substitution; or (ii) an Asparagine at position 2, e.g., a substitution at position 2 according to Kabat numbering, e.g., a Isoleucine to Asparagine substitution, a Serine to Asparagine substitution, or a Tyrosine to Asparagine substitution; or (iii) a Leucine at position 4, e.g., a substitution at position 4 according to Kabat numbering, e.g., a Methionine to Leucine substitution. In some embodiments, the substitution is relative to a human germline light chain framework region sequence. In some embodiments of any of the compositions or methods disclosed herein, the anti-TCRpV antibody molecule comprises a light chain comprising a framework region, e.g., framework region 3 (FR3), comprising one, two or all (e.g., three) of: (i) a Glycine as position 66, e.g., a substitution at position 66 according to Kabat numbering, e.g., a Lysine to Glycine substitution, or a Serine to Glycine substitution; or (ii) an Asparagine at position 69, e.g., a substitution at position 69 according to Kabat numbering, e.g., a Threonine to Asparagine substitution; or (iii) a Tyrosine at position 71, e.g., a substitution at position 71 according to Kabat numbering, e.g., a Phenylalanine to Tyrosine substitution, or an Alanine to Tyrosine substitution. In some embodiments, the substitution is relative to a human germline light chain framework region sequence. In some embodiments of any of the compositions or methods disclosed herein, the anti-TCRpV antibody molecule binds to TCRp V12, e.g., TCRp V12-4*01, TCRp V12-3*01, or TCRP V12-5*01. In some embodiments the anti-TCRpV antibody molecule binds to TCRP V12-4*01 or TCRp V12-3*01. In some embodiments, TCRp V12, e.g., TCRp V12-4*01, TCRp V12-3*01, or TCRp V12-5*01 is recognized, e.g., bound, by SEQ ID NO: 15 and / or SEQ ID NO: 16. In some embodiments, TCRp V12, e.g., TCRp V12-4*01, TCRp V12-3*01, or TCRp V12-5*01, is recognized, e.g., bound, by any one of SEQ ID NOs 23-25, and / or any one of SEQ ID NO: 2630, or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity thereto. In some embodiments TCRP V12-4*01 is recognized, e.g., bound, by any one of SEQ ID NOs 23-25, and / or any one of SEQ ID NO: 26-30, or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity thereto. In some embodiments TCRP V12-3*01 is recognized, e.g., bound, by any one of SEQ ID NOs 23-25, and / or any one of SEQ ID NO: 26-30, or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity thereto. In some embodiments of any of the compositions or methods disclosed herein, the anti-TCRpV antibody molecule comprises the anti-TCRpV antibody molecule comprises an antigen binding domain comprising a single chain Fv (scFv) or a Fab. In some embodiments of any of the compositions or methods disclosed herein, the anti-TCRpV antibody molecule comprises binds to a conformational or a linear epitope on the T cell. In some embodiments of any of the compositions or methods disclosed herein, the tumor comprises an antigen, e.g., a tumor antigen, e.g., a tumor associated antigen or a neoantigen. In some embodiments, the anti-TCRpV antibody molecule recognize, e.g., bind to, the tumor antigen. In some embodiments of any of the compositions or methods disclosed herein, the anti-TCRpV antibody molecule is a full antibody (e.g., an antibody that includes at least one, and preferably two, complete heavy chains, and at least one, and preferably two, complete light chains), or an antigen-binding fragment (e.g., a Fab, F(ab')2, Fv, a single chain Fv fragment, a single domain antibody, a diabody (dAb), a bivalent antibody, or bispecific antibody or fragment thereof, a single domain variant thereof, a camelid antibody, or a rat-derived VH. In some embodiments of any of the compositions or methods disclosed herein, the anti-TCRpV antibody molecule comprises the anti-TCRpV antibody molecule comprises one or more heavy chain constant regions chosen from IgGl, IgG2, IgG3, IgGAl, IgGA2, IgM, IgJ or IgG4, or a fragment thereof, e.g., as disclosed in Table 3. In some embodiments of any of the compositions or methods disclosed herein, the anti-TCRpV antibody molecule comprises a heavy chain constant region of an IgM or a fragment thereof, optionally wherein the IgM heavy chain constant region comprises the sequence of SEQ ID NO: 73, or a sequence with at least 85%, 90%, 95%, or 99% sequence identity thereto. In some embodiments of any of the compositions or methods disclosed herein, the anti-TCRpV antibody molecule comprising an IgM constant region, further comprises a heavy chain constant region of an IgJ or a fragment thereof, optionally wherein the IgJ heavy chain constant region comprises the sequence of SEQ ID NO: 76 or a sequence with at least 85%, 90%, 95%, or 99% sequence identity thereto. In some embodiments of any of the compositions or methods disclosed herein, the anti-TCRpV antibody molecule comprises a heavy chain constant region of an IgJ or a fragment thereof, optionally wherein the IgJ heavy chain constant region comprises the sequence of SEQ ID NO: 76 or a sequence with at least 85%, 90%, 95%, or 99% sequence identity thereto. In some embodiments of any of the compositions or methods disclosed herein, the anti-TCRpV antibody molecule comprises a heavy chain constant region of an IgGAl, or a fragment thereof, optionally wherein the IgGAl heavy chain constant region comprises the sequence of SEQ ID NO: 74, or a sequence with at least 85%, 90%, 95%, or 99% sequence identity thereto. In some embodiments of any of the compositions or methods disclosed herein, the anti-TCRpV antibody molecule comprises a heavy chain constant region of an IgGA2, or a fragment thereof, optionally wherein the IgGA2 heavy chain constant region comprises a sequence listed in Table 3, e.g., SEQ ID NO: 75, or a sequence with at least 85%, 90%, 95%, or 99% sequence identity thereto. In some embodiments of any of the compositions or methods disclosed herein, binding of the anti-TCRpV antibody molecule to a TCRpV region results in a cytokine profile, e.g., a cytokine secretion profile, (e.g., comprising one or more cytokines and / or one or more chemokines), that differs from that of a T cell engager that binds to a receptor or molecule other than a TCRpV region (“a non-TCRpV-binding T cell engager”). In some embodiments, the cytokine profile, e.g., cytokine secretion profile, comprises the level and / or activity of one or more cytokines and / or one or more chemokines (e.g., as described herein). In an embodiment, a cytokine profile, e.g., a cytokine secretion profile, comprises the level and / or activity of one or more of: IL-2 (e.g., full length, a variant, or a fragment thereof); IL-lbeta (e.g., full length, a variant, or a fragment thereof); IL-6 (e.g., full length, a variant, or a fragment thereof); TNFa (e.g., full length, a variant, or a fragment thereof); IFNg (e.g., full length, a variant, or a fragment thereof) IL-10 (e.g., full length, a variant, or a fragment thereof); IL-4 (e.g., full length, a variant, or a fragment thereof); TNF alpha (e.g., full length, a variant, or a fragment thereof);IL-12p70 (e.g., full length, a variant, or a fragment thereof); IL-13 (e.g., full length, a variant, or a fragment thereof); IL-8 (e.g., full length, a variant, or a fragment thereof); Eotaxin (e.g., full length, a variant, or a fragment thereof); Eotaxin-3 (e.g., full length, a variant, or a fragment thereof); IL-8 (HA) (e.g., full length, a variant, or a fragment thereof); IP-10 (e.g., full length, a variant, or a fragment thereof); MCP-1 (e.g., full length, a variant, or a fragment thereof); MCP-4 (e.g., full length, a variant, or a fragment thereof); MDC (e.g., full length, a variant, or a fragment thereof); MIP-la (e.g., full length, a variant, or a fragment thereof); MIP-1b (e.g., full length, a variant, or a fragment thereof); TARC (e.g., full length, a variant, or a fragment thereof); GM-CSF (e.g., full length, a variant, or a fragment thereof); IL-12 23p40 (e.g., full length, a variant, or a fragment thereof); IL-15 (e.g., full length, a variant, or a fragment thereof); IL-16 (e.g., full length, a variant, or a fragment thereof); IL-17a (e.g., full length, a variant, or a fragment thereof); IL-la (e.g., full length, a variant, or a fragment thereof); IL-5 (e.g., full length, a variant, or a fragment thereof); IL-7 (e.g., full length, a variant, or a fragment thereof); TNF-beta (e.g., full length, a variant, or a fragment thereof); or VEGF (e.g., full length, a variant, or a fragment thereof). In some embodiments, the cytokine profile, e.g., cytokine secretion profile, comprises one, two, three, four, five, six, seven, or all of the following: (i) increased level, e.g., expression level, and / or activity of IL-2; (ii) reduced level, e.g., expression level, and / or activity ofIL-1P; (iii) reduced level, e.g., expression level, and / or activity of IL-6; (iv) reduced level, e.g., expression level, and / or activity of TNFa; (v) reduced level, e.g., expression level, and / or activity of IL-10; (vi) a delay, e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more hours delay, in increased level, e.g., expression level, and / or activity of IL-2; (vii) a delay, e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 hours delay, in increased level, e.g., expression level, and / or activity of IFNg; or (viii) increased level, e.g., expression level, and / or activity of IL-15, e.g., wherein (i)-(viii) are relative to the cytokine profile, e.g., cytokine secretion profile, of the non-TCRpV-binding T cell engager. In some embodiments, binding of the anti-TCRBV antibody to a TCRpV region results in reduced cytokine storm, e.g., reduced cytokine release syndrome (CRS) and / or neurotoxicity (NT), as measured by an assay of Example 3, e.g., relative to the cytokine storm induced by the non-TCRpV-binding T cell engager. In some embodiments, binding of the anti-TCRBV antibody to a TCRpV region results in one, two, three or all of: (ix) reduced T cell proliferation kinetics; (x) cell killing, e.g., target cell killing, e.g. cancer cell killing, e.g., as measured by an assay of Example 4; (xi) increased Natural Killer (NK) cell proliferation, e.g., expansion; or (xii) expansion, e.g., at least about 1.1-10 fold expansion (e.g., at least about 1.1, 1.2, 1.3, 1.4, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, or 10 fold expansion), of a population of memory T cells, e.g., wherein (ix)-(xii) are relative to the non-TCRpV-binding T cell engager. In some embodiments, an anti-TCRpV antibody molecule disclosed herein recognizes (e.g., binds to), a structurally conserved domain on the TCRpV protein (e.g., as denoted by the circled area in FIG. 24A). In some embodiments, an anti-TCRpV antibody molecule disclosed herein does not recognize, e.g., bind to, an interface of a TCRpV:TCRalpha complex. In some embodiments, an anti-TCRpV antibody molecule disclosed herein does not recognize, e.g., bind to, a constant region of a TCRpV protein. An exemplary antibody that binds to a constant region of a TCRBV region is JOVI.l as described in Viney et al., (Hybridoma. 1992 Dec;l 1(6):701-13). In some embodiments, an anti-TCRpV antibody molecule disclosed herein does not recognize, e.g., bind to, one or more (e.g., all) of a complementarity determining region (e.g., CDR1, CDR2 and / or CDR3) of a TCRpV protein. In some embodiments of any of the compositions or methods disclosed herein, the anti-TCRpV antibody molecule comprises a light chain constant region chosen from the light chain constant regions of kappa or lambda, or a fragment thereof, e.g., as disclosed in Table 3. In some embodiments of any of the compositions or methods disclosed herein, the anti-TCRpV antibody molecule comprises a light chain constant region of a kappa chain, or a fragment thereof, optionally wherein the kappa chain constant region comprises the sequence of SEQ ID NO: 39, or a sequence with at least 85%, 90%, 95%, or 99% sequence identity thereto In some embodiments of any of the compositions or methods disclosed herein, the anti-TCRpV antibody molecule comprises: (i) one or more heavy chain constant regions comprising a heavy chain constant region chosen from from IgGl, IgG2, IgG3, IgGAl, IgGA2, IgG4, IgJ, IgM, IgD, or IgE, or a fragment thereof, e.g., as described in Table 3; and (ii) a light chain constant region comprising a light chain constant region chosen from the light chain constant regions of kappa or lambda, or a fragment thereof, e.g., as described in Table 3. In some embodiments of any of the compositions or methods disclosed herein, the anti-TCRpV antibody molecule comprises or a cell comprising an anti- TCRpV antibody molecule comprises: (i) a heavy chain comprising a variable region (VH), e.g., a VH of an antibody disclosed herein; and / or one or more heavy chain constant regions, e.g., as disclosed herein; and / or (ii) a light chain comprising a variable light (VL), e.g., a VL of an antibody disclosed herein; and / or one or more light chain constant regions, e.g., as disclosed herein. In some embodiments of any of the compositions or methods disclosed herein, the anti-TCRpV antibody molecule comprises, or a cell comprising an anti- TCRpV antibody molecule comprises: (i) a heavy chain comprising a heavy chain constant region comprising: (a) an IgM heavy chain constant region or a fragment thereof, comprising the sequence of SEQ ID NO: 73, or a sequence with at least 85%, 90%, 95%, or 99% sequence identity thereto; (b) an IgGAl heavy chain constant region or a fragment thereof, comprising the sequence of SEQ ID NO: 74, or a sequence with at least 85%, 90%, 95%, or 99% sequence identity thereto; or (c) an IgGA2 heavy chain constant region or a fragment thereof, comprising the sequence of SEQ ID NO: 75, or a sequence with at least 85%, 90%, 95%, or 99% sequence identity thereto; and (ii) a light chain comprising a light chain constant region comprising a kappa chain constant region comprising the sequence of SEQ ID NO: 39, or a sequence with at least 85%, 90%, 95%, or 99% sequence identity thereto, optionally wherein, the anti-TCRpV antibody molecule further comprises an IgJ heavy chain constant region or a fragment thereof, wherein the IgJ heavy chain constant region comprises the sequence of SEQ ID NO: 76 or a sequence with at least 85%, 90%, 95%, or 99% sequence identity thereto. In some embodiments of any of the compositions or methods disclosed herein, the anti-TCRpV antibody molecule comprises, or a cell comprising an anti- TCRpV antibody molecule comprises: (i) a heavy chain comprising: a VH chosen from a VH of Table 1 or 2, or a sequence with at least 85%, 90%, 95%, or 99% sequence identity thereto; and a heavy chain constant region comprising: (a) an IgM heavy chain constant region or a fragment thereof, comprising the sequence of SEQ ID NO: 73, or a sequence with at least 85%, 90%, 95%, or 99% sequence identity thereto; (b) an IgGAl heavy chain constant region or a fragment thereof, comprising the sequence of SEQ ID NO: 74, or a sequence with at least 85%, 90%, 95%, or 99% sequence identity thereto; or (c) an IgGA2 heavy chain constant region or a fragment thereof, comprising the sequence of SEQ ID NO: 75, or a sequence with at least 85%, 90%, 95%, or 99% sequence identity thereto; and (ii) a light chain comprising: a VL chosen from a VL of Table 1 or 2, or a sequence with at least 85%, 90%, 95%, or 99% sequence identity thereto; and a light chain constant region comprising a kappa chain constant region comprising the sequence of SEQ ID NO: 39, or a sequence with at least 85%, 90%, 95%, or 99% sequence identity thereto, optionally wherein, the anti-TCRpV antibody molecule further comprises an IgJ heavy chain constant region or a fragment thereof, wherein the IgJ heavy chain constant region comprises the sequence of SEQ ID NO: 76 or a sequence with at least 85%, 90%, 95%, or 99% sequence identity thereto. In some embodiments of any of the methods disclosed herein, the anti-TCRpV antibody molecule binds to one or more (e.g., all) of the following TCRpV subfamilies: (i) TCRP V6 subfamily comprising, e.g., one or more of TCRP V6-4*01, TCRP V6-4*02, TCRp V6-9*01, TCRp V6-8*01, TCRp V6-5*01, TCRp V6-6*02, TCRp V6-6*01, TCRp V6-2*01, TCRp V6-3*01 or TCRp V6-l*01; (ii) TCRP V10 subfamily comprising, e.g., one or more of TCRP V10-l*01, TCRP V10-1*02, TCRp V10-3*01 or TCRp V10-2*01; (iii) TCRP V5 subfamily comprising, e.g., one or more of TCRP V5-6*01, TCRP V5-4*01, or TCRp V5-8*01; (iv) TCRP V12 subfamily comprising e.g., one or more of TCRP V12-4*01, TCRP V12-3*01, or TCRp V12-5*01; (v) TCRP V7 subfamily comprising e.g., one or more of TCRP V7-7*01, TCRP V7-6*01, TCRp V7 -8*02, TCRp V7 -4*01, TCRp V7-2*02, TCRp V7-2*03, TCRp V7-2*01, TCRp V7-3*01, TCRp V7-9*03, or TCRp V7-9*01; (vi) TCRP Vil subfamily comprising e.g., one or more of TCRP VI 1-1*01, TCRP VI1-2*01 or TCRp VI 1-3*01; (vii) TCRP V14 subfamily comprising TCRP V14*01; (viii) TCRP V16 subfamily comprising TCRP VI6*01; (ix) TCRP VI8 subfamily comprising TCRP VI8*01; (x) TCRP V9 subfamily comprising T e.g., one or more of CRP V9*01 or TCRP V9*02; (xi) TCRP V13 subfamily comprising TCRP V13*01; (xii) TCRP V4 subfamily comprising e.g., one or more of e.g., one or more of TCRP V4-2*01, TCRp V4-3*01, or TCRp V4-l*01; (xiii) TCRP V3 subfamily comprising TCRP V3-l*01; (xiv) TCRP V2 subfamily comprising TCRP V2*01; (xv) TCRP V15 subfamily comprising TCRP V15*01; (xvi) TCRP V30 subfamily comprising e.g., one or more of TCRP V30*01, or TCRP V30*02; (xvii) TCRP V19 subfamily comprising e.g., one or more of TCRP V19*01, or TCRP V19*02; (xviii) TCRP V27 subfamily comprising TCRP V27*01; (xix) TCRP V28 subfamily comprising TCRP V28*01; (xx) TCRP V24 subfamily comprising TCRP V24-l*01; (xxi) TCRP V20 subfamily comprising e.g., one or more of TCRP V20-l*01, or TCRP V20-l*02; (xxii) TCRP V25 subfamily comprising TCRP V25-l*01; or (xxiii) TCRP V29 subfamily comprising TCRP V29-l*01; (xxiv) TCRp V21 subfamily; (xxv) TCRp VI subfamily; (xxvi) TCRp V17 subfamily; (xvii) TCRP V23 subfamily; or (xviii) TCRP V26 subfamily. In some embodiments of any of the methods disclosed herein, the anti-TCRpV antibody molecule binds to one or more (e.g., all) of the following TCRpV subfamilies: (i) TCRp V6, e.g., TCRp V6-4*01, TCRp V6-4*02, TCRp V6-9*01, TCRp V6-8*01, TCRp V6-5*01, TCRp V6-6*02, TCRp V6-6*01, TCRp V6-2*01, TCRp V6-3*01 or TCRp V6-1*01; (ii) TCRp V10, e.g., TCRp V10-l*01, TCRp V10-l*02, TCRp V10-3*01 or TCRp V10-2*01; (iii) TCRp V12, e.g., TCRp V12-4*01, TCRp V12-3*01, or TCRp V12-5*01; or (iv) TCRp V5, e.g., TCRp V5-5*01, TCRp V5-6*01, TCRp V5-4*01, TCRp V5-8*01, TCRp V5-l*01. In some embodiments, the anti-TCRpV antibody molecule binds to TCRP V6, e.g., TCRP V6-4*01, TCRp V6-4*02, TCRp V6-9*01, TCRp V6-8*01, TCRp V6-5*01, TCRp V6-6*02, TCRp V6-6*01, TCRp V6-2*01, TCRp V6-3*01 or TCRp V6-l*01. In some embodiments, the anti-TCRpV antibody molecule binds to TCRP V6-5*01. In some embodiments, the anti-TCRpV antibody molecule does not bind to TCRP V12. In some embodiments, the anti-TCRpV antibody molecule does not bind to TCRP V5-5*01 or TCRp V5-l*01. In some embodiments of any of the methods disclosed herein, the anti-TCRpV antibody molecule does not bind to TCRP V12, or binds to TCRP V12 with an affinity and / or binding specificity that is less than (e.g., less than about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or about 2-, 5-, or 10- fold) the affinity and / or binding specificity of the 16G8 murine antibody or a humanized version thereof as described in US Patent 5,861,155. In some embodiments of any of the methods disclosed herein, the anti-TCRpV antibody molecule binds to TCRP V12 with an affinity and / or binding specificity that is greater than (e.g., greater than about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or about 2-, 5-, or 10fold) the affinity and / or binding specificity of the 16G8 murine antibody or a humanized version thereof as described in US Patent 5,861,155. In some embodiments of any of the methods disclosed herein, the anti-TCRpV antibody molecule binds to a TCRpV region other than TCRP V12 (e.g., TCRpV region as described herein, e.g., TCRP V6 subfamily (e.g., TCRP V6-5*01) with an affinity and / or binding specificity that is greater than (e.g., greater than about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or about 2-, 5-, or 10- fold) the affinity and / or binding specificity of the 16G8 murine antibody or a humanized version thereof as described in US Patent 5,861,155. In some embodiments of any of the methods disclosed herein, the anti-TCRpV antibody molecule does not comprise at least one CDR of Antibody B. In some embodiments of any of the methods disclosed herein, the anti-TCRpV antibody molecule does not comprise the CDRs of Antibody B. In some embodiments of any of the methods disclosed herein, the anti-TCRpV antibody molecule does not bind to TCRP V5-5*01 or TCRP V5-l*01, or binds to TCRP V5-5*01 or TCRP V5-l*01 with an affinity and / or binding specificity that is less than (e.g., less than about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or about 2-, 5-, or 10- fold) the affinity and / or binding specificity of the TM23 murine antibody or a humanized version thereof as described in US Patent 5,861,155. In some embodiments of any of the methods disclosed herein, the anti-TCRpV antibody molecule binds to TCRP V5-5*01 or TCRP V5-l*01with an affinity and / or binding specificity that is greater than (e.g., greater than about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or about 2-, 5-, or 10- fold) the affinity and / or binding specificity of the TM23 murine antibody or a humanized version thereof as described in US Patent 5,861,155. In some embodiments of any of the methods disclosed herein, the anti-TCRpV antibody molecule binds to a TCRpV region other than TCRP V5-5*01 or TCRP V5-l*01 (e.g., TCRpV region as described herein, e.g., TCRP V6 subfamily (e.g., TCRP V6-5*01) with an affinity and / or binding specificity that is greater than (e.g., greater than about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or about 2-, 5-, or 10- fold) the affinity and / or binding specificity of the TM23 murine antibody or a humanized version thereof as described in US Patent 5,861,155. In some embodiments of any of the methods disclosed herein, the anti-TCRpV antibody molecule does not comprise at least one CDR of the TM23 murine antibody. In some embodiments of any of the methods disclosed herein, the anti-TCRpV antibody molecule does not comprise the CDRs of the TM23 murine antibody. In some embodiments of any of the methods disclosed herein, an anti-TCRpV antibody molecule disclosed herein does not comprise the sequence of a murine anti-rat TCR antibody R73, e.g., as disclosed in J Exp Med. 1989 Jan 1; 169(1): 73-86, herein incorporated by reference in its entirety. In some embodiments of any of the methods disclosed herein, a multispecific antibody molecule disclosed herein does not comprise the sequence of a murine anti-rat TCR antibody R73, e.g., as disclosed in J Immunol. 1993 Mar 15;150(6):2305-15, herein incorporated by reference in its entirety. In some embodiments of any of the methods disclosed herein, an anti-TCRpV antibody molecule disclosed herein does not comprise a viral peptide-MHC complex, e.g., as disclosed in Oncoimmunology. 2016; 5(1): el052930, herein incorporated by reference in its entirety. In some embodiments of any of the methods disclosed herein, a multispecific antibody molecule disclosed herein does not comprise a viral peptide-MHC complex, e.g., as disclosed in Oncoimmunology. 2016; 5(1): el052930, herein incorporated by reference in its entirety. In some embodiments of a method disclosed herein, the immune cell population comprises a T cell, a Natural Killer cell, a B cell, an antigen presenting cell, or a myeloid cell (e.g., a monocyte, a macrophage, a neutrophil or a granulocyte). In some embodiments of a method disclosed herein, the immune cell population comprises a T cell, e.g., a CD4+ T cell, a CD8+ T cell, a TCR alpha-beta T cell, or a TCR gamma-delta T cell. In some embodiments, a T cell comprises a memory T cell (e.g., a central memory T cell, or an effector memory T cell (e.g., a Temra) or an effector T cell. In some embodiments, a T cell comprises a tumor infiltrating lymphocyte (TIL). In some embodiments of a method disclosed herein, the immune cell population is obtained from a healthy subject. In some embodiments of a method disclosed herein, the immune cell population is obtained from a subject (e.g., from an apheresis sample from the subject) having a disease, e.g., a cancer, e.g., as described herein. In some embodiments, the immune cell population obtained from a subject having a disease, e.g., a cancer, comprises a tumor infiltrating lymphocyte (TIL). In some embodiments of a method disclosed herein, the method results in an expansion of at least 1.1-10 fold (e.g., at least 1.1, 1.2, 1.3, 1.4, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, or 10 fold expansion). In some embodiments of a method disclosed herein, the method further comprises contacting the population of cells with an agent that promotes, e.g., increases, immune cell expansion. In some embodiments, the agent includes an immune checkpoint inhibitor, e.g., as described herein. In some embodiments, the agent includes a 4-IBB (CD 127) agonist, e.g., an anti-4-IBB antibody. In some embodiments of a method disclosed herein, the method further comprises comprising contacting the population of cells with a non-dividing population of cells, e.g., feeder cells, e.g., irradiated allogenic human PBMCs. In some embodiments of a method disclosed herein, an expansion method described herein comprises expanding the cells for a period of at least about 4 hours, 6 hours, 10 hours, 12 hours, 15 hours, 18 hours, 20 hours, or 22 hours, or for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 1,6 17, 18, 19, 20 or 21 days, or for at least about 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks or 8 weeks. In some embodiments of a method disclosed herein, expansion of the population of immune cells, is compared to expansion of a similar population of cells with an antibody that binds to: a CD3 molecule, e.g., CD3 epsilon (CD3e) molecule; or a TCR alpha (TCRa) molecule. In some embodiments of a method disclosed herein, expansion of the population of immune cells, is compared to expansion of a similar population of cells not contacted with the anti-TCRpV antibody molecule. In some embodiments of a method disclosed herein, expansion of the population of memory effector T cells, e.g., Tem cells, e.g., Temra cells, is compared to expansion of a similar population of cells with an antibody that binds to: a CD3 molecule, e.g., CD3 epsilon (CD3e) molecule; or a TCR alpha (TCRa) molecule. In some embodiments of a method disclosed herein, the method results in expansion of, e.g., selective or preferential expansion of, T cells expressing a T cell receptor (TCR) comprising a TCR alpha and / or TCR beta molecule, e.g., TCR alpha-beta T cells (aP T cells). In some embodiments of a method disclosed herein, the method results in expansion of aPT cells over expansion of T cells expressing a TCR comprising a TCR gamma and / or TCR delta molecule, e.g., TCR gamma-delta T cells (y6 T cells). In some embodiments, expansion of aPT cells over y6 T cells results in reduced production of cytokines associated with CRS. In some embodiments, expansion of aPT cells over y6 T cells results in immune cells that have reduced capacity to, e.g., are less prone to, induce CRS upon administration into a subject. In some embodiments of a method disclosed herein, an immune cell population (e.g., T cells (e.g., Temra cells or TILs) or NK cells) cultured in the presence of, e.g., expanded with, an anti- TCRpV antibody disclosed herein does not induce CRS and / or NT when administered into a subject, e.g., a subject having a disease or condition as described herein. In some embodiments, the anti-TCRpV antibody molecule in a multispecific molecule disclosed herein is a first immune cell engager moiety. In some embodiments, the anti-TCRpV antibody molecule does not bind to TCRP V12, or binds to TCRP V12 with an affinity and / or binding specificity that is less than (e.g., less than about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or about 2-, 5-, or 10- fold) the affinity and / or binding specificity of the 16G8 murine antibody or a humanized version thereof as described in US Patent 5,861,155. In some embodiments, the anti-TCRpV antibody molecule binds to TCRP V12 with an affinity and / or binding specificity that is greater than (e.g., greater than about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or about 2-, 5-, or 10- fold) the affinity and / or binding specificity of the 16G8 murine antibody or a humanized version thereof as described in US Patent 5,861,155. In some embodiments, the anti-TCRpV antibody molecule binds to a TCRpV region other than TCRP V12 (e.g., TCRpV region as described herein, e.g., TCRP V6 subfamily (e.g., TCRP V6-5*01) with an affinity and / or binding specificity that is greater than (e.g., greater than about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or about 2-, 5-, or 10- fold) the affinity and / or binding specificity of the 16G8 murine antibody or a humanized version thereof as described in US Patent 5,861,155. In some embodiments, the anti-TCRpV antibody molecule does not comprise the CDRs of the Antibody B murine antibody. In some embodiments, the anti-TCRpV antibody molecule in a multispecific molecule disclosed herein is a first immune cell engager moiety. In some embodiments, the anti-TCRpV antibody molecule does not bind to TCRP V5-5*01 or TCRP V5-l*01, or binds to TCRP V5-5*01 or TCRP V5-l*01 with an affinity and / or binding specificity that is less than (e.g., less than about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or about 2-, 5-, or 10- fold) the affinity and / or binding specificity of the TM23 murine antibody or a humanized version thereof as described in US Patent 5,861,155. In some embodiments, the anti-TCRpV antibody molecule binds to TCRP V5-5*01 or TCRP V5-l*01with an affinity and / or binding specificity that is greater than (e.g., greater than about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or about 2-, 5-, or 10- fold) the affinity and / or binding specificity of the TM23 murine antibody or a humanized version thereof as described in US Patent 5,861,155. In some embodiments, the anti-TCRpV antibody molecule binds to a TCRpV region other than TCRP V5-5*01 or TCRP V5-1*01 (e.g., TCRpV region as described herein, e.g., TCRP V6 subfamily (e.g., TCRP V6-5*01) with an affinity and / or binding specificity that is greater than (e.g., greater than about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or about 2-, 5-, or 10- fold) the affinity and / or binding specificity of the TM23 murine antibody or a humanized version thereof as described in US Patent 5,861,155. In some embodiments, the anti-TCRpV antibody molecule does not comprise the CDRs of the TM23 murine antibody. In some embodiments, the multispecific molecule further comprises a second immune cell engager moiety. In some embodiments, the first and / or second immune cell engager binds to and activates an immune cell, e.g., an effector cell. In some embodiments, the first and / or second immune cell engager binds to, but does not activate, an immune cell, e.g., an effector cell. In some embodiments, the second immune cell engager is chosen from an NK cell engager, a T cell engager, a B cell engager, a dendritic cell engager, or a macrophage cell engager, or a combination thereof. In some embodiments, the second immune cell engager comprises a T cell engager which binds to CD3, TCRa, TCRy, TCR^, ICOS, CD28, CD27, HVEM, LIGHT, CD40, 4-1BB, OX40, DR3, GITR, CD30, TIM1, SLAM, CD2, or CD226. In some embodiments, a multispecific molecule disclosed herein comprises a tumor targeting moiety. In some embodiment, the tumor-targeting moiety comprises an antibody molecule (e.g., Fab or scFv), a receptor molecule (e.g., a receptor, a receptor fragment or functional variant thereof), or a ligand molecule (e.g., a ligand, a ligand fragment or functional variant thereof), or a combination thereof, that binds to a cancer antigen. In some embodiments, the tumor-targeting moiety binds to a cancer antigen present on a cancer, e.g., a hematological cancer, a solid tumor, a metastatic cancer, soft tissue tumor, metastatic lesion, or a combination thereof. In some embodiments, the tumor-targeting moiety binds to a cancer antigen, e.g., BCMA or FcRH5. In some embodiments, the tumor-targeting antibody molecule binds to a conformational or a linear epitope on the tumor antigen. In some embodiments of any of the compositions or methods disclosed herein, the tumortargeting moiety is an antigen, e.g., a cancer antigen. In some embodiments, the cancer antigen is a tumor antigen or stromal antigen, or a hematological antigen. In some embodiments of any of the compositions or methods disclosed herein, the tumortargeting moiety binds to a cancer antigen chosen from: BCMA, FcRH5, CD19, CD20, CD22, CD30, CD33, CD38, CD47, CD99, CD123, FcRH5, CLEC12, CD179A, SLAMF7, or NY-ESO1, PDL1, CD47, gangloside 2 (GD2), prostate stem cell antigen (PSCA), prostate specific membrane antigen (PMSA), prostate-specific antigen (PSA), carcinoembryonic antigen (CEA), Ron Kinase, c-Met, Immature laminin receptor, TAG-72, BING-4, Calcium-activated chloride channel 2, Cyclin-Bl, 9D7, Ep-CAM, EphA3, Her2 / neu, Telomerase, SAP-1, Survivin, NY-ESO-l / LAGE-1, PRAME, SSX-2, Melan-A / MART-1, Gpl00 / pmell7, Tyrosinase, TRP-1 / -2, MC1R, P-catenin, BRCA1 / 2, CDK4, CML66, Fibronectin, p53, Ras, TGF-B receptor, AFP, ETA, MAGE, MUC-1, CA-125, BAGE, GAGE, NY-ESO-1, p-catenin, CDK4, CDC27, a actinin-4, TRPl / gp75, TRP2, gplOO, Melan-A / MARTl, gangliosides, WT1, EphA3, Epidermal growth factor receptor (EGFR), MART-2, MART-1, MUC1, MUC2, MUM1, MUM2, MUM3, NA88-1, NPM, OA1, OGT, RCC, RUI1, RUI2, SAGE, TRG, TRP1, TSTA, Folate receptor alpha, Ll-CAM, CAIX, gpA33, GD3, GM2, VEGFR, Intergrins (Integrin alphaVbeta3, Integrin alpha5Betal), Carbohydrates (Le), IGF1R, EPHA3, TRAILRI, TRAILR2, RANKL, (FAP), TGF-beta, hyaluronic acid, collagen, e.g., collagen IV, tenascin C, or tenascin W. In some embodiments of any of the compositions or methods disclosed herein, the cancer is a solid tumor including but not limited to: pancreatic (e.g., pancreatic adenocarcinoma) cancer, breast cancer, colorectal cancer, lung cancer (e.g., small or non-small cell lung cancer), skin cancer, ovarian cancer, or liver cancer. In some embodiments of any of the compositions or methods disclosed herein, the cancer antigen or tumor antigen is a hematological antigen. In some embodiments, the cancer or tumor antigen is chosen from one or more of: BCMA, FcRH5, CD19, CD20, CD22, CD30, CD33, CD38, CD47, CD99, CD123, FcRH5, CLEC12, CD179A, SLAMF7, or NY-ESO1. In some embodiments, the tumor-targeting moiety binds to one or both of BCMA or FcRH5. In some embodiments, the tumor-targeting moiety binds to BCMA. In embodiments, the tumor-targeting moiety comprises a BCMA targeting moiety. In some embodiments, the tumortargeting moiety comprising a BCMA targeting moiety binds to a BCMA antigen on the surface of a cell, e.g., a cancer or hematopoietic cell. The BCMA antigen can be present on a primary tumor cell, or a metastatic lesion thereof. In some embodiments, the cancer is a hematological cancer, e.g., multiple myeloma. For example, the BCMA antigen can be present on a tumor, e.g., a tumor of a class typified by having one or more of: limited tumor perfusion, compressed blood vessels, or fibrotic tumor interstitium. In some embodiments, the tumor targeting moiety comprising a BCMA targeting moiety comprises an anti-BCMA antibody or antigen-binding fragment thereof described in US8920776, US9243058, US9340621, US8846042, US7083785, US9545086, US7276241, US9034324, US7799902, US9387237, US8821883, US861745, US20130273055, US20160176973, US20150368351, US20150376287, US20170022284, US20160015749, US20140242077, US20170037128, US20170051068, US20160368988, US20160311915, US20160131654, US20120213768, US20110177093, US20160297885, EP3137500, EP2699259, EP2982694, EP3029068, EP3023437, WO2016090327, WO2017021450, WO2016110584, WO2016118641, WO2016168149, the entire contents of which are incorporated herein by reference. In some embodiments, the BCMA-targeting moiety includes an antibody molecule (e.g., Fab or scFv) that binds to BCMA. In some embodiments, the antibody molecule to BCMA comprises one, two, or three CDRs from any of the heavy chain variable domain sequences of Table 9, or a closely related CDR, e.g., CDRs which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) from any of the CDR sequences of Table 9. In some embodiments, the antibody molecule to BCMA comprises a heavy chain variable domain sequence chosen from any of the amino acid sequences of Table 9, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions)). In some embodiments, the tumor-targeting moiety binds to FcRH5. In embodiments, the tumor-targeting moiety comprises a FcRH5targeting moiety. In some embodiments, the tumortargeting moiety comprising a FcRH5targeting moiety binds to a FcRH5antigen on the surface of a cell, e.g., a cancer or hematopoietic cell. The FcRH5antigen can be present on a primary tumor cell, or a metastatic lesion thereof. In some embodiments, the cancer is a hematological cancer, e.g., multiple myeloma. For example, the FcRH5antigen can be present on a tumor, e.g., a tumor of a class typified by having one or more of: limited tumor perfusion, compressed blood vessels, or fibrotic tumor interstitium. In some embodiments, the tumor targeting moiety comprising a FcRH5 targeting moiety comprises an anti- FcRH5antibody or antigen-binding fragment thereof described in US Patent 7,999,077 the entire contents of which are incorporated herein by reference. In some embodiments of any of the compositions or methods disclosed herein, the cancer is a hematological cancer including, but not limited to: a B-cell or T cell malignancy, e.g., Hodgkin’s lymphoma, Non-Hodgkin’s lymphoma (e.g., B cell lymphoma, diffuse large B cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma, marginal zone B-cell lymphoma, Burkitt lymphoma, lymphoplasmacytic lymphoma, hairy cell leukemia), acute myeloid leukemia (AML), chronic myeloid leukemia, myelodysplastic syndrome, multiple myeloma, and acute lymphocytic leukemia. In some embodiments, the hematological cancer is multiple myeloma. In some embodiments, a multispecific molecule disclosed herein further comprises a cytokine molecule, e.g., one or two cytokine molecules. In some embodiments, the cytokine molecule is chosen from interleukin-2 (IL-2), interleukin-7 (IL-7), interleukin-12 (IL-12), interleukin-15 (IL-15), interleukin-18 (IL-18), interleukin-21 (IL-21), or interferon gamma, or a fragment, variant or combination thereof. In some embodiments, is a monomer or a dimer. In some embodiments, the cytokine molecule further comprises a receptor dimerizing domain, e.g., an IL15Ralpha dimerizing domain. In some embodiments, the cytokine molecule (e.g., IL-15) and the receptor dimerizing domain (e.g., an IL15Ralpha dimerizing domain) are not covalently linked, e.g., are non-covalently associated. In some embodiments, a multispecific molecule disclosed herein comprises: (i) an anti-TCRpV antibody molecule (e.g., an anti-TCRpV antibody molecule as described herein); and (ii) a tumor-targeting antibody molecule (e.g., an antibody molecule that binds to a hematological antigen as described herein, e.g., chosen from one or more of BCMA, FcRH5, CD19, CD22, CD33, CD123, FcRH5, CD179a, or CLEC12). In some embodiments, the multispecific molecule disclosed herein comprises the anti-TCRpV antibody molecule of (i), the tumor-targeting antibody molecule of (ii) and a cytokine molecule as described herein, e.g., an IL-12 cytokine molecule. In some embodiments, the multispecific molecule comprises an anti-TCRpV antibody molecule as described herein; and a tumor-targeting antibody molecule that binds to one or both of BCMA or FcRH5. In some embodiments, the multispecific molecule further comprises an IL-12 cytokine molecule. The multispecific molecule can be used to treat a BCMA- or FcRH5-expressing hematological cancer, e.g., multiple myeloma. In some embodiments, the multispecific molecule comprises an anti-TCRpV antibody molecule as described herein; and a tumor-targeting antibody molecule that binds one or more of CD19, CD22, or CD123. In some embodiments, the multispecific molecule further comprises an IL-12 cytokine molecule. The multispecific molecule can be used to treat a CD19-, CD22-, or CD123-expressing hematological cancer, e.g., leukemia or lymphoma. In some embodiments, the CD19-, CD22-, or CD123-expressing hematological cancer is chosen from a B-cell or T cell malignancy, e.g., Hodgkin’s lymphoma, Non-Hodgkin’s lymphoma (e.g., B cell lymphoma, diffuse large B cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma, marginal zone B-cell lymphoma, Burkitt lymphoma, lymphoplasmacytic lymphoma, hairy cell leukemia), acute myeloid leukemia (AML), chronic myeloid leukemia, myelodysplastic syndrome, multiple myeloma, and acute lymphocytic leukemia. In some embodiments, the hematological cancer is multiple myeloma. In some embodiments, a multispecific molecule disclosed herein further comprises an immunoglobulin constant region (e.g., Fc region) chosen from the heavy chain constant regions of IgGl, IgG2, and IgG4, more particularly, the heavy chain constant region of human IgGl, IgG2 or IgG4. In some embodiments, the immunoglobulin constant region (e.g., an Fc region) is linked, e.g., covalently linked to, one or more of tumor-targeting moiety, the immune cell engager, the cytokine molecule, or the stromal modifying moiety. In some embodiments, an interface of a first and second immunoglobulin chain constant regions (e.g., Fc region) is altered, e.g., mutated, to increase or decrease dimerization, e.g., relative to a non-engineered interface. In some embodiments, the dimerization of the immunoglobulin chain constant region (e.g., Fc region) is enhanced by providing an Fc interface of a first and a second Fc region with one or more of: a paired cavity-protuberance (“knob-in-a hole”), an electrostatic interaction, or a strandexchange, such that a greater ratio of heteromultimer:homomultimer forms, e.g., relative to a non-engineered interface. In some embodiments, In some embodiments, a multispecific molecule disclosed herein further comprises a linker, e.g., a linker described herein, optionally wherein the linker is selected from: a cleavable linker, a non-cleavable linker, a peptide linker, a flexible linker, a rigid linker, a helical linker, or a non-helical linker. In some embodiments, the multispecific molecule comprises at least two non-contiguous polypeptide chains. In some embodiments, the multispecific molecule comprises the following configuration: A, B-[dimerization module]-C, -D wherein: (1) the dimerization module comprises an immunoglobulin constant domain, e.g., a heavy chain constant domain (e.g., a homodimeric or heterodimeric heavy chain constant region, e.g., an Fc region), or a constant domain of an immunoglobulin variable region (e.g., a Fab region); and (2) A, B, C, and D are independently absent; (i) an antigen binding domain that preferentially binds to a first immune cell engager comprising an anti-TCRpV antibody molecule disclosed herein; (ii) a tumor targeting moiety (e.g., a tumor-targeting antibody molecule as described herein), (iii) a second immune cell engager chosen from a T cell engager, an NK cell engager, a B cell engager, a dendritic cell engager, or a macrophage cell engager; (iv) a cytokine molecule; or (v) a stromal modifying moiety, provided that: at least one, two, or three of A, B, C, and D comprises an antigen binding domain that preferentially binds to a TCRpV region disclosed herein, and any of the remaining A, B, C, and D is absent or comprises one of a tumor targeting moiety, a second immune cell engager, a cytokine molecule, or a stromal modifying moiety. In some embodiments, the dimerization module comprises one or more immunoglobulin chain constant regions (e.g., Fc regions) comprising one or more of: a paired cavity-protuberance (“knob-in-a hole”), an electrostatic interaction, or a strand-exchange. In some embodiments, the one or more immunoglobulin chain constant regions (e.g., Fc regions) comprise an amino acid substitution at a position chosen from one or more of 347, 349, 350, 351, 366, 368, 370, 392, 394, 395, 397, 398, 399, 405, 407, or 409, e.g., of the Fc region of human IgGl. In some embodiments, the one or more immunoglobulin chain constant regions (e.g., Fc regions) comprise an amino acid substitution chosen from: T366S, L368A, or Y407V (e.g., corresponding to a cavity or hole), or T366W (e.g., corresponding to a protuberance or knob), or a combination thereof. In some embodiments, the multispecific molecule further comprises a linker, e.g., a linker between one or more of: the antigen binding domain of an anti-TCRpV antibody molecule disclosed herein and the tumor targeting moiety; the antigen binding domain of an anti-TCRpV antibody molecule disclosed herein and the second immune cell engager, the antigen binding domain of an anti-TCRpV antibody molecule disclosed herein and the cytokine molecule, the antigen binding domain of an anti-TCRpV antibody molecule disclosed herein and the stromal modifying moiety, the second immune cell engager and the cytokine molecule, the second immune cell engager and the stromal modifying moiety, the cytokine molecule and the stromal modifying moiety, the antigen binding domain of an anti-TCRpV antibody molecule disclosed herein and the dimerization module, the second immune cell engager and the dimerization module, the cytokine molecule and the dimerization module, the stromal modifying moiety and the dimerization module, the tumor targeting moiety and the dimerization module, the tumor targeting moiety and the cytokine molecule, the tumor targeting moiety and the second immune cell engager, or the tumor targeting moiety and the antigen binding domain of an anti-TCRpV antibody molecule disclosed herein. In some embodiments, the linker is chosen from: a cleavable linker, a non-cleavable linker, a peptide linker, a flexible linker, a rigid linker, a helical linker, or a non-helical linker. In some embodiments, the linker is a peptide linker. In some embodiments, the peptide linker comprises Gly and Ser. In some embodiments, the peptide linker comprises an amino acid sequence chosen from SEQ ID NOs: 142-145 or 175-178. In some embodiments of a method or composition for use disclosed herein, the disease is a cancer chosen from: a hematological cancer, a solid tumor, a metastatic cancer, soft tissue tumor, metastatic lesion, or a combination thereof. In some embodiments of a method or composition for use disclosed herein, the cancer is a solid tumor chosen from: a melanoma, a pancreatic cancer (e.g., pancreatic adenocarcinoma), a breast cancer, a colorectal cancer (CRC), a lung cancer (e.g., small or non-small cell lung cancer), a skin cancer, an ovarian cancer, or a liver cancer. In some embodiments, the cancer is melanoma or CRC. In some embodiments of a method or composition for use disclosed herein the cancer is a hematological cancer chosen from: a B-cell or T cell malignancy, e.g., Hodgkin’s lymphoma, Non-Hodgkin’s lymphoma (e.g., B cell lymphoma, diffuse large B cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma, marginal zone B-cell lymphoma, Burkitt lymphoma, lymphoplasmacytic lymphoma, hairy cell leukemia), acute myeloid leukemia (AML), chronic myeloid leukemia, myelodysplastic syndrome, multiple myeloma, or acute lymphocytic leukemia. In some embodiments, the hematological cancer is multiple myeloma. In some embodiments, the hematological cancer is CLL or DLBCL. In some embodiments of a method or composition for use disclosed herein the sample from the subject comprises a blood sample, e.g., a peripheral blood sample, a biopsy, e.g., a tumor biopsy, or a bone marrow sample. IN some embodiments, the sample comprises a biological sample comprising immune effector cells, e.g., T cells, or NK cells. In some embodiments, T cells comprise a CD4 T cell, a CD8 T cell, (e.g., an effector T cell or a memory T cell (e.g., a memory effector T cell (e.g., Tem cell, e.g., Temra cell), or a tumor infiltrating lymphocyte (TIL). Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be limiting. Other features and advantages of the invention will be apparent from the following detailed description and claims. BRIEF DESCRIPTION OF THE DRAWINGS The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee. FIGs. 1A-1B shows the alignment of the Antibody A source mouse VH and VL framework 1, CDR 1, framework 2, CDR 2, framework 3, CDR3, and framework 4 regions with their respective humanized sequences. Kabat CDRs are shown in bold, Chothia CDRs are shown in italics, and combined CDRs are shown in boxes. The framework positions that were back mutated are double underlined. FIG. 1A shows VH sequences for murine Antibody A (SEQ ID NO: 1) and humanized Antibody A-H (SEQ ID NO: 9). FIG. IB shows VL sequences for murine Antibody A (SEQ ID NO: 2) and humanized Antibody A-H (SEQ ID NO: 10 and SEQ ID NO: 11). FIGs. 2A-2B shows the alignment of the Antibody B source mouse VH and VL framework 1, CDR 1, framework 2, CDR 2, framework 3, CDR3, and framework 4 regions with their respective humanized sequences. Kabat CDRs are shown in bold, Chothia CDRs are shown in italics, and combined CDRs are shown in boxes. The framework positions that were back mutated are double underlined. FIG. 2A shows the VH sequence for murine Antibody B (SEQ ID NO: 15) and humanized VH sequences B-H.1A to B-H.1C (SEQ ID NOs: 23-25). FIG. 2B shows the VL sequence for murine Antibody B (SEQ ID NO: 16) and humanized VL sequences B-H.1D to B-H.1H (SEQ ID NOs: 26-30). FIG. 3 depicts the phylogenetic tree of TCRBV gene family and subfamilies with corresponding antibodies mapped. Subfamily identities are as follows: Subfamily A: TCRP V6; Subfamily B: TCRP V10; Subfamily C: TCRP V12; Subfamily D: TCRP V5; Subfamily E: TCRp V7; Subfamily F: TCRp Vil; Subfamily G: TCRp V14; Subfamily H: TCRp V16; Subfamily ETCRp V18; Subfamily J:TCRp V9; Subfamily K: TCRp V13; Subfamily L: TCRp V4; Subfamily M:TCRp V3; Subfamily N:TCRp V2; Subfamily O:TCRp V15; Subfamily P: TCRp V30; Subfamily Q: TCRp V19; Subfamily R:TCRp V27; Subfamily S:TCRp V28; Subfamily T: TCRP V24; Subfamily U: TCRP V20; Subfamily V: TCRP V25; and Subfamily W:TCRP V29 subfamily. Subfamily members are described in detail herein in the Section titled “TCR beta V (TCRpV)”. FIGs. 4A-4C show human CD3+ T cells activated by anti-TCR Vpi3.1 antibody (A-H.l) for 6-days. Human CD3+ T cells were isolated using magnetic-bead separation (negative selection) and activated with immobilized (plate-coated) anti-TCR Vpi3.1 (A-H.l) or anti-CD3e (OKT3) antibodies at 100 nM for 6 days. FIG. 4A shows two scatter plots (left: activated with OKT3; and right: activated with A-H.l) of expanded T cells assessed for TCR Vpi3.1 surface expression using anti-TCR Vpi3.1 (A-H.l) followed by a secondary fluorochrome- conjugated antibody for flow cytometry analysis. FIG. 4B shows percentage (%) of TCR Vpi3.1 positive T cells activated by anti-TCR Vpi3.1 (A-H.l) or anti-CD3e (OKT3) plotted against total T cells (CD3+). FIG. 4C shows relative cell count acquired by counting the number of events in each T cell subset gate (CD3 or TCR VP 13.1) for 20 seconds at a constant rate of 60pl / min. Data shown as mean value from 3 donors. FIGs. 5A-5B show cytolytic activity of human CD3+ T cells activated by anti-TCR Vpi3.1 antibody (A-H.l) against transformed cell line RPMI 8226. FIG. 5A depicts target cell lysis of human CD3+ T cells activated with A-H.lor OKT3. Human CD3+ T cells were isolated using magnetic-bead separation (negative selection) and activated with immobilized (plate-coated) A-H.l or OKT3 at the indicated concentrations for 4 days prior to co-culture with RPMI 8226 cells at a (E:T) ratio of 5:1 for 2 days. Samples were next analyzed for cell lysis of RPMI 8226 cells by FACS staining for CFSE / CD138-labeled, and membrane-impermeable DNA dyes (DRAQ7) using flow cytometry analysis. FIG. 5B shows target cell lysis of human CD3+ T cells activated with A-H.l or OKT3 incubated with RPMI-8226 at a (E:T) ratio of 5:1 for 6 days followed by cell lysis analysis of RPMI 8226 cells as described above. Percentage (%) target cell lysis was determined by normalizing to basal target cell lysis (i.e. without antibody treatment) using the following formula, [(x - basal) / (100% - basal), where x is cell lysis of sample]. Data shown is a representative of n=l donor. FIGs. 6A-6B show IFNg production by human PBMCs activated with the indicated antibodies. Human PBMCs were isolated from whole blood from the indicated number of donors, followed by solid-phase (plate-coated) stimulation with the indicated antibodies at lOONm. Supernatant was collected on Days 1, 2, 3, 5, or 6. FIG. 6A is a graph comparing the production of IFNg in human PBMCs activated with the antibodies indicated activated with anti-TCR Vpi3.1 antibodies (A-H.l or A-H.2) or anti-CD3e antibodies (OKT3 or SP34-2) on Day 1, 2, 3, 5, or 6 post-activation. FIG. 6B shows IFNg production in human PBMCs activated with the antibodies indicated activated with the indicated anti-TCR Vpi3.1 antibodies or anti-CD3e antibody (OKT3) on Day 1, 2, 3, 5, or 6 post-activation. FIGs. 7A-7B show IL-2 production by human PBMCs activated with the indicated antibodies. A similar experimental setup as described for FIGs 6A-6B was used. FIGs. 8A- 8B show IL-6 production by human PBMCs activated with the indicated antibodies. A similar experimental setup as described for FIGs 6A-6B was used. FIGs. 9A- 9B show TNF-alpha production by human PBMCs activated with the indicated antibodies. A similar experimental setup as described for FIGs 6A-6B was used. FIGs. 10A-10B show IL-lbeta production by human PBMCs activated with the indicated antibodies. A similar experimental setup as described for FIGs 6A-6B was used. FIGs. 11A-11B are graphs showing delayed kinetics of IFNg secretion in human PMBCs activated by anti-TCR Vpi3.1 antibody A-H.l when compared to PBMCs activated by anti-CD3e antibody OKT3. FIG. 11A shows IFNg secretion data from 4 donors. FIG. 11B shows IFNg secretion data from 4 additional donors. Data shown is representative of n=8 donors. FIG. 12 depicts increased CD8+ TSCM and Temra T cell subsets in human PBMCs activated by anti-TCR Vpi3.1 antibodies (A-H.l or A-H.2) compared to PBMCs activated by anti-CD3e antibodies (OKT3 or SP34-2). FIGS. 13A-13F show characterization of an anti-TCRVb antibody. FIG. 13A is a graph depicting proliferation of T cells activated with anti-CD3 (OKT3) antibody or anti-TCRVb antibody.FIG. 13B shows selective expansion of CD45RA+ effector memory CD8+ and CD4+ T cells (TEMRA) cells with anti- TCRVb antibodies. Tn= naive T cell; Tscm= stem cell memory T cell; Tcm= central memory T cell; Tem=effector memory T cell; Temra=effector memory CD45RA+ T cell. FIG. 13C is a graph showing IFN-g secretion by PBMCs stimulated with an anti-TCRVb antibody, or anti-CD3 antibodies. FIG. 13D shows target cell lysis by T cells stimulated with an anti-TCRVb antibody, or anti-CD3 antibodies. Cells were stimulated for 4 days followed by 2 days incubation with multiple myeloma target cells for assessment of cell killing. FIG. 13E is a graph showing perforin secretion by T cells stimulated with an anti-TCRVb antibody, or an anti-CD3 antibody. Perforin was analyzed by FACS staining in TCRVB-positive and TCRVB-negative T cells in PBMCs after 5 days of stimulation with lOOng / ml platebound antibody. FIG. 13F is a graph showing Granzyme B by T cells stimulated with an anti-TCRVb antibody, or an anti-CD3 antibody. Granzyme B was analyzed by FACS staining in TCRVB-positive and TCRVB-negative T cells in PBMCs after 5 days of stimulation with lOOng / ml plate-bound antibody. FIGs 14A-14B show production of IL-2 and IL-15 and expansion of human NK cells by stimulation of PBMCs with anti-TCRVb antibody for 6 days at a dose of lOOnM. FIG. 14A shows secretion of IL-2 or IL-15 in T cells stimulated with an anti-TCRVb antibody, or anti-CD3 antibodies. FIG. 14B depicts flow cytometry dot plots showing NKp46 staining vs CD56 antibody staining in cells stimulated with an anti-TCRVb antibody or an anti-CD3 antibody or a control sample. FIGS. 15A-15C show secretion of cytokines in PBMCs stimulated with an anti-TCRVb antibody, or anti-CD3 antibodies. FIGs 16A-16B show killing of MM cells by dual targeting BCMA-TCRvb antibody molecules. FIG.16A shows in vitro killing by one of the following dual-targeting antibody molecules: BCMA-TCRVb (Molecule I), BCMA-CD3, or Control-TCRVb; or an isotype control. FIG. 16B shows in vivo killing of MM cells by a dual-targeting BCM-TCRVb antibody (Molecule I). FIG. 17 shows lysis of MM target cells with a dual targeting antibody (Molecule E) which recognized FcRH5 on one arm and TCRVb on the other arm. FIGs 18A-18B demonstrate cytokine production from human PBMCs activated by anti-TCR Vp8a antibodies (B-H.l) when compared to those activated by anti-CD3e antibodies (OKT3 or SP34-2). FIG. 18A shows that human PBMCs activated by anti-TCR Vp8a antibodies (B-H.l) produce similar or reduced levels of IFNy. FIG. 18B shows human PBMCs activated by anti-TCR Vp8a antibodies (B-H.l) produce higher levels of IL-2 when compared to those activated by anti-CD3e antibodies (OKT3 or SP34-2). Data shown is representative of n = 6 donors. FIGs 19A-19C demonstrate cytokine production from human PBMCs activated by anti-TCR Vp8a antibodies (B-H.l). Human PBMCs activated by anti-TCR Vp8a antibodies (B-H.l) do not significantly produce IL-6 (FIG. 19A), ILlb (FIG. 19B), and less TNFa (FIG. 19C), when compared to PBMCs activated by anti-CD3e antibodies (OKT3 or SP34-2). Data shown is representative of n = 6 donors. FIGs. 20A-20E demonstrate cytokine production from human PBMCs activated by anti-TCRpV Antibody D antibody compared to control anti-CD3e antibody (OKT3). FIG. 20A shows that human PBMCs activated by anti-TCRpV Antibody D antibody produce similar or reduced levels of IFNy. FIG. 20B shows human PBMCs activated by anti-TCRpV Antibody D antibody produce higher levels of IL-2 when compared to those activated by anti-CD3e antibodies (OKT3). Human PBMCs activated by anti- TCRpV Antibody D antibody do not significantly produce IL-lbeta (FIG. 20C), IL-6, (FIG. 20D), or TNFalpha (FIG. 20E). Data shown is representative of n = 4 donors. FIGs. 21A-21B demonstrate cytokine production from human PBMCs activated by anti-TCR Vp5 antibody (Antibody E). FIG. 21A shows that human PBMCs activated by anti-TCR VP5 antibody produce similar or reduced levels of IFNy compared to PBMCS activated by anti-CD3e antibodies (OKT3 or SP34-2). FIG. 21B shows human PBMCs activated by the anti- TCR Vp5 1 antibody produce higher levels of IL-2 when compared to those activated by anti-CD3e antibodies (OKT3 or SP34-2). Data shown is representative of n = 4 donors. FIGs. 22A-2D demonstrate cytokine production from human PBMCs activated by an anti-TCR Vp5 antibody (Antibody E). Human PBMCs activated by anti-TCR Vp5 antibody do not significantly produce IL-lbeta (FIG. 22A), IL-6, (FIG. 22B), TNFalpha (FIG. 22C), or IL-10 (FIG. 22D) as compared to PBMCs activated by anti-CD3e antibodies (OKT3 or SP34-2). Data shown is representative of n = 4 donors. FIGs. 23A-23E demonstrate cytokine production from human PBMCs activated by a dual targeting (bispecific molecule) comprising an anti-TCRpV binding moiety and a BCMA binding moiety. FIG. 23A shows that human PBMCs activated by the bispecific molecule produce similar or reduced levels of IFNy as PBMCS activated by anti-CD3e antibodies (OKT3). FIG. 23B shows human PBMCs activated by the bispecific molecule produce higher levels of IL-2 when compared to PBMCs activated by anti-CD3e antibodies (OKT3). Human PBMCs activated by the bispecific molecule do not significantly produce IL-lbeta (FIG. 23C), IL-6, (FIG. 23D), TNFalpha (FIG. 23E), or IL-10 (FIG. 23F). Data shown is representative of n = 3 donors. FIGs. 24A-24B show the structure and sequence of eight TCRPV proteins from seven different subfamilies: TCRPV6 subfamily (TCRPV6-5 and TCRPV6-4 are shown), TCRPV28 subfamily, TCRpV19 subfamily, TCRpV9 subfamily, TCRpV5 subfamily, TCRpV20 subfamily and TCRPV12 subfamily. FIG. 24A shows the structural alignment of the different TCRPV proteins. The circled area represents the outward facing region comprising the proposed binding site for the anti-TCRpV antibodies disclosed herein. FIG. 24B shows the amino acid sequence alignment of the proteins shown in FIG. 24A. The various TCRPV proteins (from 7 different TCRPV subfamilies) have diverse sequences but share a conserved (similar) structure and function. FIGs. 25A-25J show cytokine or chemokine secretion of PBMCs activated with anti-TCRVb antibodies (A-H.l, B-H.l), a bispecific molecule comprising an anti-TCRVb antibody (Molecule H), control isotype (122) or anti-CD3e antibody (OKT3). Data shown is representative of n = 2 donors and representative of 2 independent experiments. FIGs. 26A-26H show cytokine or chemokine secretion of PBMCs activated with anti-TCRVb antibodies (A-H.l, B-H.l), a bispecific molecule comprising an anti-TCRVb antibody (Molecule H), control isotype (122) or anti-CD3e antibody (OKT3). Data shown is representative of n = 2 donors and representative of 2 independent experiments. FIGs. 27A-27L show cytokine or chemokine secretion of PBMCs activated with anti-TCRVb antibodies (A-H.l, B-H.l), a bispecific molecule comprising an anti-TCRVb antibody (Molecule H), control isotype (122) or anti-CD3e antibody (OKT3). Data shown is representative of n = 2 donors and representative of 2 independent experiments. FIG. 28 is a graph depicting mean tumor volume in NOD / SCID / IL-2Rynull (NSG) mice engrafted with Raji-luc cells at days 10 to 28. The Star denotes PBMC implantation. Open triangles denote antibody treatment with the indicated antibodies. FIGs. 29A-B depicting Mean tumor burden (Total Flux) in NOD / SCID / IL-2Rynull (NSG) mice engrafted with cancer cells and treated with the indicated antibody. NSG mice were implanted with PBMCs on Day 1 followed by injection with cancer cells on Day 7 (Raji-luc in FIG. 29A; K562-Luc control in FIG. 29B). Antibody treatment with the indicated antibodies began on Day 16. FIG. 29A shows mean tumor burden at days 16 to 37 in NOD / SCID / IL-2Rynull (NSG) mice engrafted with Raji-luc cells. FIG. 29B shows mean tumor burden (Total Flux) at days 16 to 30 in animals engrafted with K562-luc cells. FIG. 30 is a graph depicting Mean tumor burden (Total Flux) mean tumor volume in NOD / SCID / IL-2Rynull (NSG) mice engrafted with RPMI-8226 cells. The RPMI-8226 cells were engrafted on Day 1. On Day 11, PBMCs were implanted into the mice and antibody treatment began on Day 17. FIGs. 31A-31B are graphs showing % target cell lysis at different antibody concentrations. FIG.31A shows data generated using anti-TCR Vpi3.1 / anti-CD19 (Molecule F), anti-CD3 / anti-CD19, and anti-TCR Vpi3.1 (A-H.l). FIG. 31B shows data generated using anti-TCR Vpl3.1 / anti-BCMA (Molecule G), anti-CD3 / anti-BCMA, and anti-TCR Vpl3.1 (A-H.l). FIGs. 32A-32F are graphs showing cytokine secretion stimulated by anti-TCR Vp / anti-BCMA (Molecule H) or anti-CD3 (OKT3) at Days 1, 2, 3, and 5. Cytokines examined include: IFNy, IL-2, IL-Ip, IL-6, IL-10, and TNFa (FIGs. 32A-32F, respectively). FIGs. 33A-33F are graphs showing cytokine secretion stimulated by anti-TRBCl (Antibody F) or anti-CD3 (OKT3) at Days 2 and 5. Cytokines examined include: IFNy, IL-2, IL-ip, IL-6, IL-10, and TNFa (FIGs. 33A-33F, respectively). DETAILED DESCRIPTION OF THE INVENTION Current bispecific constructs designed to redirect T cells to promote tumor cell lysis for cancer immunotherapy typically utilize antibody fragments (Fab, scFv, VH, etc.) that are derived from monoclonal antibodies (mAb) directed against the CD3e subunit of the T cell receptor (TCR). However, there are limitations to this approach which may prevent the full realization of the therapeutic potential for such bispecific constructs. Previous studies have shown that even low “activating” doses of anti-CD3e mAb can cause long-term T cell dysfunction and exert immunosuppressive effects. In addition, anti-CD3e mAbs have been associated with side effects that result from massive T cell activation. The large number of activated T cells secrete substantial amounts of cytokines, the most important of which is Interferon gamma (IFNg). This excess amount of IFNg in turn activates macrophages which then overproduce proinflammatory cytokines such as IL-lbeta, IL-6, IL-10 and TNF-alpha, causing a “cytokine storm” known as the cytokine release syndrome (CRS) (Shimabukuro-Vomhagen et al., J Immunother Cancer. 2018 Jun 15;6( 1 ):56, herein incorporated by reference in its entirety). Thus, the need exists for developing antibodies that are capable of binding and activating only a subset of effector T cells, e.g., to reduce the CRS and / or neurotoxicity (NT). This invention features molecules targeting the TCRpV chain of TCR and methods thereof. Without wishing to be bound by theory, such molecules are capable of binding, activating, and / or expanding only a subset of T cells, avoiding or reducing CRS and / or NT and minimizing potential immunosuppressive effects of anti-CD3 mAbs. TCR is a disulfide-linked membrane-anchored heterodimeric protein normally consisting of the highly variable alpha (a) and beta (P) chains expressed as part of a complex with the invariant CD3 chain molecules. TCR on aP T cells is formed by a heterodimer of one alpha chain and one beta chain. Each alpha or beta chain consists of a constant domain and a highly variable domain classified as the Immunoglobulin superfamily (IgSF) fold. The TCRpV chains can be further classified into 30 subfamilies (TRBV1-30). Despite their high structural and functional homology, the amino acid sequence homology in the TRBV genes is very low. Only 4 amino acids out of -95 are identical while 10 additional amino acids are conserved among all subfamilies (see an alignment of TCRBV amino acid sequences in Table 9). Nevertheless, TCRs formed between alpha and beta chains of highly diverse sequences show a remarkable structural homology (FIGs. 24A and 24B) and elicit a similar function, e.g., activation of T cells. Disclosed herein is the discovery of a novel class of antibodies, i.e., anti-TCRpV antibody molecules disclosed herein, which despite having low sequence similarity (e.g., low sequence identity among the different antibody molecules that recognize different TCRpV subfamilies), recognize a structurally conserved, yet sequence-wise variable, region, e.g., domain, on the TCRpV protein (as denoted by the circled area in FIG. 24A) and have a similar function (e.g., activation of T cells and a similar cytokine profile as described herein). Thus, the anti-TCRpV antibody molecules disclosed herein share a structure-function relationship. Without wishing to be bound by theory, it is believed that in some embodiments, the anti-TCRpV antibody molecules disclosed herein bind to an outward facing epitope of a TCRpV protein when it is in a complex with a TCRalpha protein, e.g., as denoted by the circled area in FIG. 24A. In some embodiments, the anti-TCRpV antibody molecules disclosed herein recognize (e.g., bind to), a domain (e.g., an epitope) on the TCRpV protein that is: (1) structurally conserved among different TCRPV subfamilies; and (2) has minimal sequence identity among the different TCRpV subfamilies. As shown in Table 9, TCRpV proteins from the different TCRBV subfamilies share minimal sequence similarity. However, as shown in FIG. 24A-B, TCRpV proteins which have minimal sequence similarity, share a similar 3D conformation and structure. In some embodiments, the anti-TCRpV antibody molecules disclosed herein do not recognize, e.g., bind to, an interface of a TCRpV:TCRalpha complex. In some embodiments, the anti-TCRpV antibody molecules disclosed herein do not recognize, e.g., bind to, a constant region of a TCRpV protein. In some embodiments, the anti-TCRpV antibody molecules disclosed herein do not recognize, e.g., bind to, one or more (e.g., all) of a complementarity determining region (e.g., CDR1, CDR2 and / or CDR3) of a TCRpV protein. This disclosure provides, inter alia, antibody molecules directed to the variable chain of the beta subunit of TCR (TCRpV) which bind and, e.g., activate a subset of T cells. The anti-TCRpV antibody molecules disclosed herein result in lesser or no production of cytokines associated with CRS, e.g., IL-6, IL-lbeta, IL-10 and TNF alpha; and enhanced and / or delayed production of IL-2 and IFNg. In some embodiments, the anti-TCRpV antibodies disclosed herein have a cytokine profile, e.g., as described herein, which differs from a cytokine profile of a T cell engager that binds to a receptor or molecule other than a TCRpV region (“a non-TCRpV-binding T cell engager”). In some embodiments, the anti-TCRpV antibodies disclosed herein result in expansion of TCRPV+ T cells, e.g., a subset of memory effector T cells known as Temra. Without wishing to be bound by theory, it is believed that in some embodiments, Temra cells can promote tumor cell lysis but not CRS. Accordingly, provided herein are methods of making said anti-TCRpV antibody molecules and uses thereof. Also disclosed herein are multispecific molecules, e.g., bispecific molecules comprising said anti-TCRpV antibody molecules. In some embodiments, compositions comprising anti-TCRpV antibody molecules of the present disclosure, can be used, e.g., to: (1) activate and redirect T cells to promote tumor cell lysis for cancer immunotherapy; and / or (2) expand TCRPV+ T cells. In some embodiments, compositions comprising anti-TCRpV antibody molecules as disclosed herein limit the harmful side-effects of CRS and / or NT, e.g., CRS and / or NT associated with anti-CD3e targeting. In some embodiments, the anti-TCRpV antibody molecule does not bind to TCRP V12, or binds to TCRP V12 with an affinity and / or binding specificity that is less than (e.g., less than about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or about 2-, 5-, or 10- fold) the affinity and / or binding specificity of the 16G8 murine antibody or a humanized version thereof as described in US Patent 5,861,155. In some embodiments, the anti-TCRpV antibody molecule binds to TCRP V12 with an affinity and / or binding specificity that is greater than (e.g., greater than about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or about 2-, 5-, or 10- fold) the affinity and / or binding specificity of the 16G8 murine antibody or a humanized version thereof as described in US Patent 5,861,155. In some embodiments, the anti-TCRpV antibody molecule binds to a TCRpV region other than TCRP V12 (e.g., TCRpV region as described herein, e.g., TCRP V6 subfamily (e.g., TCRP V6-5*01) with an affinity and / or binding specificity that is greater than (e.g., greater than about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or about 2-, 5-, or 10- fold) the affinity and / or binding specificity of the 16G8 murine antibody or a humanized version thereof as described in US Patent 5,861,155. In some embodiments, the anti-TCRpV antibody molecule does not comprise the CDRs of the Antibody B murine antibody. In some embodiments, the anti-TCRpV antibody molecule does not bind to TCRP V5-5*01 or TCRP V5-l*01, or binds to TCRP V5-5*01 or TCRP V5-l*01 with an affinity and / or binding specificity that is less than (e.g., less than about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or about 2-, 5-, or 10- fold) the affinity and / or binding specificity of the TM23 murine antibody or a humanized version thereof as described in US Patent 5,861,155. In some embodiments, the anti-TCRpV antibody molecule binds to TCRP V5-5*01 or TCRP V5-l*01with an affinity and / or binding specificity that is greater than (e.g., greater than about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or about 2-, 5-, or 10- fold) the affinity and / or binding specificity of the TM23 murine antibody or a humanized version thereof as described in US Patent 5,861,155. In some embodiments, the anti-TCRpV antibody molecule binds to a TCRpV region other than TCRP V5-5*01 or TCRP V5-l*01 (e.g., TCRpV region as described herein, e.g., TCRP V6 subfamily (e.g., TCRP V6-5*01) with an affinity and / or binding specificity that is greater than (e.g., greater than about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or about 2-, 5-, or 10- fold) the affinity and / or binding specificity of the TM23 murine antibody or a humanized version thereof as described in US Patent 5,861,155. In some embodiments, the anti-TCRpV antibody molecule does not comprise the CDRs of the TM23 murine antibody. Accordingly, provided herein are, inter alia, anti-TCRpV antibody molecules, multispecific or multifunctional molecules (e.g., multispecific or multifunctional antibody molecules) that comprise anti-TCRpV antibody molecules, nucleic acids encoding the same, methods of producing the aforesaid molecules, pharmaceutical compositions comprising aforesaid molecules, and methods of treating a disease or disorder, e.g., cancer, using the aforesaid molecules. The antibody molecules and pharmaceutical compositions disclosed herein can be used (alone or in combination with other agents or therapeutic modalities) to treat, prevent and / or diagnose disorders and conditions, e.g., cancer, e.g., as described herein. Definitions Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. The term “a” and “an” refers to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element. The term “about” when referring to a measurable value such as an amount, a temporal duration, and the like, is meant to encompass variations of ±20% or in some instances ±10%, or in some instances ±5%, or in some instances ±1%, or in some instances ±0.1% from the specified value, as such variations are appropriate to perform the disclosed methods. The term “acquire” or “acquiring” as the terms are used herein, refer to obtaining possession of a physical entity (e.g., a sample, a polypeptide, a nucleic acid, or a sequence), or a value, e.g., a numerical value, by “directly acquiring” or “indirectly acquiring” the physical entity or value. “Directly acquiring” means performing a process (e.g., performing a synthetic or analytical method) to obtain the physical entity or value. “Indirectly acquiring” refers to receiving the physical entity or value from another party or source (e.g., a third party laboratory that directly acquired the physical entity or value). Directly acquiring a physical entity includes performing a process that includes a physical change in a physical substance, e.g., a starting material. Directly acquiring a value includes performing a process that includes a physical change in a sample or another substance, e.g., performing an analytical process which includes a physical change in a substance, e.g., a sample. As used herein, the term “T cell receptor beta variable chain” or “TCRpV,” refers to an extracellular region of the T cell receptor beta chain which comprises the antigen recognition domain of the T cell receptor. The term TCRpV includes isoforms, mammalian, e.g., human TCRpV, species homologs of human and analogs comprising at least one common epitope with TCRpV. Human TCRpV comprises a gene family comprising subfamilies including, but not limited to: a TCRP V6 subfamily, a TCRP V10 subfamily, a TCRP V12 subfamily, a TCRP V5 subfamily, a TCRP V7 subfamily, a TCRP Vil subfamily, a TCRP V14 subfamily, a TCRP V16 subfamily, a TCRp VI8 subfamily, a TCRp V9 subfamily, a TCRp V13 subfamily, a TCRp V4 subfamily, a TCRp V3 subfamily, a TCRp V2 subfamily, a TCRp V15 subfamily, a TCRp V30 subfamily, a TCRp V19 subfamily, a TCRp V27 subfamily, a TCRp V28 subfamily, a TCRp V24 subfamily, a TCRp V20 subfamily, TCRp V25 subfamily, a TCRp V29 subfamily, a TCRp VI subfamily, a TCRP V17 subfamily, a TCRP V21 subfamily, a TCRP V23 subfamily, or a TCRP V26 subfamily, as well as family members of said subfamilies, and variants thereof (e.g., a structural or functional variant thereof). In some embodiments, the TCRP V6 subfamily comprises: TCRp V6-4*01, TCRp V6-4*02, TCRp V6-9*01, TCRp V6-8*01, TCRp V6-5*01, TCRp V6-6*02, TCRp V6-6*01, TCRp V6-2*01, TCRp V6-3*01 or TCRp V6-l*01. In some embodiments, TCRpV comprises TCRP V6-5*01, or a variant thereof, e.g., a variant having 85%, 90%, 95%, 99% or more identity the naturally-occurring sequence. TCRP V6-5*01 is also known as TRBV65; TCRBV6S5; TCRBV13S1, or TCRp V13.1. The amino acid sequence of TCRP V6-5*01, e.g., human TCRP V6-5*01, is known in that art, e.g., as provided by IMGT ID L36092. In some embodiments, TCRP V6-5*01 is encoded by the nucleic acid sequence of SEQ ID NO: 43, or a sequence having 85%, 90%, 95%, 99% or more identity thereof. In some embodiments, TCRP V6-5*01 comprises the amino acid sequence of SEQ ID NO: 44, or a sequence having 85%, 90%, 95%, 99% or more identity thereof. The term “human-like antibody molecule” as used herein refers to a humanized antibody molecule, human antibody molecule or an antibody molecule having at least 95% identity with a non-murine germline framework region, e.g., FR1, FR2, FR3 and / or FR4. In some embodiments, the human-like antibody molecule comprises a framework region having at least 95% identity to a human germline framework region, e.g., a FR1, FR2, FR3 and / or FR4 of a human germline framework region. In some embodiments, the human-like antibody molecule is a recombinant antibody. In some embodiments, the human-like antibody molecule is a humanized antibody molecule. In some embodiments, the human-like antibody molecule is human antibody molecule. In some embodiments, the human-like antibody molecule is a phage display or a yeast display antibody molecule. In some embodiments, the human-like antibody molecule is a chimeric antibody molecule. In some embodiments, the human-like antibody molecule is a CDR grafted antibody molecule. The term “cytokine profile” as used herein, refers to the level and / or activity of on one or more cytokines or chemokines, e.g., as described herein. In some embodiments, a cytokine profile comprises the level and / or activity of a naturally occurring cytokine, a fragment or a variant thereof. In an embodiment, a cytokine profile comprises the level and / or activity of one or more cytokines and / or one or more chemokines (e.g., as described herein). In some embodiments, a cytokine profile comprises the level and / or activity of a naturally occurring cytokine, a fragment or a variant thereof. In some embodiments, a cytokine profile comprises the level and / or activity of a naturally occurring chemokine, a fragment or a variant thereof. In an embodiment, a cytokine profile comprises the level and / or activity of one or more of: IL-2 (e.g., full length, a variant, or a fragment thereof); IL-lbeta (e.g., full length, a variant, or a fragment thereof); IL-6 (e.g., full length, a variant, or a fragment thereof); TNFa (e.g., full length, a variant, or a fragment thereof); IFNg (e.g., full length, a variant, or a fragment thereof) IL-10 (e.g., full length, a variant, or a fragment thereof); IL-4 (e.g., full length, a variant, or a fragment thereof); TNF alpha (e.g., full length, a variant, or a fragment thereof) ;IL-12p70 (e.g., full length, a variant, or a fragment thereof); IL-13 (e.g., full length, a variant, or a fragment thereof); IL-8 (e.g., full length, a variant, or a fragment thereof); Eotaxin (e.g., full length, a variant, or a fragment thereof); Eotaxin-3 (e.g., full length, a variant, or a fragment thereof); IL-8 (HA) (e.g., full length, a variant, or a fragment thereof); IP-10 (e.g., full length, a variant, or a fragment thereof); MCP-1 (e.g., full length, a variant, or a fragment thereof); MCP-4 (e.g., full length, a variant, or a fragment thereof); MDC (e.g., full length, a variant, or a fragment thereof); MIP-la (e.g., full length, a variant, or a fragment thereof); MIP-lb (e.g., full length, a variant, or a fragment thereof); TARC (e.g., full length, a variant, or a fragment thereof); GM-CSF (e.g., full length, a variant, or a fragment thereof); IL-12 23p40 (e.g., full length, a variant, or a fragment thereof); IL-15 (e.g., full length, a variant, or a fragment thereof); IL-16 (e.g., full length, a variant, or a fragment thereof); IL-17a (e.g., full length, a variant, or a fragment thereof); IL-la (e.g., full length, a variant, or a fragment thereof); IL-5 (e.g., full length, a variant, or a fragment thereof); IL-7 (e.g., full length, a variant, or a fragment thereof); TNF-beta (e.g., full length, a variant, or a fragment thereof); or VEGF (e.g., full length, a variant, or a fragment thereof). In some embodiments, a cytokine profile includes secretion of one or more cytokines or chemokines. In an embodiment, a cytokine in a cytokine profile can be modulated, e.g., increased or decreased, by an anti-TCRBV antibody molecule described herein. In one embodiment, the cytokine profile includes cytokines associated with a cytokine storm or cytokine release syndrome (CRS), e.g., IL-6, IL-lbeta, TNFalpha and IL-10. The term “variant” refers to a polypeptide that has a substantially identical amino acid sequence to the naturally-occurring sequence, or are encoded by a substantially identical nucleotide sequence. In some embodiments, the variant is a functional variant. In some embodiments, a TCRpV variant can bind to TCRa and form a TCR a:P complex. The term “functional variant” refers to a polypeptide that has a substantially identical amino acid sequence to the naturally-occurring sequence, or are encoded by a substantially identical nucleotide sequence, and are capable of having one or more activities of the naturally-occurring sequence. As used herein, a “multifunctional” or a “multispecific” molecule refers to molecule, e.g., a polypeptide, that has two or more functionalities, e.g., two or more binding specificities. In some embodiments, the functionalities can include one or more immune cell engagers, one or more tumor binding molecules, one or more cytokine molecules, one or more stromal modifiers, and other moieties described herein. In some embodiments, the multispecific molecule is a multispecific antibody molecule, e.g., a bispecific antibody molecule. In some embodiments, the multispecific molecule includes an anti-TCRVb antibody molecule as described herein. In some embodiments, the multifunctional molecule includes an immune cell engager. “An immune cell engager” refers to one or more binding specificities that bind and / or activate an immune cell, e.g., a cell involved in an immune response. In embodiments, the immune cell is chosen from a T cell, an NK cell, a B cell, a dendritic cell, and / or the macrophage cell. The immune cell engager can be an antibody molecule, a receptor molecule (e.g., a full length receptor, receptor fragment, or fusion thereof (e.g., a receptor-Fc fusion)), or a ligand molecule (e.g., a full length ligand, ligand fragment, or fusion thereof (e.g., a ligand-Fc fusion)) that binds to the immune cell antigen (e.g., the T cell, the NK cell antigen, the B cell antigen, the dendritic cell antigen, and / or the macrophage cell antigen). In embodiments, the immune cell engager specifically binds to the target immune cell, e.g., binds preferentially to the target immune cell. For example, when the immune cell engager is an antibody molecule, it binds to an immune cell antigen (e.g., a T cell antigen, an NK cell antigen, a B cell antigen, a dendritic cell antigen, and / or a macrophage cell antigen) with a dissociation constant of less than about 10 nM. In some embodiments, the multifunctional molecule includes a cytokine molecule. As used herein, a “cytokine molecule” refers to full length, a fragment or a variant of a cytokine; a cytokine further comprising a receptor domain, e.g., a cytokine receptor dimerizing domain; or an agonist of a cytokine receptor, e.g., an antibody molecule (e.g., an agonistic antibody) to a cytokine receptor, that elicits at least one activity of a naturally-occurring cytokine. In some embodiments the cytokine molecule is chosen from interleukin-2 (IL-2), interleukin-7 (IL-7), interleukin-12 (IL-12), interleukin-10 (IL-10), interleukin-15 (IL-15), interleukin-18 (IL-18), interleukin-21 (IL-21), or interferon gamma, or a fragment or variant thereof, or a combination of any of the aforesaid cytokines. The cytokine molecule can be a monomer or a dimer. In embodiments, the cytokine molecule can further include a cytokine receptor dimerizing domain. In other embodiments, the cytokine molecule is an agonist of a cytokine receptor, e.g., an antibody molecule (e.g., an agonistic antibody) to a cytokine receptor chosen from an IL-15Ra or IL-21R. As used herein, the term “molecule” as used in, e.g., antibody molecule, cytokine molecule, receptor molecule, includes full-length, naturally-occurring molecules, as well as variants, e.g., functional variants (e.g., truncations, fragments, mutated (e.g., substantially similar sequences) or derivatized form thereof), so long as at least one function and / or activity of the unmodified (e.g., naturally-occurring) molecule remains. In some embodiments, the multifunctional molecule includes a stromal modifying moiety. A “stromal modifying moiety,” as used herein refers to an agent, e.g., a protein (e.g., an enzyme), that is capable of altering, e.g., degrading a component of, the stroma. In embodiments, the component of the stroma is chosen from, e.g., an ECM component, e.g., a glycosaminoglycan, e.g., hyaluronan (also known as hyaluronic acid or HA), chondroitin sulfate, chondroitin, dermatan sulfate, heparin sulfate, heparin, entactin, tenascin, aggrecan and keratin sulfate; or an extracellular protein, e.g., collagen, laminin, elastin, fibrinogen, fibronectin, and vitronectin. Certain terms are defined below. As used herein, the articles “a” and “an” refer to one or more than one, e.g., to at least one, of the grammatical object of the article. The use of the words "a" or "an" when used in conjunction with the term "comprising" herein may mean "one," but it is also consistent with the meaning of "one or more," "at least one," and "one or more than one." As used herein, “about” and “approximately” generally mean an acceptable degree of error for the quantity measured given the nature or precision of the measurements. Exemplary degrees of error are within 20 percent (%), typically, within 10%, and more typically, within 5% of a given range of values. “Antibody molecule” as used herein refers to a protein, e.g., an immunoglobulin chain or fragment thereof, comprising at least one immunoglobulin variable domain structure and / or sequence. An antibody molecule encompasses antibodies (e.g., full-length antibodies) and antibody fragments. In an embodiment, an antibody molecule comprises an antigen binding or functional fragment of a full length antibody, or a full length immunoglobulin chain. For example, a full-length antibody is an immunoglobulin (Ig) molecule (e.g., an IgG antibody) that is naturally occurring or formed by normal immunoglobulin gene fragment recombinatorial processes). In embodiments, an antibody molecule refers to an immunologically active, antigenbinding portion of an immunoglobulin molecule, such as an antibody fragment. An antibody fragment, e.g., functional fragment, is a portion of an antibody, e.g., Fab, Fab', F(ab')2, F(ab)2, variable fragment (Fv), domain antibody (dAb), or single chain variable fragment (scFv). A functional antibody fragment binds to the same antigen as that recognized by the intact (e.g., fulllength) antibody. The terms “antibody fragment” or “functional fragment” also include isolated fragments consisting of the variable regions, such as the “Fv” fragments consisting of the variable regions of the heavy and light chains or recombinant single chain polypeptide molecules in which light and heavy variable regions are connected by a peptide linker (“scFv proteins”). In some embodiments, an antibody fragment does not include portions of antibodies without antigen binding activity, such as Fc fragments or single amino acid residues. Exemplary antibody molecules include full length antibodies and antibody fragments, e.g., dAb (domain antibody), single chain, Fab, Fab’, and F(ab’)2fragments, and single chain variable fragments (scFvs). In some embodiments, the antibody molecule is an antibody mimetic. In some embodiments, the antibody molecule is, or comprises, an antibody-like framework or scaffold, such as, fibronectins, ankyrin repeats (e.g., designed ankyrin repeat proteins (DARPins)), avimers, affibody affinity ligands, anticalins, or affilin molecules. As used herein, an “immunoglobulin variable domain sequence” refers to an amino acid sequence which can form the structure of an immunoglobulin variable domain. For example, the sequence may include all or part of the amino acid sequence of a naturally-occurring variable domain. For example, the sequence may or may not include one, two, or more N- or C-terminal amino acids, or may include other alterations that are compatible with formation of the protein structure. In embodiments, an antibody molecule is monospecific, e.g., it comprises binding specificity for a single epitope. In some embodiments, an antibody molecule is multispecific, e.g., it comprises a plurality of immunoglobulin variable domain sequences, where a first immunoglobulin variable domain sequence has binding specificity for a first epitope and a second immunoglobulin variable domain sequence has binding specificity for a second epitope. In some embodiments, an antibody molecule is a bispecific antibody molecule. “Bispecific antibody molecule” as used herein refers to an antibody molecule that has specificity for more than one (e.g., two, three, four, or more) epitope and / or antigen. “Antigen” (Ag) as used herein refers to a molecule that can provoke an immune response, e.g., involving activation of certain immune cells and / or antibody generation. Any macromolecule, including almost all proteins or peptides, can be an antigen. Antigens can also be derived from genomic recombinant or DNA. For example, any DNA comprising a nucleotide sequence or a partial nucleotide sequence that encodes a protein capable of eliciting an immune response encodes an “antigen.” In embodiments, an antigen does not need to be encoded solely by a full length nucleotide sequence of a gene, nor does an antigen need to be encoded by a gene at all. In embodiments, an antigen can be synthesized or can be derived from a biological sample, e.g., a tissue sample, a tumor sample, a cell, or a fluid with other biological components. As used, herein a “tumor antigen” or interchangeably, a “cancer antigen” includes any molecule present on, or associated with, a cancer, e.g., a cancer cell or a tumor microenvironment that can provoke an immune response. As used, herein an “immune cell antigen” includes any molecule present on, or associated with, an immune cell that can provoke an immune response. The “antigen-binding site,” or “binding portion” of an antibody molecule refers to the part of an antibody molecule, e.g., an immunoglobulin (Ig) molecule, that participates in antigen binding. In embodiments, the antigen binding site is formed by amino acid residues of the variable (V) regions of the heavy (H) and light (L) chains. Three highly divergent stretches within the variable regions of the heavy and light chains, referred to as hypervariable regions, are disposed between more conserved flanking stretches called “framework regions,” (FRs). FRs are amino acid sequences that are naturally found between, and adjacent to, hypervariable regions in immunoglobulins. In embodiments, in an antibody molecule, the three hypervariable regions of a light chain and the three hypervariable regions of a heavy chain are disposed relative to each other in three dimensional space to form an antigen-binding surface, which is complementary to the three-dimensional surface of a bound antigen. The three hypervariable regions of each of the heavy and light chains are referred to as “complementarity-determining regions,” or “CDRs.” The framework region and CDRs have been defined and described, e.g., in Kabat, E.A., et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242, and Chothia, C. et al. (1987) J. Mol. Biol. 196:901-917. Each variable chain (e.g., variable heavy chain and variable light chain) is typically made up of three CDRs and four FRs, arranged from amino-terminus to carboxyterminus in the amino acid order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. “Cancer” as used herein can encompass all types of oncogenic processes and / or cancerous growths. In embodiments, cancer includes primary tumors as well as metastatic tissues or malignantly transformed cells, tissues, or organs. In embodiments, cancer encompasses all histopathologies and stages, e.g., stages of invasiveness / severity, of a cancer. In embodiments, cancer includes relapsed and / or resistant cancer. The terms “cancer” and “tumor” can be used interchangeably. For example, both terms encompass solid and liquid tumors. As used herein, the term “cancer” or “tumor” includes premalignant, as well as malignant cancers and tumors. As used herein, an “immune cell” refers to any of various cells that function in the immune system, e.g., to protect against agents of infection and foreign matter. In embodiments, this term includes leukocytes, e.g., neutrophils, eosinophils, basophils, lymphocytes, and monocytes. Innate leukocytes include phagocytes (e.g., macrophages, neutrophils, and dendritic cells), mast cells, eosinophils, basophils, and natural killer cells. Innate leukocytes identify and eliminate pathogens, either by attacking larger pathogens through contact or by engulfing and then killing microorganisms, and are mediators in the activation of an adaptive immune response. The cells of the adaptive immune system are special types of leukocytes, called lymphocytes. B cells and T cells are important types of lymphocytes and are derived from hematopoietic stem cells in the bone marrow. B cells are involved in the humoral immune response, whereas T cells are involved in cell-mediated immune response. The term “immune cell” includes immune effector cells. “Immune effector cell,” as that term is used herein, refers to a cell that is involved in an immune response, e.g., in the promotion of an immune effector response. Examples of immune effector cells include, but are not limited to, T cells, e.g., alpha / beta T cells and gamma / delta T cells, B cells, natural killer (NK) cells, natural killer T (NK T) cells, and mast cells. The term “effector function” or “effector response” refers to a specialized function of a cell. Effector function of a T cell, for example, may be cytolytic activity or helper activity including the secretion of cytokines. The compositions and methods of the present invention encompass polypeptides and nucleic acids having the sequences specified, or sequences substantially identical or similar thereto, e.g., sequences at least 80%, 85%, 90%, 95% identical or higher to the sequence specified. In the context of an amino acid sequence, the term "substantially identical" is used herein to refer to a first amino acid that contains a sufficient or minimum number of amino acid residues that are i) identical to, or ii) conservative substitutions of aligned amino acid residues in a second amino acid sequence such that the first and second amino acid sequences can have a common structural domain and / or common functional activity. For example, amino acid sequences that contain a common structural domain having at least about 80%, 85%, 90%. 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to a reference sequence, e.g., a sequence provided herein. In the context of nucleotide sequence, the term "substantially identical" is used herein to refer to a first nucleic acid sequence that contains a sufficient or minimum number of nucleotides that are identical to aligned nucleotides in a second nucleic acid sequence such that the first and second nucleotide sequences encode a polypeptide having common functional activity, or encode a common structural polypeptide domain or a common functional polypeptide activity. For example, nucleotide sequences having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to a reference sequence, e.g., a sequence provided herein. The term “variant” refers to a polypeptide that has a substantially identical amino acid sequence to a reference amino acid sequence, or is encoded by a substantially identical nucleotide sequence. In some embodiments, the variant is a functional variant. The term “functional variant” refers to a polypeptide that has a substantially identical amino acid sequence to a reference amino acid sequence, or is encoded by a substantially identical nucleotide sequence, and is capable of having one or more activities of the reference amino acid sequence. Calculations of homology or sequence identity between sequences (the terms are used interchangeably herein) are performed as follows. To determine the percent identity of two amino acid sequences, or of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, the length of a reference sequence aligned for comparison purposes is at least 30%, preferably at least 40%, more preferably at least 50%, 60%, and even more preferably at least 70%, 80%, 90%, 100% of the length of the reference sequence. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid "identity" is equivalent to amino acid or nucleic acid "homology"). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch ((1970) J. Mol. Biol. 48:444-453 ) algorithm which has been incorporated into the GAP program in the GCG software package (available at http: / / www.gcg.com), using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (available at http: / / www.gcg.com), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. A particularly preferred set of parameters (and the one that should be used unless otherwise specified) are a Blossum 62 scoring matrix with a gap penalty of 12, a gap extend penalty of 4, and a frameshift gap penalty of 5. The percent identity between two amino acid or nucleotide sequences can be determined using the algorithm of E. Meyers and W. Miller ((1989) CABIOS, 4:11-17) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. The nucleic acid and protein sequences described herein can be used as a "query sequence" to perform a search against public databases to, for example, identify other family members or related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. (1990) J. Mol. Biol. 215:403-10. BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to a nucleic acid molecule of the invention. BLAST protein searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al., (1997) Nucleic Acids Res. 25:3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. It is understood that the molecules of the present invention may have additional conservative or non-essential amino acid substitutions, which do not have a substantial effect on their functions. The term "amino acid" is intended to embrace all molecules, whether natural or synthetic, which include both an amino functionality and an acid functionality and capable of being included in a polymer of naturally-occurring amino acids. Exemplary amino acids include naturally-occurring amino acids; analogs, derivatives and congeners thereof; amino acid analogs having variant side chains; and all stereoisomers of any of any of the foregoing. As used herein the term "amino acid" includes both the D- or L- optical isomers and peptidomimetics. A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). The terms "polypeptide", "peptide" and "protein" (if single chain) are used interchangeably herein to refer to polymers of amino acids of any length. The polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by nonamino acids. The terms also encompass an amino acid polymer that has been modified; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component. The polypeptide can be isolated from natural sources, can be a produced by recombinant techniques from a eukaryotic or prokaryotic host, or can be a product of synthetic procedures. The terms "nucleic acid," "nucleic acid sequence," "nucleotide sequence," or "polynucleotide sequence," and "polynucleotide" are used interchangeably. They refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof. The polynucleotide may be either single-stranded or double-stranded, and if single-stranded may be the coding strand or non-coding (antisense) strand. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs. The sequence of nucleotides may be interrupted by non-nucleotide components. A polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component. The nucleic acid may be a recombinant polynucleotide, or a polynucleotide of genomic, cDNA, semisynthetic, or synthetic origin which either does not occur in nature or is linked to another polynucleotide in a non-natural arrangement. The term "isolated," as used herein, refers to material that is removed from its original or native environment (e.g., the natural environment if it is naturally occurring). For example, a naturally-occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or polypeptide, separated by human intervention from some or all of the co-existing materials in the natural system, is isolated. Such polynucleotides could be part of a vector and / or such polynucleotides or polypeptides could be part of a composition, and still be isolated in that such vector or composition is not part of the environment in which it is found in nature. Various aspects of the invention are described in further detail below. Additional definitions are set out throughout the specification. Human T cell receptor (TCR) complex T cell receptors (TCR) can be found on the surface of T cells. TCRs recognize antigens, e.g., peptides, presented on, e.g., bound to, major histocompatibility complex (MHC) molecules on the surface of cells, e.g., antigen-presenting cells. TCRs are heterodimeric molecules and can comprise an alpha chain, a beta chain, a gamma chain or a delta chain. TCRs comprising an alpha chain and a beta chain are also referred to as TCRap. The TCR beta chain consists of the following regions (also known as segments): variable (V), diversity (D), joining (J) and constant (C) (see Mayer G. and Nyland J. (2010) Chapter 10: Major Histocompatibility Complex and T-cell Receptors-Role in Immune Responses. In: Microbiology and Immunology on-line, University of South Carolina School of Medicine). The TCR alpha chain consists of V, J and C regions. The rearrangement of the T-cell receptor (TCR) through somatic recombination of V (variable), D (diversity), J (joining), and C (constant) regions is a defining event in the development and maturation of a T cell. TCR gene rearrangement takes place in the thymus. TCRs can comprise a receptor complex, known as the TCR complex, which comprises a TCR heterodimer comprising of an alpha chain and a beta chain, and dimeric signaling molecules, e.g., CD3 co-receptors, e.g., CD36 / s, and / or CD3y / s. TCR beta V (TCRpV) Diversity in the immune system enables protection against a huge array of pathogens. Since the germline genome is limited in size, diversity is achieved not only by the process of V(D)J recombination but also by junctional (junctions between V-D and D-J segments) deletion of nucleotides and addition of pseudo-random, non-templated nucleotides. The TCR beta gene undergoes gene arrangement to generate diversity. The TCR V beta repertoire varies between individuals and populations because of, e.g., 7 frequently occurring inactivating polymorphisms in functional gene segments and a large insertion / deletion-related polymorphism encompassing 2 V beta gene segments. This disclosure provides, inter alia, antibody molecules and fragments thereof, that bind, e.g., specifically bind, to a human TCR beta V chain (TCRpV), e.g., a TCRpV gene family (also referred to as a group), e.g., a TCRpV subfamily (also referred to as a subgroup), e.g., as described herein. TCR beta V families and subfamilies are known in the art, e.g., as described in Yassai et al., (2009) Immunogenetics 61(7)pp:493-502; Wei S. and Concannon P. (1994) Human Immunology 41(3) pp: 201-206. The antibodies described herein can be recombinant antibodies, e.g., recombinant non-murine antibodies, e.g., recombinant human or humanized antibodies. In an aspect, the disclosure provides an anti-TCRpV antibody molecule that binds to human TCRpV, e.g., a TCRpV family, e.g., gene family or a variant thereof. In some embodiments a TCRBV gene family comprises one or more subfamilies, e.g., as described herein, e.g., in FIG. 3, Table 8A or Table 8B. In some embodiments, the TCRpV gene family comprises: a TCRP V6 subfamily, a TCRP V10 subfamily, a TCRP V12 subfamily, a TCRP V5 subfamily, a TCRP V7 subfamily, a TCRP Vil subfamily, a TCRP V14 subfamily, a TCRP V16 subfamily, a TCRp VI8 subfamily, a TCRp V9 subfamily, a TCRp V13 subfamily, a TCRp V4 subfamily, a TCRp V3 subfamily, a TCRp V2 subfamily, a TCRp V15 subfamily, a TCRp V30 subfamily, a TCRp V19 subfamily, a TCRp V27 subfamily, a TCRp V28 subfamily, a TCRp V24 subfamily, a TCRp V20 subfamily, TCRp V25 subfamily, a TCRp V29 subfamily, a TCRp VI subfamily, a TCRP V17 subfamily, a TCRP V21 subfamily, a TCRP V23 subfamily, or a TCRP V26 subfamily. In some embodiments, TCRP V6 subfamily is also known as TCRP V13.1. In some embodiments, the TCRP V6 subfamily comprises: TCRP V6-4*01, TCRP V6-4*02, TCRP V6-9*01, TCRp V6-8*01, TCRp V6-5*01, TCRp V6-6*02, TCRp V6-6*01, TCRp V6-2*01, TCRp V6-3*01 or TCRP V6-l*01, or a variant thereof. In some embodiments, TCRP V6 comprises TCRP V6-4*01, or a variant thereof. In some embodiments, TCRP V6 comprises TCRP V6-4*02, or a variant thereof. In some embodiments, TCRP V6 comprises TCRP V6-9*01, or a variant thereof. In some embodiments, TCRP V6 comprises TCRP V6-8*01, or a variant thereof. In some embodiments, TCRP V6 comprises TCRP V6-5*01, or a variant thereof. In some embodiments, TCRP V6 comprises TCRP V6-6*02, or a variant thereof. In some embodiments, TCRP V6 comprises TCRP V6-6*01, or a variant thereof. In some embodiments, TCRP V6 comprises TCRP V6-2*01, or a variant thereof. In some embodiments, TCRP V6 comprises TCRP V6-3*01, or a variant thereof. In some embodiments, TCRP V6 comprises TCRP V6-1*01, or a variant thereof. In some embodiments, TCRP V6 comprises TCRP V6-5*01, or a variant thereof. In some embodiments, TCRP V6, e.g., TCRP V6-5*01, is recognized, e.g., bound, by SEQ ID NO: 1 and / or SEQ ID NO: 2. In some embodiments, TCRP V6, e.g., TCRP V6-5*01, is recognized, e.g., bound, by SEQ ID NO: 9 and / or SEQ ID NO: 10. In some embodiments, TCRP V6 is recognized, e.g., bound, by SEQ ID NO: 9 and / or SEQ ID NO: 11. In some embodiments, TCRP V10 subfamily is also known as TCRP V12. In some embodiments, the TCRP V10 subfamily comprises: TCRP V10-l*01, TCRP V10-l*02, TCRP V10-3*01 or TCRP V10-2*01, or a variant thereof. In some embodiments, TCRP V12 subfamily is also known as TCRP V8.1. In some embodiments, the TCRP V12 subfamily comprises: TCRP V12-4*01, TCRP V12-3*01, or TCRP V12-5*01, or a variant thereof. In some embodiments, TCRP V12 is recognized, e.g., bound, by SEQ ID NO: 15 and / or SEQ ID NO: 16. In some embodiments, TCRP V12 is recognized, e.g., bound, by any one of SEQ ID NOs 23-25, and / or any one of SEQ ID NO: 26-30: In some embodiments, the TCRP V5 subfamily is chosen from: TCRP V5-5*01, TCRP V5-6*01, TCRp V5-4*01, TCRp V5-8*01, TCRp V5-l*01, or a variant thereof. In some embodiments, the TCRP V7 subfamily comprises TCRP V7-7*01, TCRP V7-6*01, TCRp V7 -8*02, TCRp V7 -4*01, TCRp V7-2*02, TCRp V7-2*03, TCRp V7-2*01, TCRp V7-3*01, TCRp V7-9*03, or TCRp V7-9*01, or a variant thereof. In some embodiments, the TCRP Vil subfamily comprises: TCRP VI 1-1*01, TCRP VI 1-2*01 or TCRP VI 1-3*01, or a variant thereof. In some embodiments, the TCRP V14 subfamily comprises TCRP V14*01, or a variant thereof. In some embodiments, the TCRP V16 subfamily comprises TCRP V16*01, or a variant thereof. In some embodiments, the TCRP V18 subfamily comprises TCRP V18*01, or a variant thereof. In some embodiments, the TCRP V9 subfamily comprises TCRP V9*01 or TCRP V9*02, or a variant thereof. In some embodiments, the TCRP V13 subfamily comprises TCRP V13*01, or a variant thereof. In some embodiments, the TCRP V4 subfamily comprises TCRP V4-2*01, TCRP V4-3*01, or TCRP V4-l*01, or a variant thereof. In some embodiments, the TCRP V3 subfamily comprises TCRP V3-l*01, or a variant thereof. In some embodiments, the TCRP V2 subfamily comprises TCRP V2*01, or a variant thereof. In some embodiments, the TCRP V15 subfamily comprises TCRP V15*01, or a variant thereof. In some embodiments, the TCRP V30 subfamily comprises TCRP V30*01, or TCRP V30*02, or a variant thereof. In some embodiments, the TCRP V19 subfamily comprises TCRP V19*01, or TCRP VI9*02, or a variant thereof. In some embodiments, the TCRP V27 subfamily comprises TCRP V27*01, or a variant thereof. In some embodiments, the TCRP V28 subfamily comprises TCRP V28*01, or a variant thereof. In some embodiments, the TCRP V24 subfamily comprises TCRP V24-l*01, or a variant thereof. 5         In some embodiments, the TCRP V20 subfamily comprises TCRP V20-l*01, or TCRP V20-l*02, or a variant thereof. In some embodiments, the TCRP V25 subfamily comprises TCRP V25-l*01, or a variant thereof. In some embodiments, the TCRP V29 subfamily comprises TCRP V29-l*01, or a variant 10 thereof. Table 8A: List of TCRpV subfamilies and subfamily members Reference in Fig. 3 Subfamily Subfamily members A TCRp V6 Also referred to as: TCR VB 13.1 TCRp V6-4*01, TCRp V6-4*02, TCRp V6-9*01, TCRp V6-8*01, TCRp V6-5*01, TCRp V6-6*02, TCRp V6-6*01, TCRp V6-2*01, TCRp V6-3*01 or TCRp V6-l*01. B TCRp V10 Also referred to as: TCRp V12 TCRp V10-l*01, TCRp V10-l*02, TCRp V10-3*01 or TCRp V10-2*01 C TCRp V12 Also referred to as: TCRp V8.1 TCRp V12-4*01, TCRp V12-3*01, or TCRp V12-5*01 D TCRp V5 TCRp V5-5*01, TCRp V5-6*01, TCRp V5-4*01, TCRp V5-8*01, TCRp V5-l*01 E TCRp V7 TCRp V7-7*01, TCRp V7-6*01, TCRp V7 -8*02, TCRp V7 -4*01, TCRp V7-2*02, TCRp V7-2*03, TCRp V7-2*01, TCRp V7-3*01, TCRp V7-9*03, or TCRp V7-9*01 F TCRp Vil TCRp VI 1-1*01, TCRp VI 1-2*01 or TCRp VI1-3*01 G TCRp V14 TCRp V14*01 H TCRp V16 TCRp V16*01 I TCRp VI8 TCRp V18*01 J TCRp V9 TCRp V9*01 or TCRp V9*02 K TCRp V13 TCRp V13*01 L TCRp V4 TCRp V4-2*01, TCRp V4-3*01, or TCRp V4- 1*01 M TCRp V3 TCRp V3-l*01 N TCRp V2 TCRp V2*01 O TCRp V15 TCRp V15*01 P TCRp V30 TCRp V30*01, or TCRp V30*02 Q TCRp V19 TCRp V19*01, or TCRp V19*02 R TCRp V27 TCRp V27*01. S TCRp V28 TCRp V28*01. T TCRp V24 TCRp V24-l*01 U TCRp V20 TCRp V20-l*01, or TCRp V20-l*02 V TCRp V25 TCRp V25-l*01 W TCRp V29 TCRp V29-l*01 Table 8B: Additional TCRpV subfamilies Subfamily_______ TCRp VI______ TCRp V17_____ TCRp V21______ TCRp V23______ TCRp V26 Exemplary amino acid sequences for TCRPV subfamily members can be found on the 5 ImMunoGeneTics Information System website: http: / / www.imgt.org / , or in a similar resource. Table 9: Alignment of TCRBV amino acid sequences FR1-IMGT CDR1-IMGT FR2-IMGT CDR2-IMGT FR3-IMGT CDR3-IMGT (1-26) (27-38) (39- -55) (5 6- -65) ( 6 6- -104) (105-117) Gene A B BC c C C C" C" D E F FG (1-15) (16-26) (27-38) (39-46) (47-55) (5 6- -65) (66-74) (75-84) (85-96) (97-104) ------------------> -------------> ---------> ----------> ----------> ------------> --------------> ---------> 1           10   15 16    23 26 27 38 3941  46 47      55 56 65 66      74 75       84 85  89     96 97   104 105 1........1     - - - - 1 1......1     - - 1 1..........1            1 - 1 - - - - 1 1.......1            1........1            1.......1            1........1            1 - - - 1......1            1......1            1..... TRBV1 DTGITQTPKYLVTAM GSKRTMKREHL GH....... DS MYWYRQKA KKSLEFMFY YNC . . .KEF IENKTVP.N HFTPECP.DS SRLYLHWALQQ EDSAAYLC TSSQ TRBV2 EPEVTQTPSHQVTQM GQEVILRCVPI SNH...... LY FYWYRQIL GQKVEFLVS FYN. . .NEI SEKSEIFDD QFSVERP.DG SNFTLKIRSTKL EDSAMYFC ASSE TRBV3-1 DTAVSQTPKYLVTQM GNDKSIKCEQN LGH...... DT MYWYKQDS KKFLKIMFS YNN. . . KEL IINETVP.N RFSPKSP.DK AHLNLHINSLEL GDSAVYFC ASSQ TRBV3-2 DTAVSQTPKYLVTQM GKKESLK*EQN LGH...... NA MYWYKQDS KKFLKTMFI YSN. . .KEP ILNETVP.N rfspdsp.dk AHLNLHINSLEL GDSAVYFC ASSQ TRBV4-1 DTEVTQTPKHLVMGM TNKKSLKCEQH MGH...... RA MYWYKQKA KKPPELMFV YSY. . . EKL SINESVP .S RFSPECP.NS SLLNLHLHALQP EDSALYLC ASSQ TRBV4-2 ETGVTQTPRHLVMGM TNKKSLKCEQH LGH...... NA MYWYKQSA KKPLELMFV YNF . . . KEQ TENNSVP.S RFSPECP.NS SHLFLHLHTLQP EDSALYLC ASSQ TRBV4-3 ETGVTQTPRHLVMGM TNKKSLKCEQH LGH...... NA MYWYKQSA KKPLELMFV YSL . . .EER VENNSVP.S RFSPECP.NS SHLFLHLHTLQP EDSALYLC ASSQ TRBV5-1 KAGVTQTPRYLIKTR GQQVTLSCSPI SGH...... RS VSWYQQTP GQGLQFLFE YFS . - -ETQ RNKGNFP.G RFSGRQF.SN SRSEMNVSTLEL GDSALYLC ASSL TRBV5-3 EAGVTQSPTHLIKTR GQQVTLRCSPI SGH...... ss VSWYQQAP GQGPQFIFE YAN. . . ELR RSEGNFP.N RFSGRQF.HD CCSEMNVSALEL GDSALYLC ARSL TRBV5-4 ETGVTQSPTHLIKTR GQQVTLRCSSQ SGH...... NT VSWYQQAL GQGPQFIFQ YYR. . .EEE NGRGNFP.P RFSGLQF.PN YSSELNVNALEL DDSALYLC ASSL TRBV5-5 DAGVTQSPTHLIKTR GQQVTLRCSPI SGH...... KS VSWYQQVL GQGPQFIFQ YYE . . . KEE RGRGNFP.D RFSARQF.PN YSSELNVNALLL GDSALYLC ASSL TRBV5-6 DAGVTQSPTHLIKTR GQQVTLRCSPK SGH...... DT VSWYQQAL GQGPQFIFQ YYE . . .EEE RQRGNFP.D RFSGHQF.PN YSSELNVNALLL GDSALYLC ASSL TRBV5-7 DAGVTQSPTHLIKTR GQHVTLRCSPI SGH...... TS VSSYQQAL GQGPQFIFQ YYE . . .KEE RGRGNFP.D QFSGHQF.PN YSSELNVNALLL GDSALYLC ASSL TRBV5-8 EAGVTQSPTHLIKTR GQQATLRCSPI SGH...... TS VYWYQQAL GLGLQFLLW YDE . . .GEE RNRGNFP.P RFSGRQF.PN YSSELNVNALEL EDSALYLC ASSL TRBV6-1 NAGVTQTPKFQVLKT GQSMTLQCAQD MNH...... NS MYWYRQDP GMGLRLIYY SAS . . . EGT TDKGEVP.N GYNVSRL.NK REFSLRLESAAP SQTSVYFC ASSE TRBV6-2 NAGVTQTPKFRVLKT GQSMTLLCAQD MNH...... EY MYWYRQDP GMGLRLIHY SVG. . .EGT TAKGEVP.D GYNVSRL.KK QNFLLGLESAAP SQTSVYFC ASSY TRBV6-3 NAGVTQTPKFRVLKT GQSMTLLCAQD MNH...... EY MYWYRQDP GMGLRLIHY SVG. . .EGT TAKGEVP.D GYNVSRL.KK QNFLLGLESAAP SQTSVYFC ASSY WO 2020 / 010250                                                 PCT / US2019 / 040592 TRBV6-4 IAGITQAPTSQILAA GRRMTLRCTQD MRH... . . .NA MYWYRQDL GLGLRLIHY SNT . . . . AGT TGKGEVP.D GYSVSRA.NT DDFPLTLASAVP SQTSVYFC ASSD TRBV6-5 NAGVTQTPKFQVLKT GQSMTLQCAQD MNH... . . .EY MSWYRQDP GMGLRLIHY SVG. . . .AGI TDQGEVP.N GYNVSRS.TT EDFPLRLLSAAP SQTSVYFC ASSY TRBV6-6 NAGVTQTPKFRILKI GQSMTLQCTQD MNH... . . .NY MYWYRQDP GMGLKLIYY SVG. . . .AGI TDKGEVP.N GYNVSRS.TT EDFPLRLELAAP SQTSVYFC ASSY TRBV6-7 NAGVTQTPKFHVLKT GQSMTLLCAQD MNH... . . .EY MYRYRQDP GKGLRLIYY SVA. . . . AAL TDKGEVP.N GYNVSRS.NT EDFPLKLESAAP SQTSVYFC ASSY TRBV6-8 NAGVTQTPKFHILKT GQSMTLQCAQD MNH... . . .GY MSWYRQDP GMGLRLIYY SAA. . . .AGT TDK . EVP .N GYNVSRL.NT EDFPLRLVSAAP SQTSVYLC ASSY TRBV6-9 NAGVTQTPKFHILKT GQSMTLQCAQD MNH... . . .GY LSWYRQDP GMGLRRIHY SVA. . . .AGI TDKGEVP.D GYNVSRS.NT EDFPLRLESAAP SQTSVYFC ASSY TRBV7-1 GAGVS QS LRHKVAKK GKDVALRYDPI SGH... . . .NA LYWYRQSL GQGLEFPIY FQG. . . . KDA ADKSGLPRD RFSAQRS.EG SISTLKFQRTQQ GDLAVYLC ASSS TRBV7-2 GAGVSQSPSNKVTEK GKDVELRCDPI SGH... . . .TA LYWYRQSL GQGLEFLIY FQG. . . . NSA PDKSGLPSD RFSAERT.GG SVSTLTIQRTQQ EDSAVYLC ASSL TRBV7-3 GAGVS QTP SNKVTEK GKYVELRCDPI SGH... . . .TA LYWYRQSL GQGPEFLIY FQG. . . . TGA ADDSGLPND RFFAVRP. EG SVSTLKIQRTER GDSAVYLC ASSL TRBV7-4 GAGVS Q S P RYKVAKR GRDVALRCDSI SGH... . . . VT LYWYRQTL GQGSEVLTY SQS . . . . DAQ RDKSGRPSG RFSAERP.ER SVSTLKIQRTEQ GDSAVYLC ASSL TRBV7-6 GAGVS Q S P RYKVTKR GQDVALRCDPI SGH... . . .VS LYWYRQAL GQGPEFLTY FNY. . . . EAQ QDKSGLPND RFSAERP.EG SISTLTIQRTEQ RDSAMYRC ASSL TRBV7-7 GAGVS Q S P RYKVTKR GQDVTLRCDPI SSH... . . .AT LYWYQQAL GQGPEFLTY FNY. . . .EAQ PDKSGLPSD RFSAERP.EG SISTLTIQRTEQ RDSAMYRC ASSL TRBV7-8 GAGVS Q S P RYKVAKR GQDVALRCDPI SGH... . . .VS LFWYQQAL GQGPEFLTY FQN. . . .EAQ LDKSGLPSD RFFAERP.EG SVSTLKIQRTQQ EDSAVYLC ASSL TRBV7-9 DTGVSQNPRHKITKR GQNVTFRCDPI SEH... . . .NR LYWYRQTL GQGPEFLTY FQN. . . .EAQ LEKSRLLSD RFSAERP.KG SFSTLEIQRTEQ GDSAMYLC ASSL TRBV9 DSGVTQTPKHLITAT GQRVTLRCSPR SGD... . . .LS VYWYQQSL DQGLQFLIQ YYN. . . .GEE RAKGNIL.E RFSAQQF.RD LHSELNLSSLEL GDSALYFC ASSV TRBV10-1 DAEITQSPRHKITET GRQVTLACHQT WNH... . . .NN MFWYRQDL GHGLRLIHY SYG. . . .VQD TNKGEVS.D GYSVSRS.NT EDLPLTLESAAS SQTSVYFC ASSE TRBV10-2 DAGITQSPRYKITET GRQVTLMCHQT WSH... . . .SY MFWYRQDL GHGLRLIYY SAA. . . .ADI TDKGEVP.D GYWSRS .KT ENFPLTLESATR SQTSVYFC ASSE TRBV10-3 DAGITQSPRHKVTET GTPVTLRCHQT ENH... . . .RY MYWYRQDP GHGLRLIHY SYG. . . . VKD TDKGEVS.D GYSVSRS.KT EDFLLTLESATS SQTSVYFC AISE TRBV11-1 EAEVAQSPRYKITEK SQAVAFWCDPI SGH... . . .AT LYWYRQIL GQGPELLVQ FQD . . . .ESV VDDSQLPKD RFSAERL.KG VDSTLKIQPAEL GDSAMYLC ASSL TRBV11 -2 EAGVAQSPRYKIIEK RQSVAFWCNPI SGH... . . .AT LYWYQQIL GQGPKLLIQ FQN. . . . NGV VDDSQLPKD RFSAERL.KG VDSTLKIQPAKL EDSAVYLC ASSL TRBV11 -3 EAGWQSPRYKI IEK KQPVAFWCNPI SGH... . . .NT LYWYLQNL GQGPELLIR YEN. . . . EEA VDDSQLPKD RFSAERL.KG VDSTLKIQPAEL GDSAVYLC ASSL TRBV12-1 DAGVIQSPRHKVTEM GQSVTLRCEPI SGH... . . .ND LLWYRQTF VQGLELLNY FCS . . . . WTL VDDSGVSKD *FSAQMP.DV SFSTLRIQPMEP RDLGLYFC ASSF TRBV12-2 DAGIIQSPKHEVTEM GQTVTLRCEPI FGH... . . .NF LFWYRDTF VQGLELLSY FRS . . . . *SI IDNAGMPTE RFSAERP.DG SFSTLKIQPAEQ GDSAVYVC ASRL TRBV12-3 DAGVIQSPRHEVTEM GQEVTLRCKPI SGH... . . .NS LFWYRQTM MRGLELLIY FNN. . . . NVP IDDSGMPED RFSAKMP.NA SFSTLKIQPSEP RDSAVYFC ASSL TRBV12-4 DAGVIQSPRHEVTEM GQEVTLRCKPI SGH... . . .DY LFWYRQTM MRGLELLIY FNN. . . .NVP IDDSGMPED RFSAKMP.NA SFSTLKIQPSEP RDSAVYFC ASSL TRBV12-5 DARVTQTPRHKVTEM GQEVTMRCQPI LGH... . . .NT VFWYRQTM MQGLELLAY FRN. . . .RAP LDDSGMPKD RFSAEMP.DA TLATLKIQPSEP RDSAVYFC ASGL TRBV13 AAGVIQSPRHLIKEK RETATLKCYPI PRH... . . .DT VYWYQQGP GQDPQFLIS FYE . . . . KMQ SDKGSIP.D RFSAQQF.SD YHSELNMSSLEL GDSALYFC ASSL WO 2020 / 010250                                                 PCT / US2019 / 040592 KJ TRBV14 EAGVTQFPSHSVIEK GQTVTLRCDPI SGH... . . . .DN LYWYRRVM GKEIKFLLH FVK. . .ESK QDESGMPNN RFLAERT.GG TYSTLKVQPAEL EDSGVYFC ASSQ TRBV15 DAMVIQNPRYQVTQF GKPVTLSCSQT LNH... ....NV MYWYQQKS SQAPKLLFH YYD . . . KDF NNEADTP.D NFQSRRP.NT SFCFLDIRSPGL GDTAMYLC ATSR TRBV16 GEEVAQTPKHLVRGE GQKAKLYCAPI KGH... . . . .SY VFWYQQVL KNEFKFLIS FQN. . . ENV FDETGMPKE RFSAKCL.PN SPCSLEIQATKL EDSAVYFC ASSQ TRBV17 EP GVS QTPRHKVTNM GQEVILRCDPS SGH... ....MF VHWYRQNL RQEMKLLIS FQY. . . QNI AVDSGMPKE RFTAERP.NG TSSTLKIHPAEP RDSAVYLY SSG TRBV18 NAGVMQNPRHLVRRR GQEARLRCSPM KGH... ....SH VYWYRQLP EEGLKFMVY LQK. . .ENI IDESGMPKE RFSAEFP.KE GPSILRIQQWR GDSAAYFC ASSP TRBV19 DGGITQSPKYLFRKE GQNVTLSCEQN LNH... ....DA MYWYRQDP GQGLRLIYY SQI . . . VND FQKGDIA.E GYSVSRE.KK ESFPLTVTSAQK NPTAFYLC ASSI TRBV20-1 GAWSQHPSWVICKS GTSVKIECRSL DFQ... ...ATT MFWYRQFP KQSLMLMAT SNEG. . SKA TYEQGVEKD KFLINHA.SL TLSTLTVTSAHP EDSSFYIC SAR TRBV21-1 D TKVT QRP RL LVKAS EQKAKMDCVPI KAH... ....SY VYWYRKKL EEELKFLVY FQN. . .EEL IQKAEIINE RFLAQCS.KN SSCTLEIQSTES GDTALYFC ASSK TRBV23-1 HAKVTQTPGHLVKGK GQKTKMDCTPE KGH... ....TF VYWYQQNQ NKEFMLLIS FQN. . . EQV LQETEMHKK RFSSQCP.KN APCSLAILSSEP GDTALYLC ASSQ TRBV24-1 DADVTQTPRNRITKT GKRIMLECSQT KGH... ....DR MYWYRQDP GLGLRLIYY SFD . . . VKD INKGEIS.D GYSVSRQ.AQ AKFSLSLESAIP NQTALYFC ATSDL TRBV25-1 EADIYQTPRYLVIGT GKKITLECSQT MGH... . . . .DK MYWYQQDP GMELHLIHY SYG. . . VNS TEKGDLS.S ESTVSRI.RT EHFPLTLESARP SHTSQYLC ASSE TRBV26 DAWTQFPRHRII GT GKEFILQCSQN MNH... ....VT MYWYRQDP GLGLKLVYY SPG. . . TGS TEKGDIS.E GYHVS*N.TI ASFPLTLKSAST NQTSVYLY ASSS TRBV27 EAQVTQNPRYLITVT GKKLTVTCSQN MNH... ....EY MSWYRQDP GLGLRQIYY SMN. . . VEV TDKGDVP.E GYKVSRK.EK RNFPLILESPSP NQTSLYFC ASSL TRBV28 DVKVT Q S S RYLVKRT GEKVFLECVQD MDH... . . . .EN MFWYRQDP GLGLRLIYF SYD . . . VKM KEKGDIP.E GYSVSRE.KK ERFSLILESAST NQTSMYLC ASSL TRBV29-1 SAVISQKPSRDICQR GTSLTIQCQVD SQV... ....TM MFWYRQQP GQSLTLIAT ANQG. . SEA TYESGFVID KFPISRP.NL TFSTLTVSNMSP EDSSIYLC SVE TRBV30 SQTIHQWPATLVQPV GSPLSLECTVE GTS . . . ...NPN LYWYRQAA GRGLQLLFY SVG. . . . IG QISSEVP.Q NLSASRP.QD RQFILSSKKLLL SDSGFYLC AWS The alignment of TCRBV amino acid sequences in Table 9 underscores the diversity of TCR sequences. In particular, the TRBV sequences from different subfamilies are considerably different from each other. WO 2020 / 010250                                                 PCT / US2019 / 040592 Anti-TCRpV antibodies Disclosed herein, is the discovery of a novel class of antibodies, i.e. anti-TCRpV antibody molecules disclosed herein, which despite having low sequence similarity (e.g., low sequence identity among the different antibody molecules that recognize different TCRpV subfamilies), recognize a structurally conserved region, e.g., domain, on the TCRPV protein (e.g., as denoted by the circled area in FIG. 24A) and have a similar function (e.g., a similar cytokine profile). Thus, the anti-TCRpV antibody molecules disclosed herein share a structurefunction relationship. Without wishing to be bound by theory, it is believed that in some embodiments, the anti-TCRpV antibody molecules disclosed herein bind to an outward facing epitope of a TCRpV protein when it is in a complex with a TCRalpha protein, e.g., as described by the circled area in FIG. 24A. In some embodiments, the anti-TCRpV antibody molecules disclosed herein recognize (e.g., bind to), a structurally conserved domain on the TCRpV protein (e.g., as denoted by the circled area in FIG. 24A). In some embodiments, the anti-TCRpV antibody molecules disclosed herein do not recognize, e.g., bind to, an interface of a TCRpV:TCRalpha complex. In some embodiments, the anti-TCRpV antibody molecules disclosed herein do not recognize, e.g., bind to, a constant region of a TCRpV protein. An exemplary antibody that binds to a constant region of a TCRBV region is JOVI.l as described in Viney et al., (Hybridoma. 1992 Dec;l 1(6):701-13). In some embodiments, the anti-TCRpV antibody molecules disclosed herein do not recognize, e.g., bind to, one or more (e.g., all) of a complementarity determining region (e.g., CDR1, CDR2 and / or CDR3) of a TCRpV protein. In some embodiments, the anti-TCRpV antibody molecules disclosed herein binds (e.g., specifically binds) to a TCRpV region. In some embodiments, binding of anti-TCRpV antibody molecules disclosed herein results in a cytokine profile that differs from a cytokine profile of a T cell engager that binds to a receptor or molecule other than a TCRpV region (“a non-TCRpV-binding T cell engager”). In some embodiments, the non-TCRpV-binding T cell engager comprises an antibody that binds to a CD3 molecule (e.g., CD3 epsilon (CD3e) molecule); or a TCR alpha (TCRa) molecule. In some embodiments, the non-TCRpV-binding T cell engager is an OKT3 antibody or an SP34-2 antibody. In an aspect, the disclosure provides an anti-TCRpV antibody molecule that binds to human TCRpV, e.g., a TCRpV gene family, e.g., one or more of a TCRpV subfamily, e.g., as described herein, e.g., in FIG. 3, Table 8A, or Table 8B. In some embodiments, the anti-TCRpV antibody molecule binds to one or more TCRpV subfamilies chosen from: a TCRP V6 subfamily, a TCRp V10 subfamily, a TCRp V12 subfamily, a TCRp V5 subfamily, a TCRp V7 subfamily, a TCRP Vil subfamily, a TCRP V14 subfamily, a TCRP V16 subfamily, a TCRP VI8 subfamily, a TCRp V9 subfamily, a TCRp V13 subfamily, a TCRp V4 subfamily, a TCRp V3 subfamily, a TCRp V2 subfamily, a TCRp VI5 subfamily, a TCRp V30 subfamily, a TCRp V19 subfamily, a TCRp V27 subfamily, a TCRp V28 subfamily, a TCRp V24 subfamily, a TCRp V20 subfamily, TCRp V25 subfamily, a TCRp V29 subfamily, a TCRp VI subfamily, a TCRP V17 subfamily, a TCRP V21 subfamily, a TCRP V23 subfamily, or a TCRP V26 subfamily, or a variant thereof. In some embodiments, the anti-TCRpV antibody molecule binds to a TCRP V6 subfamily comprising: TCRp V6-4*01, TCRp V6-4*02, TCRp V6-9*01, TCRp V6-8*01, TCRp V6-5*01, TCRp V6-6*02, TCRp V6-6*01, TCRp V6-2*01, TCRp V6-3*01 or TCRp V6-l*01, or a variant thereof. In some embodiments the TCRP V6 subfamily comprises TCRP V6-5*01, or a variant thereof. In some embodiments, TCRP V6 comprises TCRP V6-4*01, or a variant thereof. In some embodiments, TCRP V6 comprises TCRP V6-4*02, or a variant thereof. In some embodiments, TCRP V6 comprises TCRP V6-9*01, or a variant thereof. In some embodiments, TCRP V6 comprises TCRP V6-8*01, or a variant thereof. In some embodiments, TCRP V6 comprises TCRP V6-5*01, or a variant thereof. In some embodiments, TCRP V6 comprises TCRP V6-6*02, or a variant thereof. In some embodiments, TCRP V6 comprises TCRP V6-6*01, or a variant thereof. In some embodiments, TCRP V6 comprises TCRP V6-2*01, or a variant thereof. In some embodiments, TCRP V6 comprises TCRP V6-3*01, or a variant thereof. In some embodiments, TCRP V6 comprises TCRP V6-1*01, or a variant thereof. In some embodiments, the anti-TCRpV antibody molecule binds to a TCRP V10 subfamily comprising: TCRp V10-l*01, TCRp V10-l*02, TCRp V10-3*01 or TCRp V10-2*01, or a variant thereof. In some embodiments, the anti-TCRpV antibody molecule binds to a TCRP V12 subfamily comprising: TCRP V12-4*01, TCRP V12-3*01 or TCRP V12-5*01, or a variant thereof. In some embodiments, the anti-TCRpV antibody molecule binds to a TCRP V5 5 subfamily comprising: TCRp V5-5*01, TCRp V5-6*01, TCRp V5-4*01, TCRp V5-8*01, TCRp V5-l*01, or a variant thereof. Exemplary anti-TCRpV antibody molecules and the corresponding TCRpV subfamily recognized by said anti-TCRpV antibody molecules is disclosed in Table 10A. 10 Table 10A: Exemplary anti-TCRpV antibody molecules TRBV gene name TRBV allele name Reagents monoclonal antibodies Clone name and Specificity Company product Isotype | TRBV2 TRBV2*01 IsMMU 546 (TRBV2) Serotec V BETA 22 Coulter Vbeta22 Mouse IgGl TRBV2*02 TRBV2*03 TRBV3-1 TRBV3-l*01 FIN9 (TRBV3-1) AMKB1-2 (TRBV3-1) Serotec Vbeta9 Coulter Vbeta9 Mouse IgG2a N Mouse IgGl J[ TRBV3-l*02 BD Biosciences Vbeta9 TRBV4-1 TRBV4-l*01 ZOE (TRBV4-1, TRBV4-2, TRBV4-3) 3G5 (TRBV4-1) Serotec V BETA 7 Coulter Vbeta7 Mouse IgG2a TRBV4-l*02 Pierce EndogenV beta 7.1 Mouse IgG2b TRBV4-2 TRBV4-2*01 ZOE (TRBV4-1, TRBV4-2, TRBV4-3) Serotec V BETA 7 Coulter Vbeta7 Mouse IgG2a TRBV4-2*02 TRBV4-3 TRBV4-3*01 ZOE (TRBV4-1, TRBV4-2, TRBV4-3) Serotec V BETA 7 Coulter Vbeta7 Mouse IgG2a TRBV4-3*02 TRBV4-3*03 TRBV4-3*04 ZIZOU4 (TRBV4-3) Coulter Vbeta7.2 Mouse IgG2a _ ][ TRBV5-1 TRBV5-l*01 IMMU157 (TRBV5-1) Serotec Vbeta5.1 Coulter Vbeta5.1 Mouse IgG2a TRBV5-l*02 LC4 (TRBV5-1) Pierce Endogen V beta 5(c) Mouse IgGl J BD Biosciences Vbeta5(c) | TRBV5-4 TRBV5-4*01 TRBV5-4*02 TRBV5-4*03 TRBV5-4*04 1 TRBV5-5*01 3D11 (TRBV5-5) Serotec VBETA5.3 Coulter Vbeta5.3 Mouse IgGl J TRBV5-5*02 1C1 (TRBV5-5, TRBV5-6) Pierce Endogen V beta 5(a) BD Biosciences Vbeta5(a) Mouse IgGl TRBV5-5 W112 (TRBV5-5) MH3-2 (TRBV5-5, TRBV5-6) Pierce Endogen V beta 5(b) Serotec V beta 5.2 / 5.3 BD Biosciences Vbeta5(b) Mouse IgGl TRBV5-5*03 BD Biosciences Vbeta5 Mouse IgG2a 4H11 (TM27) as disclosed in U.S. Patent 5,861,155 । TRBV5-6 TRBV5-6*01 36213 (TRBV5-6) 1C1 (TRBV5-5, TRBV5-6) MH3-2 (TRBV5-5, TRBV5-6) Serotec Vbeta5.2 BD Biosciences Vbeta5(a) BD Biosciences Vbeta5 Mouse ]| IgGl Mouse IgGl Mouse IgG2a _ ][ TRBV5-8 TRBV5-8*01 TRBV5-8*02 | TRBV6-1 TRBV6-l*01 BAM13 (TRBV6-1, TRBV6-5) Pierce Endogen V beta 13 BD Biosciences Vbetal3.1, 13.3 Mouse IgGl TRBV6-2 TRBV6-2*01 H132 Coulter Vbetal3.2 Mouse IgGl || TRBV6-3 TRBV6-3*01 ________________1[ TRBV6-4 TRBV6-4*01 | TRBV6-4*02 TRBV6-5 TRBV6-5*01 IMMU 222 (TRBV6-5, TRBV6-6 and TRBV6-9) BAM13 (TRBV6-1, TRBV6-5) Serotec VBETA 13.1 Coulter Vbetal3.1 Mouse IgG2b Pierce Endogen V beta 13 BD Biosciences Vbetal3.1, 13.3 Mouse IgGl TRBV6-6 TRBV6-6*01 JU-74 (TRBV6-6) JU74.3 (TRBV6-6) IMMU 222 (TRBV6-5, TRBV6-6 and TRBV6-9) Serotec Vbetal3.6 Coulter Vbetal3.6 Mouse IgGl TRBV6-6*02 TRBV6-6*03 TRBV6-6*04 Serotec VBETA 13.1 Coulter Vbetal3.1 Mouse IgG2b TRBV6-6*05 TRBV6-8 TRBV6-8*01 TRBV6-9 TRBV6-9*01 IMMU 222 (TRBV6-5, TRBV6-6 and TRBV6-9) Serotec VBETA 13.1 Coulter Vbetal3.1 Mouse IgG2b _ ][ TRBV7-2 TRBV7-2*01 OT145 (TRBV7-2) Pierce Endogen V beta 6.7 BD Biosciences Vbeta6.7 Mouse IgGl TRBV7-2*02 TRBV7-2*03 TRBV7-2*04 TRBV7-3 TRBV7-3*01 । TRBV7-3*04 TRBV7-3*05 TRBV7-4 TRBV7-4*01 1 TRBV7-6 TRBV7-6*01 1 TRBV7-6*02 TRBV7-7 TRBV7-7*01 1 TRBV7-7*02 TRBV7-8 TRBV7-8*01 1 TRBV7-8*02 TRBV7-8*03 TRBV7-9 TRBV7-9*01 TRBV7-9*02 TRBV7-9*03 TRVB7-9*04 TRBV7-9*05 TRBV7-9*06 TRBV7-9*07 1 TRBV9 TRBV9*01 BL37.2 (TRBV9) Serotec Vbetal Coulter Vbetal RatlgGl TRBV9*02 TRBV9*03 TRBV10-1 TRBV10-2 TRBV10-l*01 S511 (TRBV10-1, TRBV10-2, TRBV10-3) Pierce Endogen V beta 12 BD Biosciences Vbetal 2 Mouse IgG2b TRBV10-l*02 TRBV10-2*01 TRBV10-2*02 TRBV10-3 TRBV10-3*01 VER2.32.1 (TRBV10-3) S511 (TRBV10-1, TRBV10-2, TRBV10-3) Serotec Vbetal2 Coulter Vbetal 2 Mouse IgG2a TRBV10-3*02 TRBV1O-3*O3 Pierce Endogen V beta 12 BD Biosciences Vbetal 2 Mouse IgG2b TRBV10-3*04 TRBV11-1 TRBV11-1*O1 1 TRBV11-2 TRB VI 1-2*01 IG125 (TRBVI1-2) Serotec Vbeta21.3 Coulter Vbeta21.3 Mouse IgG2a TRB VI 1-2*02 TRB VI 1-2*03 TRBV11-3 TRBV11-3*01 1 TRBV11-3*02 TRBV11-3*03 TRBV11-3*04 TRBV12-3 TRBV12-3*01 56C5 (TRBV12-3, TRBV12-4) 56C5.2 (TRBV12-3, TRBV12-4) 16G8 (TRBV12-3, TRBV12-4) MX-6 (TRBV12-3, TRBV12-4) JR2 (TRBV12-3, TRBV12-4, TRBV12-5) Serotec Vbeta8.1 / 8.2 Coulter Vbeta8 Mouse IgG2a TRBV12-4 TRBV12-4*01 Pierce Endogen V beta 8(a) BD Biosciences Vbeta8 Mouse IgG2b TRBV12-4*02 Pierce Endogen V beta 8(b) Mouse IgG2a BD Biosciences Vbeta8 Mouse IgG2b TRBV12-5 TRBV12-5*01 JR2 (TRBV12-3, TRBV12-4, TRBV12-5) BD Biosciences Vbeta8 Mouse IgG2b TRBV13 TRBV13*01 AF-23 (TRBV13) AF23 (TRBV13) AHUT7 (Vbeta23) Serotec Vbeta23 Coulter Vbeta23 BD Biosciences Vbeta23 Mouse 11 IgGl TRBV13*02 TRBV14 TRBV14*01 TAMAYA1.2 (TRBV 14) Serotec Vbetal6 Coulter Vbetal6 Mouse IgGl J TRBV14*02 TRBV15 TRBV 15*01 । TRBV 15*02 TRBV 15*03 TRBV16 TRBV16*01 | TRBV16*03 TRBV18 TRBV18*01 BA62 (TRBV 18) BA62.6 (TRBV 18) Serotec V BETA 18 Coulter Vbetal8 Mouse IgGl J[ TRBV19 TRBV19*01 Cl (TRBV 19) E17.5F3 (TRBV 19) E17.5F3.15.13 (TRBV19) Pierce Endogen V beta 17 BD Biosciences Vbetal7 Mouse IgGl TRBV 19*02 Serotec Vbetal7 Coulter Vbetal7 Mouse IgGl TRBV19*03 TRBV20-1 TRBV20-l*01 MPB2D5 (TRBV20-1) Serotec VBETA2 Coulter Vbeta2 Mouse IgGl TRBV20-l*02 TRBV20-l*03 TRBV20-l*04 TRBV20-l*05 TRBV20-l*06 TRBV20-l*07 TRBV24-1 TRBV24-l*01 II TRBV25-1 TRBV25-l*01 C21 (TRBV25-1) Serotec V BETA 11 Coulter Vbetal 1 Mouse IgG2a _ ][ TRBV27 TRBV27*01 CAS1.1.3 (TRBV27) Serotec Vbetal4 Coulter Vbetal 4 Mouse IgGl J[ TRBV28 TRBV28*01 CH92 (TRBV28) 8F10 (TRBV28) JOVI-3 (TRBV28) Serotec Vbeta3 Coulter Vbeta3 Mouse IgM J Pierce Endogen V beta 3.1 BD Biosciences Vbeta3 Mouse IgGl Mouse IgG2a TRBV29-1 TRBV29-l*01 TRBV29-l*02 TRBV29-l*03 WJF24 Coulter Vbeta4 Rat IgM TRBV30 TRBV30*01 TRBV30*02 TRBV30*04 TRBV30*05 ELL1.4 (TRBV30) Serotec Vbeta20 Coulter Vbeta20 Mouse IgGl In some embodiments, the anti-TCRpV antibody molecule does not bind to TCRP V12, or binds to TCRP V12 with an affinity and / or binding specificity that is less than (e.g., less than about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or about 2-, 5-, or 10- fold) the affinity and / or binding specificity of the 16G8 murine antibody or a humanized version thereof as described in US Patent 5,861,155. In some embodiments, the anti-TCRpV antibody molecule binds to TCRP V12 with an affinity and / or binding specificity that is greater than (e.g., greater than about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or about 2-, 5-, or 10- fold) the affinity and / or binding specificity of the 16G8 murine antibody or a humanized version thereof as described in US Patent 5,861,155. In some embodiments, the anti-TCRpV antibody molecule binds to a TCRpV region other than TCRP V12 (e.g., TCRpV region as described herein, e.g., TCRP V6 subfamily (e.g., TCRP V6-5*01) with an affinity and / or binding specificity that is greater than (e.g., greater than about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or about 2-, 5-, or 10- fold) the affinity and / or binding specificity of the 16G8 murine antibody or a humanized version thereof as described in US Patent 5,861,155. In some embodiments, the anti-TCRpV antibody molecule does not bind to TCRP V5-5*01 or TCRP V5-l*01, or binds to TCRP V5-5*01 or TCRP V5-l*01 with an affinity and / or binding specificity that is less than (e.g., less than about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or about 2-, 5-, or 10- fold) the affinity and / or binding specificity of the TM23 murine antibody or a humanized version thereof as described in US Patent 5,861,155. In some embodiments, the anti-TCRpV antibody molecule binds to TCRP V5-5*01 or TCRP V5-l*01with an affinity and / or binding specificity that is greater than (e.g., greater than about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or about 2-, 5-, or 10- fold) the affinity and / or binding specificity of the TM23 murine antibody or a humanized version thereof as described in US Patent 5,861,155. In some embodiments, the anti-TCRpV antibody molecule binds to a TCRpV region other than TCRP V5-5*01 or TCRP V5-l*01 (e.g., TCRpV region as described herein, e.g., TCRP V6 subfamily (e.g., TCRP V6-5*01) with an affinity and / or binding specificity that is greater than (e.g., greater than about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or about 2-, 5-, or 10- fold) the affinity and / or binding specificity of the TM23 murine antibody or a humanized version thereof as described in US Patent 5,861,155. Anti-TCRp V6 antibodies Accordingly, in one aspect, the disclosure provides an anti-TCRpV antibody molecule that binds to human TCRP V6, e.g., a TCRP V6 subfamily comprising: TCRP V6-4*01, TCRP V6-4*02, TCRp V6-9*01, TCRp V6-8*01, TCRp V6-5*01, TCRp V6-6*02, TCRp V6-6*01, TCRp V6-2*01, TCRp V6-3*01 or TCRp V6-l*01. In some embodiments the TCRp V6 subfamily comprises TCRP V6-5*01 or a variant thereof. In some embodiments, TCRP V6 comprises TCRP V6-4*01, or a variant thereof. In some embodiments, TCRP V6 comprises TCRP V6-4*02, or a variant thereof. In some embodiments, TCRP V6 comprises TCRP V6-9*01, or a variant thereof. In some embodiments, TCRP V6 comprises TCRP V6-8*01, or a variant thereof. In some embodiments, TCRP V6 comprises TCRP V6-5*01, or a variant thereof. In some embodiments, TCRP V6 comprises TCRP V6-6*02, or a variant thereof. In some embodiments, TCRP V6 comprises TCRP V6-6*01, or a variant thereof. In some embodiments, TCRP V6 comprises TCRP V6-2*01, or a variant thereof. In some embodiments, TCRP V6 comprises TCRP V6-3*01, or a variant thereof. In some embodiments, TCRP V6 comprises TCRP V6-1*01, or a variant thereof. In some embodiments, TCRP V6-5*01 is encoded by the nucleic acid sequence of SEQ ID NO: 43, or a sequence having 85%, 90%, 95%, 99% or more identity thereof. SEQ ID NO: 43 ATGAGCATCGGCCTCCTGTGCTGTGCAGCCTTGTCTCTCCTGTGGGCAGGTCCAGTG AATGCTGGTGTCACTCAGACCCCAAAATTCCAGGTCCTGAAGACAGGACAGAGCAT GACACTGCAGTGTGCCCAGGATATGAACCATGAATACATGTCCTGGTATCGACAAG ACCCAGGCATGGGGCTGAGGCTGATTCATTACTCAGTTGGTGCTGGTATCACTGACC AAGGAGAAGTCCCCAATGGCTACAATGTCTCCAGATCAACCACAGAGGATTTCCCG CTCAGGCTGCTGTCGGCTGCTCCCTCCCAGACATCTGTGTACTTCTGTGCCAGCAGTT ACTC In some embodiments, TCRP V6-5*01 comprises the amino acid sequence of SEQ ID NO: 44, or an amino acid sequence having 85%, 90%, 95%, 99% or more identity thereof. SEQ ID NO: 44 MSIGLLCCAALSLLWAGPVNAGVTQTPKFQVLKTGQSMTLQCAQDMNHEYMSWYRQ DPGMGLRLIHYSVGAGITDQGEVPNGYNVSRSTTEDFPLRLLSAAPSQTSVYFCASSY In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, is a non-murine antibody molecule, e.g., a human or humanized antibody molecule. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule is a human antibody molecule. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule is a humanized antibody molecule. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, is isolated or recombinant. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, comprises at least one antigen-binding region, e.g., a variable region or an antigen-binding fragment thereof, from an antibody described herein, e.g., an antibody chosen from A-H.l or A-H.2, or an antibody described in Table 1, or encoded by a nucleotide sequence in Table 1, or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or higher identical) to any of the aforesaid sequences. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, comprises at least one, two, three or four variable regions from an antibody described herein, e.g., an antibody chosen from A-H.l or A-H.2, or an antibody described in Table 1, or encoded by a nucleotide sequence in Table 1, or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or higher identical) to any of the aforesaid sequences. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, comprises at least one or two heavy chain variable regions from an antibody described herein, e.g., an antibody chosen from A-H.l or A-H.2, or an antibody molecule described in Table 1, or encoded by a nucleotide sequence in Table 1, or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or higher identical) to any of the aforesaid sequences. In some embodiments, the anti-TCRpV antibody molecule comprises a heavy chain variable region (VH) having a consensus sequence of SEQ ID NO: 231 or 3290. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, comprises at least one or two light chain variable regions from an antibody described herein, e.g., an antibody chosen from A-H.l or A-H.2, or an antibody described in Table 1, or encoded by a nucleotide sequence in Table 1, or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or higher identical) to any of the aforesaid sequences. In some embodiments, the anti-TCRpV antibody molecule comprises a light chain variable region (VL) having a consensus sequence of SEQ ID NO: 230 or 3289. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, comprises a heavy chain constant region for an IgG4, e.g., a human IgG4. In still another embodiment, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule includes a heavy chain constant region for an IgGl, e.g., a human IgGl. In one embodiment, the heavy chain constant region comprises an amino sequence set forth in Table 3, or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or higher identical) thereto. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, includes a kappa light chain constant region, e.g., a human kappa light chain constant region. In one embodiment, the light chain constant region comprises an amino sequence set forth in Table 3, or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or higher identical) thereto. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, includes at least one, two, or three complementarity determining regions (CDRs) from a heavy chain variable region (VH) of an antibody described herein, e.g., an antibody chosen from A-H.l or A-H.2, or an antibody described in Table 1, or encoded by a nucleotide sequence in Table 1, or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or higher identical) to any of the aforesaid sequences. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, includes at least one, two, or three CDRs (or collectively all of the CDRs) from a heavy chain variable region comprising an amino acid sequence shown in Table 1, or encoded by a nucleotide sequence shown in Table 1. In one embodiment, one or more of the CDRs (or collectively all of the CDRs) have one, two, three, four, five, six or more changes, e.g., amino acid substitutions or deletions, relative to the amino acid sequence shown in Table 1, or encoded by a nucleotide sequence shown in Table 1. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, includes at least one, two, or three complementarity determining regions (CDRs) from a light chain variable region of an antibody described herein, e.g., an antibody chosen from A-H.l or A-H.2, or an antibody described in Table 1, or encoded by a nucleotide sequence in Table 1, or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or higher identical) to any of the aforesaid sequences. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, includes at least one, two, or three CDRs (or collectively all of the CDRs) from a light chain variable region comprising an amino acid sequence shown in Table 1, or encoded by a nucleotide sequence shown in Table 1. In one embodiment, one or more of the CDRs (or collectively all of the CDRs) have one, two, three, four, five, six or more changes, e.g., amino acid substitutions or deletions, relative to the amino acid sequence shown in Table 1, or encoded by a nucleotide sequence shown in Table 1. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, includes at least one, two, three, four, five or six CDRs (or collectively all of the CDRs) from a heavy and light chain variable region comprising an amino acid sequence shown in Table 1, or encoded by a nucleotide sequence shown in Table 1. In one embodiment, one or more of the CDRs (or collectively all of the CDRs) have one, two, three, four, five, six or more changes, e.g., amino acid substitutions or deletions, relative to the amino acid sequence shown in Table 1, or encoded by a nucleotide sequence shown in Table 1. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, molecule includes all six CDRs from an antibody described herein, e.g., an antibody chosen from A-H.l or A-H.2, or an antibody described in Table 1, or encoded by a nucleotide sequence in Table 1, or closely related CDRs, e.g., CDRs which are identical or which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions). In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, may include any CDR described herein. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule includes at least one, two, or three CDRs according to Kabat et al. (e.g., at least one, two, or three CDRs according to the Kabat definition as set out in Table 1) from a heavy chain variable region of an antibody described herein, e.g., an antibody chosen from A-H.l or A-H.2, or an antibody described in Table 1, or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or higher identical) to any of the aforesaid sequences; or which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) relative to one, two, or three CDRs according to Kabat et al. shown in Table 1. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule includes at least one, two, or three CDRs according to Kabat et al. (e.g., at least one, two, or three CDRs according to the Kabat definition as set out in Table 1) from a light chain variable region of an antibody described herein, e.g., an antibody chosen from A-H.l or A-H.2, or an antibody described in Table 1, or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or higher identical) to any of the aforesaid sequences; or which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) relative to one, two, or three CDRs according to Kabat et al. shown in Table 1. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, includes at least one, two, three, four, five, or six CDRs according to Kabat et al. (e.g., at least one, two, three, four, five, or six CDRs according to the Kabat definition as set out in Table 1) from the heavy and light chain variable regions of an antibody described herein, e.g., an antibody chosen from A-H.l or A-H.2, or an antibody described in Table 1, or encoded by a nucleotide sequence in Table 1; or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or higher identical) to any of the aforesaid sequences; or which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) relative to one, two, three, four, five, or six CDRs according to Kabat et al. shown in Table 1. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, includes all six CDRs according to Kabat et al. (e.g., all six CDRs according to the Kabat definition as set out in Table 1) from the heavy and light chain variable regions of an antibody described herein, e.g., an antibody chosen from A-H.l or A-H.2, or an antibody described in Table 1, or encoded by a nucleotide sequence in Table 1; or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or higher identical) to any of the aforesaid sequences; or which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) relative to all six CDRs according to Kabat et al. shown in Table 1. In one embodiment, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, may include any CDR described herein. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, includes at least one, two, or three hypervariable loops that have the same canonical structures as the corresponding hypervariable loop of an antibody described herein, e.g., an antibody chosen from chosen from A-H.l or A-H.2 e.g., the same canonical structures as at least loop 1 and / or loop 2 of the heavy and / or light chain variable domains of an antibody described herein. See, e.g., Chothia et al., (1992) J. Mol. Biol. 227:799817; Tomlinson et al., (1992) J. Mol. Biol. 227:776-798 for descriptions of hypervariable loop canonical structures. These structures can be determined by inspection of the tables described in these references. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule includes at least one, two, or three CDRs according to Chothia et al. (e.g., at least one, two, or three CDRs according to the Chothia definition as set out in Table 1) from a heavy chain variable region of an antibody described herein, e.g., an antibody chosen from A-H.l or A-H.2, or as described in Table 1, or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or higher identical) to any of the aforesaid sequences; or which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) relative to one, two, or three CDRs according to Chothia et al. shown in Table 1. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule includes at least one, two, or three CDRs according to Chothia et al. (e.g., at least one, two, or three CDRs according to the Chothia definition as set out in Table 1) from a light chain variable region of an antibody described herein, e.g., an antibody chosen from A-H.l or A-H.2, or an antibody described in Table 1, or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or higher identical) to any of the aforesaid sequences; or which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) relative to one, two, or three CDRs according to Chothia et al. shown in Table 1. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, includes at least one, two, three, four, five, or six CDRs according to Chothia et al. (e.g., at least one, two, three, four, five, or six CDRs according to the Chothia definition as set out in Table 1) from the heavy and light chain variable regions of an antibody described herein, e.g., an antibody chosen from A-H.l or A-H.2, or an antibody described in Table 1, or encoded by the nucleotide sequence in Table 1; or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or higher identical) to any of the aforesaid sequences; or which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) relative to one, two, three, four, five, or six CDRs according to Chothia et al. shown in Table 1. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, includes all six CDRs according to Chothia et al. (e.g., all six CDRs according to the Chothia definition as set out in Table 1) from the heavy and light chain variable regions of an antibody described herein, e.g., an antibody chosen from A-H.l or A-H.2, or an antibody described in Table 1, or encoded by a nucleotide sequence in Table 1; or a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or higher identical) to any of the aforesaid sequences; or which have at least one amino acid alteration, but not more than two, three or four alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) relative to all six CDRs according to Chothia et al. shown in Table 1. In one embodiment, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, may include any CDR described herein. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, molecule includes a combination of CDRs or hypervariable loops defined according to Kabat et al., Chothia et al., or as described in Table 1. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, can contain any combination of CDRs or hypervariable loops according to the Kabat and Chothia definitions. In some embodiments, a combined CDR as set out in Table 1 is a CDR that comprises a Kabat CDR and a Chothia CDR. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, molecule includes a combination of CDRs or hypervariable loops identified as combined CDRs in Table 1. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, can contain any combination of CDRs or hypervariable loops according the “combined” CDRs are described in Table 1. In an embodiment, e.g., an embodiment comprising a variable region, a CDR (e.g., a combined CDR, Chothia CDR or Kabat CDR), or other sequence referred to herein, e.g., in Table 1, the antibody molecule is a monospecific antibody molecule, a bispecific antibody molecule, a bivalent antibody molecule, a biparatopic antibody molecule, or an antibody molecule that comprises an antigen binding fragment of an antibody, e.g., a half antibody or antigen binding fragment of a half antibody. In certain embodiments the antibody molecule comprises a multispecific molecule, e.g., a bispecific molecule, e.g., as described herein. In an embodiment, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule includes: (i) one, two or all of a light chain complementarity determining region 1 (LC CDR1), a light chain complementarity determining region 2 (LC CDR2), and a light chain complementarity determining region 3 (LC CDR3) of SEQ ID NO: 2, SEQ ID NO: 10 or SEQ ID NO: 11, and / or (ii) one, two or all of a heavy chain complementarity determining region 1 (HC CDR1), heavy chain complementarity determining region 2 (HC CDR2), and a heavy chain complementarity determining region 3 (HC CDR3) of SEQ ID NO: 1 or SEQ ID NO: 9. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule comprises a LC CDR1, LC CDR2, and LC CDR3 of SEQ ID NO: 2, and a HC CDR1, HC CDR2, and HC CDR3 of SEQ ID NO: 1. In some embodiments the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRp V6-5*01) antibody molecule comprises a LC CDR1, LC CDR2, and LC CDR3 of SEQ ID NO: 10, and a HC CDR1, HC CDR2, and HC CDR3 of SEQ ID NO: 9. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule comprises a LC CDR1, LC CDR2, and LC CDR3 of SEQ ID NO: 11, and a HC CDR1, HC CDR2, and HC CDR3 of SEQ ID NO: 9. In an embodiment, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule comprises: (i) a LC CDR1 amino acid sequence of SEQ ID NO: 6, a LC CDR2 amino acid sequence of SEQ ID NO: 7, or a LC CDR3 amino acid sequence of SEQ ID NO: 8; and / or (ii) a HC CDR1 amino acid sequence of SEQ ID NO: 3, a HC CDR2 amino acid sequence of SEQ ID NO: 4, or a HC CDR3 amino acid sequence of SEQ ID NO: 5. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule comprises: (i) a light chain variable region (VL) comprising a LC CDR1 amino acid sequence of SEQ ID NO: 6, a LC CDR2 amino acid sequence of SEQ ID NO: 7, or a LC CDR3 amino acid sequence of SEQ ID NO: 8; and / or (ii) a heavy chain variable region (VH) comprising a HC CDR1 amino acid sequence of SEQ ID NO: 3, a HC CDR2 amino acid sequence of SEQ ID NO: 4, or a HC CDR3 amino acid sequence of SEQ ID NO: 5. In an embodiment, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule comprises: (i) a LC CDR1 amino acid sequence of SEQ ID NO: 51, a LC CDR2 amino acid sequence of SEQ ID NO: 52, or a LC CDR3 amino acid sequence of SEQ ID NO: 53; and / or (ii) a HC CDR1 amino acid sequence of SEQ ID NO: 45, a HC CDR2 amino acid sequence of SEQ ID NO: 46, or a HC CDR3 amino acid sequence of SEQ ID NO: 47. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule comprises: (i) a light chain variable region (VL) comprising a LC CDR1 amino acid sequence of SEQ ID NO: 51, a LC CDR2 amino acid sequence of SEQ ID NO: 52, or a LC CDR3 amino acid sequence of SEQ ID NO: 53; and / or (ii) a heavy chain variable region (VH) comprising a HC CDR1 amino acid sequence of SEQ ID NO: 45, a HC CDR2 amino acid sequence of SEQ ID NO: 46, or a HC CDR3 amino acid sequence of SEQ ID NO: 47. In an embodiment, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule comprises: (i) a LC CDR1 amino acid sequence of SEQ ID NO: 54, a LC CDR2 amino acid sequence of SEQ ID NO: 55, or a LC CDR3 amino acid sequence of SEQ ID NO: 56; and / or (ii) a HC CDR1 amino acid sequence of SEQ ID NO: 48, a HC CDR2 amino acid sequence of SEQ ID NO: 49, or a HC CDR3 amino acid sequence of SEQ ID NO: 50. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule comprises: (i) a light chain variable region (VL) comprising a LC CDR1 amino acid sequence of SEQ ID NO: 54, a LC CDR2 amino acid sequence of SEQ ID NO: 55, or a LC CDR3 amino acid sequence of SEQ ID NO: 56; and / or (ii) a heavy chain variable region (VH) comprising a HC CDR1 amino acid sequence of SEQ ID NO: 48, a HC CDR2 amino acid sequence of SEQ ID NO: 49, or a HC CDR3 amino acid sequence of SEQ ID NO: 50. In one embodiment, the light or the heavy chain variable framework (e.g., the region encompassing at least FR1, FR2, FR3, and optionally FR4) of the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule can be chosen from: (a) a light or heavy chain variable framework including at least 80%, 85%, 87% 90%, 92%, 93%, 95%, 97%, 98%, or 100% of the amino acid residues from a human light or heavy chain variable framework, e.g., a light or heavy chain variable framework residue from a human mature antibody, a human germline sequence, or a human consensus sequence; (b) a light or heavy chain variable framework including from 20% to 80%, 40% to 60%, 60% to 90%, or 70% to 95% of the amino acid residues from a human light or heavy chain variable framework, e.g., a light or heavy chain variable framework residue from a human mature antibody, a human germline sequence, or a human consensus sequence; (c) a non-human framework (e.g., a rodent framework); or (d) a non-human framework that has been modified, e.g., to remove antigenic or cytotoxic determinants, e.g., deimmunized, or partially humanized. In one embodiment, the light or heavy chain variable framework region (particularly FR1, FR2 and / or FR3) includes a light or heavy chain variable framework sequence at least 70, 75, 80, 85, 87, 88, 90, 92, 94, 95, 96, 97, 98, 99% identical or identical to the frameworks of a VL or VH segment of a human germline gene. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, comprises a heavy chain variable domain having at least one, two, three, four, five, six, seven, ten, fifteen, twenty or more changes, e.g., amino acid substitutions or deletions, from an amino acid sequence of A-H.l or A-H.2, e.g., the amino acid sequence of the FR region in the entire variable region, e.g., shown in FIG. 1A, or in SEQ ID NO: 9. Alternatively, or in combination with the heavy chain substitutions described herein, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, comprises a light chain variable domain having at least one, two, three, four, five, six, seven, ten, fifteen, twenty or more amino acid changes, e.g., amino acid substitutions or deletions, from an amino acid sequence of A-H.l or A-H.2 .e.g., the amino acid sequence of the FR region in the entire variable region, e.g., shown in FIG. IB, or in SEQ ID NO: 10 or SEQ ID NO: 11. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, includes one, two, three, or four heavy chain framework regions shown in FIG. 1A, or a sequence substantially identical thereto. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, includes one, two, three, or four light chain framework regions shown in FIG. IB, or a sequence substantially identical thereto. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, comprises the light chain framework region 1 of A-H.l or A-H.2, e.g., as shown in FIG. IB. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, comprises the light chain framework region 2 of A-H.l or A-H.2, e.g., as shown in FIG. IB. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, comprises the light chain framework region 3 of A-H.l or A-H.2, e.g., as shown in FIG. IB. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, comprises the light chain framework region 4 of A-H.l or A-H.2, e.g., as shown in FIG. IB. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, comprises a light chain variable domain comprising a framework region, e.g., framework region 1 (FR1), comprising a change, e.g., a substitution (e.g., a conservative substitution) at position 10 according to Kabat numbering. In some embodiments, the FR1 comprises a Phenylalanine at position 10, e.g., a Serine to Phenyalanine substitution. In some embodiments, the substitution is relative to a human germline light chain framework region sequence. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, comprises a light chain variable domain comprising a framework region, e.g., framework region 2 (FR2), comprising a change, e.g., a substitution (e.g., a conservative substitution) at a position disclosed herein according to Kabat numbering. In some embodiments, FR2 comprises a Histidine at position 36, e.g., a substitution at position 36 according to Kabat numbering, e.g., a Tyrosine to Histidine substitution. In some embodiments, FR2 comprises an Alanine at position 46, e.g., a substitution at position 46 according to Kabat numbering, e.g., an Arginine to Alanine substitution. In some embodiments, the substitution is relative to a human germline light chain framework region sequence. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, comprises a light chain variable domain comprising a framework region, e.g., framework region 3 (FR3), comprising a change, e.g., a substitution (e.g., a conservative substitution) at a position disclosed herein according to Kabat numbering. In some embodiments, FR3 comprises a Phenyalanine at position 87, e.g., a substitution at position 87 according to Kabat numbering, e.g., a Tyrosine to Phenyalanine substitution. In some embodiments, the substitution is relative to a human germline light chain framework region sequence. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, comprises a light chain variable domain comprising: (a) a framework region 1 (FR1) comprising a Phenylalanine at position 10, e.g., a substitution at position 10 according to Kabat numbering, e.g., a Serine to Phenyalanine substitution; (b) a framework region 2 (FR2) comprising a Histidine at position 36, e.g., a substitution at position 36 according to Kabat numbering, e.g., a Tyrosine to Histidine substitution, and a Alanine at position 46, e.g., a substitution at position 46 according to Kabat numbering, e.g., a Arginine to Alanine substitution; and (c) a framework region 3 (FR3) comprising a Phenylalanine at position 87, e.g., a substitution at position 87 according to Kabat numbering, e.g., a Tyrosine to Phenyalanine substitution, e.g., as shown in the amino acid sequence of SEQ ID NO: 10. In some embodiments, the substitution is relative to a human germline light chain framework region sequence. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, comprises a light chain variable domain comprising: (a) a framework region 2 (FR2) comprising a Histidine at position 36, e.g., a substitution at position 36 according to Kabat numbering, e.g., a Tyrosine to Histidine substitution, and a Alanine at position 46, e.g., a substitution at position 46 according to Kabat numbering, e.g., a Arginine to Alanine substitution; and (b) a framework region 3 (FR3) comprising a Phenylalanine at position 87, e.g., a substitution at position 87 according to Kabat numbering, e.g., a Tyrosine to Phenyalanine substitution, e.g., as shown in the amino acid sequence of SEQ ID NO: 11. In some embodiments, the substitution is relative to a human germline light chain framework region sequence. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, comprises a light chain variable domain comprising: (a) a framework region 1 (FR1) comprising a change, e.g., a substitution (e.g., a conservative substitution) at one or more (e.g., all) positions disclosed herein according to Kabat numbering, ; (b) a framework region 2 (FR2) comprising a change, e.g., a substitution (e.g., a conservative substitution) at one or more (e.g., all) position disclosed herein according to Kabat numbering and (c) a framework region 3 (FR3) comprising a change, e.g., a substitution (e.g., a conservative substitution) at one or more (e.g., all) position disclosed herein according to Kabat numbering. In some embodiments, the substitution is relative to a human germline light chain framework region sequence. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, comprises the heavy chain framework region 1 of A-H.l or A-H.2, e.g., as shown in FIG. 1A. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, comprises the heavy chain framework region 2 of A-H.l or A-H.2, e.g., as shown in FIG. 1A In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, comprises the heavy chain framework region 3 of A-H.l or A-H.2, e.g., as shown in FIG. 1A. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, comprises the heavy chain framework region 4 of A-H.l or A-H.2, e.g., as shown in FIG. 1A. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, comprises a heavy chain variable domain comprising a framework region, e.g., framework region 3 (FR3), comprising a change, e.g., a substitution (e.g., a conservative substitution) at a position disclosed herein according to Kabat numbering. In some embodiments, FR3 comprises a Threonine at position 73, e.g., a substitution at position 73 according to Kabat numbering, e.g., a Glutamic Acid to Threonine substitution. In some embodiments, FR3 comprises a Glycine at position 94, e.g., a substitution at position 94 according to Kabat numbering, e.g., an Arginine to Glycine substitution. In some embodiments, the substitution is relative to a human germline heavy chain framework region sequence. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, comprises a heavy chain variable domain comprising a framework region 3 (FR3) comprising a Threonine at position 73, e.g., a substitution at position 73 according to Kabat numbering, e.g., a Glutamic Acid to Threonine substitution, and a Glycine at position 94, e.g., a substitution at position 94 according to Kabat numbering, e.g., a Arginine to Glycine substitution, e.g., as shown in the amino acid sequence of SEQ ID NO: 10. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, comprises the heavy chain framework regions 1-4 of A-H.l or A-H.2, e.g., SEQ ID NO: 9, or as shown in FIGs. 1A and IB. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, comprises the light chain framework regions 1-4 of A-H.l, e.g., SEQ ID NO: 10, or as shown in FIGs. 1A and IB. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, comprises the light chain framework regions 1-4 of A-H.2, e.g., SEQ ID NO: 11, or as shown in FIGs. 1A and IB. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, comprises the heavy chain framework regions 1-4 of A-H.l, e.g., SEQ ID NO: 9; and the light chain framework regions 1-4 of A-H.l, e.g., SEQ ID NO: 10, or as shown in FIGs. 1A and IB. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, comprises the heavy chain framework regions 1-4 of A-H.2, e.g., SEQ ID NO: 9; and the light chain framework regions 1-4 of A-H.2, e.g., SEQ ID NO: 11, or as shown in FIGs. 1A and IB. In some embodiments, the heavy or light chain variable domain, or both, of the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, includes an amino acid sequence, which is substantially identical to an amino acid disclosed herein, e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or higher identical to a variable region of an antibody described herein, e.g., an antibody chosen from A-H.l or A-H.2, or as described in Table 1, or encoded by the nucleotide sequence in Table 1; or which differs at least 1 or 5 residues, but less than 40, 30, 20, or 10 residues, from a variable region of an antibody described herein. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, comprises at least one, two, three, or four antigenbinding regions, e.g., variable regions, having an amino acid sequence as set forth in Table 1, or a sequence substantially identical thereto (e.g., a sequence at least about 85%, 90%, 95%, 99% or more identical thereto, or which differs by no more than 1, 2, 5, 10, or 15 amino acid residues from the sequences shown in Table 1. In another embodiment, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule includes a VH and / or VL domain encoded by a nucleic acid having a nucleotide sequence as set forth in Table 1, or a sequence substantially identical thereto (e.g., a sequence at least about 85%, 90%, 95%, 99% or more identical thereto, or which differs by no more than 3, 6, 15, 30, or 45 nucleotides from the sequences shown in Table 1. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, comprises: a VH domain comprising the amino acid sequence of SEQ ID NO: 9, an amino acid sequence at least about 85%, 90%, 95%, 99% or more identical to the amino acid sequence of SEQ ID NO: 9, or an amino acid sequence which differs by no more than 1, 2, 5, 10, or 15 amino acid residues from the amino acid sequence of SEQ ID NO: 9; and / or a VL domain comprising the amino acid sequence of SEQ ID NO: 10, an amino acid sequence at least about 85%, 90%, 95%, 99% or more identical to the amino acid sequence of SEQ ID NO: 10, or an amino acid sequence which differs by no more than 1, 2, 5, 10, or 15 amino acid residues from the amino acid sequence of SEQ ID NO: 10. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, comprises: a VH domain comprising the amino acid sequence of SEQ ID NO: 9, an amino acid sequence at least about 85%, 90%, 95%, 99% or more identical to the amino acid sequence of SEQ ID NO: 9, or an amino acid sequence which differs by no more than 1, 2, 5, 10, or 15 amino acid residues from the amino acid sequence of SEQ ID NO: 9; and / or a VL domain comprising the amino acid sequence of SEQ ID NO: 11, an amino acid sequence at least about 85%, 90%, 95%, 99% or more identical to the amino acid sequence of SEQ ID NO: 11, or an amino acid sequence which differs by no more than 1, 2, 5, 10, or 15 amino acid residues from the amino acid sequence of SEQ ID NO: 11. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule is a full antibody or fragment thereof (e.g., a Fab, F(ab')2, Fv, or a single chain Fv fragment (scFv)). In embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule is a monoclonal antibody or an antibody with single specificity. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, can also be a humanized, chimeric, camelid, shark, or an in vz / ro-generated antibody molecule. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, is a humanized antibody molecule. The heavy and light chains of the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, can be full-length (e.g., an antibody can include at least one, and preferably two, complete heavy chains, and at least one, and preferably two, complete light chains) or can include an antigen-binding fragment (e.g., a Fab, F(ab')2, Fv, a single chain Fv fragment, a single domain antibody, a diabody (dAb), a bivalent antibody, or bispecific antibody or fragment thereof, a single domain variant thereof, or a camelid antibody). In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, is in the form of a multispecific molecule, e.g., a bispecific molecule, e.g., as described herein. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, has a heavy chain constant region (Fc) chosen from, e.g., the heavy chain constant regions of IgGl, IgG2, IgG3, IgG4, IgM, IgAl, IgA2, IgD, and IgE. In some embodiments, the Fc region is chosen from the heavy chain constant regions of IgGl, IgG2, IgG3, and IgG4. In some embodiments, the Fc region is chosen from the heavy chain constant region of IgGl or IgG2 (e.g., human IgGl, or IgG2). In some embodiments, the heavy chain constant region is human IgGl. In some embodiments, the anti-TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule, has a light chain constant region chosen from, e.g., the light chain constant regions of kappa or lambda, preferably kappa (e.g., human kappa). In one embodiment, the constant region is altered, e.g., mutated, to modify the properties of the anti- TCRpV antibody molecule, e.g., anti-TCRP V6 (e.g., anti-TCRP V6-5*01) antibody molecule (e.g., to increase or decrease one or more of: Fc receptor binding, antibody glycosylation, the number of cysteine residues, effector cell function, or complement function). For example, the constant region is mutated at positions 296 (M to Y), 298 (S to T), 300 (T to E), 477 (H to K) 5 and 478 (N to F) to alter Fc receptor binding (e.g., the mutated positions correspond to positions 132 (M to Y), 134 (S to T), 136 (T to E), 313 (H to K) and 314 (N to F) of SEQ ID NOs: 212 or 214; or positions 135 (M to Y), 137 (S to T), 139 (T to E), 316 (H to K) and 317 (N to F) of SEQ ID NOs: 215, 216, 217 or 218), e.g., relative to human IgGl. Antibody A-H.l comprises a heavy chain comprising the amino acid sequence of SEQ ID 10 NO: 3278 and a light chain comprising the amino acid sequence of SEQ ID NO: 72. Antibody A-H.2 comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 3278 and a light chain comprising the amino acid sequence of SEQ ID NO: 3279. Table 1: Amino acid and nucleotide sequences for murine, chimeric and humanized antibody 15 molecules. The antibody molecules include murine mAb Antibody A, and humanized mAb Antibody A-H Clones A-H.l and A-H.2. The amino acid the heavy and light chain CDRs, and the amino acid and nucleotide sequences of the heavy and light chain variable regions, and the heavy and light chains are shown. Antibody A (murine) SEQ ID NO: 3 HC CDR1 (Combined) GYSFTTYYIH SEQ ID NO: 4 HC CDR2 (Combined) WFFPGSGNIKYNEKFKG SEQ ID NO: 5 HC CDR3 (Combined) SYYSYDVLDY SEQ ID NO: 45 HC CDR1 (Kabat) TYYIH SEQ ID NO: 46 HC CDR2 (Kabat) WFFPGSGNIKYNEKFKG SEQ ID NO: 47 HC CDR3 (Kabat) SYYSYDVLDY SEQ ID NO:48 HC CDR1 (Chothia) GYSFTTY SEQ ID NO: 49 HC CDR2 (Chothia) FPGSGN SEQ ID NO: 50 HC CDR3 (Chothia) SYYSYDVLDY SEQ ID NO: 1 VH QVQLQQSGPELVKPGTSVKISCKASGYSFTT YYIHWVKQRPGQGLEWIGWFFPGSGNIKYN EKFKGKATLTADTSSSTAYMQLSSLTSEESA VYFCAGSYYSYDVLDYWGHGTTLTVSS SEQ ID NO: 6 LC CDR1 (Combined) KASQNVGINVV SEQ ID NO: 7 LC CDR2 (Combined)) SSSHRYS SEQ ID NO: 8 LC CDR3 (Combined) QQFKSYPLT SEQ ID NO: 51 LC CDR1 (Kabat) KASQNVGINVV SEQ ID NO: 52 LC CDR2 (Kabat) SSSHRYS SEQ ID NO: 53 LC CDR3 (Kabat) QQFKSYPLT SEQ ID NO: 54 LC CDR1 (Chothia) KASQNVGINVV SEQ ID NO: 55 LC CDR2 (chothia) SSSHRYS SEQ ID NO: 56 LC CDR3 (chothia) QQFKSYPLT SEQ ID NO: 2 VL DILMTQSQKFMSTSLGDRVSVSCKASQNVG IN V VWHQQKPGQS PK ALIYS SSHRYSGVPD RFTGSGSGTDFTLTINNVQSEDLAEYFCQQF KSYPLTFGAGTKLELK Antibody A humanized (A-H antibody) A-H.l antibody SEQ ID NO: 3 HC CDR1 (Combined) GYSFTTYYIH SEQ ID NO: 4 HC CDR2 (Combined) WFFPGSGNIKYNEKFKG SEQ ID NO: 5 HC CDR3 (Combined) SYYSYDVLDY SEQ ID NO: 9 VH QVQLVQSGAEVKKPGSSVKVSCKASGYSFT TYYIHWVRQAPGQGLEWMGWFFPGSGNIK YNEKFKGRVTITADTSTSTAYMELSSLRSED TAVYYCAGSYYSYDVLDYWGQGTTVTVSS SEQ ID NO: 12 DNA VH CAGGTGCAGCTGGTTCAGTCTGGCGCCGA AGTGAAGAAACCTGGCTCCTCCGTGAAGG TGTCCTGCAAGGCTTCCGGCTACTCCTTCA CCACCTACTACATCCACTGGGTCCGACAG GCCCCTGGACAAGGATTGGAATGGATGG GCTGGTTCTTCCCCGGCTCCGGCAACATC AAGTACAACGAGAAGTTCAAGGGCCGCG TGACCATCACCGCCGACACCTCTACCTCT ACCGCCTACATGGAACTGTCCAGCCTGAG ATCTGAGGACACCGCCGTGTACTACTGCG CCGGCTCCTACTACTCTTACGACGTGCTG GATTACTGGGGCCAGGGCACCACAGTGAC AGTGTCCTCT SEQ ID NO: 69 VH-IgM constant delta CDC METDTLLLWVLLLWVPGSTGQVQLVQSGA EVKKPGSSVKVSCKASGYSFTTYYIHWVRQ APGQGLEWMGWFFPGSGNIKYNEKFKGRV TITADTSTSTAYMELSSLRSEDTAVYYCAGS YYSYDVLDYWGQGTTVTVSSGSASAPTLFP LVSCENSPSDTSSVAVGCLAQDFLPDSITFS WKYKNNSDISSTRGFPSVLRGGKYAATSQV LLPSKDVMQGTDEHVVCKVQHPNGNKEKN VPLPVIAELPPKVSVFVPPRDGFFGNPRKSK LICQATGFSPRQIQVSWLREGKQVGSGVTT DQVQAEAKESGPTTYKVTSTLTIKESDWLG QSMFTCRVDHRGLTFQQNASSMCVPDQDT AIRVFAIPPSFASIFLTKSTKLTCLVTDLTTY DSVTISWTRQNGEAVKTHTNISESHPNATFS AVGEASICEDDWNSGERFTCTVTHTDLASS LKQTISRPKGVALHRPDVYLLPPAREQLNLR ESATITCLVTGFSPADVFVQWMQRGQPLSP EKYVTSAPMPEPQAPGRYFAHSILTVSEEE WNTGETYTCVVAHEALPNRVTERTVDKST GKPTLYNVSLVMSDTAGTCY SEQ ID NO: 70 VH-IgGAl METDTLLLWVLLLWVPGSTGQVQLVQSGA EVKKPGSSVKVSCKASGYSFTTYYIHWVRQ APGQGLEWMGWFFPGSGNIKYNEKFKGRV TITADTSTSTAYMELSSLRSEDTAVYYCAGS YYSYDVLDYWGQGTTVTVSSASPTSPKVFP LSLCSTQPDGNVVIACLVQGFFPQEPLSVTW SESGQGVTARNFPPSQDASGDLYTTSSQLTL PATQCLAGKSVTCHVKHYTNPSQDVTVPCP VPSTPPTPSPSTPPTPSPSCCHPRLSLHRPALE DLLLGSEANLTCTLTGLRDASGVTFTWTPSS GKSAVQGPPERDLCGCYSVSSVLPGCAEPW NHGKTFTCTAAYPESKTPLTATLSKSGNTFR PEVHLLPPPSEELALNELVTLTCLARGFSPK DVLVRWLQGSQELPREKYLTWASRQEPSQ GTTTFAVTSILRVAAEDWKKGDTFSCMVG HEALPLAFTQKTIDRLAGKPTHVNVSVVMA EVDGTCY SEQ ID NO: 71 VH-IgGA2 METDTLLLWVLLLWVPGSTGQVQLVQSGA EVKKPGSSVKVSCKASGYSFTTYYIHWVRQ APGQGLEWMGWFFPGSGNIKYNEKFKGRV TITADTSTSTAYMELSSLRSEDTAVYYCAGS YYSYDVLDYWGQGTTVTVSSASPTSPKVFP LSLDSTPQDGNVVVACLVQGFFPQEPLSVT WSESGQNVTARNFPPSQDASGDLYTTSSQL TLPATQCPDGKSVTCHVKHYTNSSQDVTVP CRVPPPPPCCHPRLSLHRPALEDLLLGSEAN LTCTLTGLRDASGATFTWTPSSGKSAVQGP PERDLCGCYSVSSVLPGCAQPWNHGETFTC TAAHPELKTPLTANITKSGNTFRPEVHLLPP PSEELALNELVTLTCLARGFSPKDVLVRWL QGSQELPREKYLTWASRQEPSQGTTTYAVT SILRVAAEDWKKGETFSCMVGHEALPLAFT QKTIDRMAGKPTHINVSVVMAEADGTCY SEQ ID NO: 3278 Heavy chain METDTLLLWVLLLWVPGSTGQVQLVQSGA EVKKPGSSVKVSCKASGYSFTTYYIHWVRQ APGQGLEWMGWFFPGSGNIKYNEKFKGRV TITADTSTSTAYMELSSLRSEDTAVYYCAGS YYSYDVLDYWGQGTTVTVSSASTKGPSVFP LAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVT VPSSSLGTQTYICNVNHKPSNTKVDKRVEP KSCDKTHTCPPCPAPELLGGPSVFLFPPKPK DTLMISRTPEVTCVVVDVSHEDPEVKFNWY VDGVEVHNAKTKPREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSREEMTKNQVSLTC LVKGFYPSDIAVEWESNGQPENNYKTTPPV LDSDGSFFLYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK SEQ ID NO: 6 LC CDR1 (Combined) KASQNVGINVV SEQ ID NO: 7 LC CDR2 (Combined)) SSSHRYS SEQ ID NO: 8 LC CDR3 (Combined) QQFKSYPLT SEQ ID NO: 10 VL DIQMTQSPSFLSASVGDRVTITCKASQNVGI NVVWHQQKPGKAPKALIYSSSHRYSGVPSR FSGSGSGTEFTLTISSLQPEDFATYFCQQFKS YPLTFGQGTKLEIK SEQ ID NO: 13 DNA VL GACATCCAGATGACCCAGTCTCCATCCTT CCTGTCCGCCTCTGTGGGCGACAGAGTGA CCATCACATGCAAGGCCTCTCAGAACGTG GGCATCAACGTCGTGTGGCACCAGCAGAA GCCTGGCAAGGCTCCTAAGGCTCTGATCT ACTCCTCCAGCCACCGGTACTCTGGCGTG CCCTCTAGATTTTCCGGCTCTGGCTCTGGC ACCGAGTTTACCCTGACAATCTCCAGCCT GCAGCCTGAGGACTTCGCCACCTACTTTT GCCAGCAGTTCAAGAGCTACCCTCTGACC TTTGGCCAGGGCACCAAGCTGGAAATCAA G SEQ ID NO: 72 VL and kappa constant region / light chain METDTLLLWVLLLWVPGSTGDIQMTQSPSF LSASVGDRVTITCKASQNVGINVVWHQQKP GKAPKALIYSSSHRYSGVPSRFSGSGSGTEF TLTISSLQPEDFATYFCQQFKSYPLTFGQGT KLEIKRTVAAPSVFIFPPSDEQLKSGTASVVC LLNNFYPREAKVQWKVDNALQSGNSQESV TEQDSKDSTYSLSSTLTLSKADYEKHKVYA CEVTHQGLSSPVTKSFNRGEC A-H.2 antibody SEQ ID NO: 3 HC CDR1 (Combined) GYSFTTYYIH SEQ ID NO: 4 HC CDR2 (Combined) WFFPGSGNIKYNEKFKG SEQ ID NO: 5 HC CDR3 (Combined) SYYSYDVLDY SEQ ID NO: 9 VH QVQLVQSGAEVKKPGSSVKVSCKASGYSFT TYYIHWVRQAPGQGLEWMGWFFPGSGNIK YNEKFKGRVTITADTSTSTAYMELSSLRSED TAVYYCAGSYYSYDVLDYWGQGTTVTVSS SEQ ID NO: 12 DNA VH CAGGTGCAGCTGGTTCAGTCTGGCGCCGA AGTGAAGAAACCTGGCTCCTCCGTGAAGG TGTCCTGCAAGGCTTCCGGCTACTCCTTCA CCACCTACTACATCCACTGGGTCCGACAG GCCCCTGGACAAGGATTGGAATGGATGG GCTGGTTCTTCCCCGGCTCCGGCAACATC AAGTACAACGAGAAGTTCAAGGGCCGCG TGACCATCACCGCCGACACCTCTACCTCT ACCGCCTACATGGAACTGTCCAGCCTGAG ATCTGAGGACACCGCCGTGTACTACTGCG CCGGCTCCTACTACTCTTACGACGTGCTG GATTACTGGGGCCAGGGCACCACAGTGAC AGTGTCCTCT SEQ ID NO: 3278 Heavy chain METDTLLLWVLLLWVPGSTGQVQLVQSGA EVKKPGSSVKVSCKASGYSFTTYYIHWVRQ APGQGLEWMGWFFPGSGNIKYNEKFKGRV TITADTSTSTAYMELSSLRSEDTAVYYCAGS YYSYDVLDYWGQGTTVTVSSASTKGPSVFP LAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVT VPSSSLGTQTYICNVNHKPSNTKVDKRVEP KSCDKTHTCPPCPAPELLGGPSVFLFPPKPK DTLMISRTPEVTCVVVDVSHEDPEVKFNWY VDGVEVHNAKTKPREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSREEMTKNQVSLTC LVKGFYPSDIAVEWESNGQPENNYKTTPPV LDSDGSFFLYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK SEQ ID NO: 6 LC CDR1 (Combined) KASQNVGINVV SEQ ID NO: 7 LC CDR2 (Combined)) SSSHRYS SEQ ID NO: 8 LC CDR3 (Combined) QQFKSYPLT SEQ ID NO: 11 VL DIQMTQSPSSLSASVGDRVTITCKASQNVGI NVVWHQQKPGKVPKALIYSSSHRYSGVPSR FSGSGSGTDFTLTISSLQPEDVATYFCQQFKS YPLTFGQGTKLEIK SEQ ID NO: 14 DNA VL GACATCCAGATGACCCAGTCTCCATCCTC TCTGTCCGCCTCTGTGGGCGACAGAGTGA CCATCACATGCAAGGCCTCTCAGAACGTG GGCATCAACGTCGTGTGGCACCAGCAGAA ACCTGGCAAGGTGCCCAAGGCTCTGATCT ACTCCTCCAGCCACAGATACTCCGGCGTG CCCTCTAGATTCTCCGGCTCTGGCTCTGGC ACCGACTTTACCCTGACAATCTCCAGCCT GCAGCCTGAGGACGTGGCCACCTACTTTT GCCAGCAGTTCAAGAGCTACCCTCTGACC TTTGGCCAGGGCACCAAGCTGGAAATCAA G SEQ ID NO: 3279 Light chain METDTLLLWVLLLWVPGSTGDIQMTQSPSS LSASVGDRVTITCKASQNVGINVVWHQQKP GKVPKALIYSSSHRYSGVPSRFSGSGSGTDF TLTISSLQPEDVATYFCQQFKSYPLTFGQGT KLEIKRTVAAPSVFIFPPSDEQLKSGTASVVC LLNNFYPREAKVQWKVDNALQSGNSQESV TEQDSKDSTYSLSSTLTLSKADYEKHKVYA CEVTHQGLSSPVTKSFNRGEC A-H.3 antibody SEQ ID NO: 80 VH+VL QVQLVQSGAEVKKPGSSVKVSCKASGTDF KLTYIHWVRQAPGQGLEWMGRVSPGSGNT KYNEKFKGRVTITADTSTSTAYMELSSLRSE DTAVYYCAGSYYSYDVLDYWGQGTTVTVS SGGGGSGGGGSGGGGSGGGGSDIQMTQSPS FLSASVGDRVTITCKASQNVEDRVAWYQQ KPGKAPKALIYSSSHRYKGVPSRFSGSGSGT EFTLTISSLQPEDFATYFCQQFKSYPLTFGQG TKLEIK SEQ ID NO: 81 VL DIQMTQSPSFLSASVGDRVTITCKASQNVED RVAWYQQKPGKAPKALIYSSSHRYKGVPSR FSGSGSGTEFTLTISSLQPEDFATYFCQQFKS YPLTFGQGTKLEIK SEQ ID NO: 82 VH QVQLVQSGAEVKKPGSSVKVSCKASGTDF KLTYIHWVRQAPGQGLEWMGRVSPGSGNT KYNEKFKGRVTITADTSTSTAYMELSSLRSE DTAVYYCAGSYYSYDVLDYWGQGTTVTVS S A-H.4 SEQ ID NO: 83 VH+VL QVQLVQSGAEVKKPGSSVKVSCKASGTDF DKIYIHWVRQAPGQGLEWMGRISAGSGNV KYNEKFKGRVTITADTSTSTAYMELSSLRSE DTAVYYCAGSYYSYDVLDYWGQGTTVTVS SGGGGSGGGGSGGGGSGGGGSDIQMTQSPS FLSASVGDRVTITCKASQNVEDRVAWYQQ KPGKAPKALIYSSSHRYKGVPSRFSGSGSGT EFTLTISSLQPEDFATYFCQQFKSYPLTFGQG TKLEIK SEQ ID NO: 84 VL DIQMTQSPSFLSASVGDRVTITCKASQNVED RVAWYQQKPGKAPKALIYSSSHRYKGVPSR FSGSGSGTEFTLTISSLQPEDFATYFCQQFKS YPLTFGQGTKLEIK SEQ ID NO: 85 VH QVQLVQSGAEVKKPGSSVKVSCKASGTDF DKIYIHWVRQAPGQGLEWMGRISAGSGNV KYNEKFKGRVTITADTSTSTAYMELSSLRSE DTAVYYCAGSYYSYDVLDYWGQGTTVTVS S A-H.5 SEQ ID NO: 86 VH+VL QVQLVQSGAEVKKPGSSVKVSCKASGHDF RDFYIHWVRQAPGQGLEWMGRVYPGSGSY RYNEKFKGRVTITADTSTSTAYMELSSLRSE DTAVYYCAGSYYSYDVLDYWGQGTTVTVS SGGGGSGGGGSGGGGSGGGGSDIQMTQSPS FLSASVGDRVTITCKASQNVDDRVAWYQQ KPGKAPKALIYSSSHRYKGVPSRFSGSGSGT EFTLTISSLQPEDFATYFCQQFKSYPLTFGQG TKLEIK SEQ ID NO: 87 VL DIQMTQSPSFLSASVGDRVTITCKASQNVDD RVAWYQQKPGKAPKALIYSSSHRYKGVPSR FSGSGSGTEFTLTISSLQPEDFATYFCQQFKS YPLTFGQGTKLEIK SEQ ID NO: 88 VH QVQLVQSGAEVKKPGSSVKVSCKASGHDF RDFYIHWVRQAPGQGLEWMGRVYPGSGSY RYNEKFKGRVTITADTSTSTAYMELSSLRSE DTAVYYCAGSYYSYDVLDYWGQGTTVTVS S A-H.6 SEQ ID NO: 89 VH+VL QVQLVQSGAEVKKPGSSVKVSCKASGHDF KLTYIHWVRQAPGQGLEWMGRISAGSGNV KYNEKFKGRVTITADTSTSTAYMELSSLRSE DTAVYYCAGSYYSYDVLDYWGQGTTVTVS SGGGGSGGGGSGGGGSGGGGSDIQMTQSPS FLSASVGDRVTITCKASQNVDNRVAWYQQ KPGKAPKALIYSSSHRYKGVPSRFSGSGSGT EFTLTISSLQPEDFATYFCQQFKSYPLTFGQG TKLEIK SEQ ID NO: 90 VL DIQMTQSPSFLSASVGDRVTITCKASQNVDN RVAWYQQKPGKAPKALIYSSSHRYKGVPSR FSGSGSGTEFTLTISSLQPEDFATYFCQQFKS YPLTFGQGTKLEIK SEQ ID NO: 91 VH QVQLVQSGAEVKKPGSSVKVSCKASGHDF KLTYIHWVRQAPGQGLEWMGRISAGSGNV KYNEKFKGRVTITADTSTSTAYMELSSLRSE DTAVYYCAGSYYSYDVLDYWGQGTTVTVS S A-H.7 SEQ ID NO: 92 VH+VL QVQLVQSGAEVKKPGSSVKVSCKASGTDF KLTYIHWVRQAPGQGLEWMGRIFPGSGNV KYNEKFKGRVTITADTSTSTAYMELSSLRSE DTAVYYCAGSYYSYDVLDYWGQGTTVTVS SGGGGSGGGGSGGGGSGGGGSDIQMTQSPS FLSASVGDRVTITCKASQNVENKVAWHQQ KPGKAPKALIYSSSHRYKGVPSRFSGSGSGT EFTLTISSLQPEDFATYFCQQFKSYPLTFGQG TKLEIK SEQ ID NO: 93 VL DIQMTQSPSFLSASVGDRVTITCKASQNVEN KVAWHQQKPGKAPKALIYSSSHRYKGVPS RFSGSGSGTEFTLTISSLQPEDFATYFCQQFK SYPLTFGQGTKLEIK SEQ ID NO: 94 VH QVQLVQSGAEVKKPGSSVKVSCKASGTDF KLTYIHWVRQAPGQGLEWMGRIFPGSGNV KYNEKFKGRVTITADTSTSTAYMELSSLRSE DTAVYYCAGSYYSYDVLDYWGQGTTVTVS S A-H.8 SEQ ID NO: 95 VH+VL QVQLVQSGAEVKKPGSSVKVSCKASGTDF DKIYIHWVRQAPGQGLEWMGRIFAGSGNT KYNEKFKGRVTITADTSTSTAYMELSSLRSE DTAVYYCAGSYYSYDVLDYWGQGTTVTVS SGGGGSGGGGSGGGGSGGGGSDIQMTQSPS FLSASVGDRVTITCKASQNVDDRVAWYQQ KPGKAPKALIYSSSHRYKGVPSRFSGSGSGT EFTLTISSLQPEDFATYFCQQFKSYPLTFGQG TKLEIK SEQ ID NO: 96 VL DIQMTQSPSFLSASVGDRVTITCKASQNVDD RVAWYQQKPGKAPKALIYSSSHRYKGVPSR FSGSGSGTEFTLTISSLQPEDFATYFCQQFKS YPLTFGQGTKLEIK SEQ ID NO: 97 VH QVQLVQSGAEVKKPGSSVKVSCKASGTDF DKIYIHWVRQAPGQGLEWMGRIFAGSGNT KYNEKFKGRVTITADTSTSTAYMELSSLRSE DTAVYYCAGSYYSYDVLDYWGQGTTVTVS S A-H.9 SEQ ID NO: 98 VH+VL QVQLVQSGAEVKKPGSSVKVSCKASGHDF DKFYIHWVRQAPGQGLEWMGRVSAGSGN VKYNEKFKGRVTITADTSTSTAYMELSSLRS EDTAVYYCAGSYYSYDVLDYWGQGTTVT VSSGGGGSGGGGSGGGGSGGGGSDIQMTQ SPSFLSASVGDRVTITCKASQNVGNRVAWY QQKPGKAPKALIYSSSHRYSGVPSRFSGSGS GTEFTLTISSLQPEDFATYFCQQFKSYPLTFG QGTKLEIK SEQ ID NO: 99 VL DIQMTQSPSFLSASVGDRVTITCKASQNVGN RVAWYQQKPGKAPKALIYSSSHRYSGVPSR FSGSGSGTEFTLTISSLQPEDFATYFCQQFKS YPLTFGQGTKLEIK SEQ ID NO: 100 VH QVQLVQSGAEVKKPGSSVKVSCKASGHDF DKFYIHWVRQAPGQGLEWMGRVSAGSGN VKYNEKFKGRVTITADTSTSTAYMELSSLRS EDTAVYYCAGSYYSYDVLDYWGQGTTVT VSS A-H.10 SEQ ID NO: 101 VH+VL QVQLVQSGAEVKKPGSSVKVSCKASGHDF DKFYIHWVRQAPGQGLEWMGRIFAGSGNV KYNEKFKGRVTITADTSTSTAYMELSSLRSE DTAVYYCAGSYYSYDVLDYWGQGTTVTVS SGGGGSGGGGSGGGGSGGGGSDIQMTQSPS FLSASVGDRVTITCKASQNVGDRVAWYQQ KPGKAPKALIYSSSHRYKGVPSRFSGSGSGT EFTLTISSLQPEDFATYFCQQFKSYPLTFGQG TKLEIKs SEQ ID NO: 102 VL DIQMTQSPSFLSASVGDRVTITCKASQNVGD RVAWYQQKPGKAPKALIYSSSHRYKGVPSR FSGSGSGTEFTLTISSLQPEDFATYFCQQFKS YPLTFGQGTKLEIK SEQ ID NO: 103 VH QVQLVQSGAEVKKPGSSVKVSCKASGHDF DKFYIHWVRQAPGQGLEWMGRIFAGSGNV KYNEKFKGRVTITADTSTSTAYMELSSLRSE DTAVYYCAGSYYSYDVLDYWGQGTTVTVS S A-H.ll SEQ ID NO: 104 VH+VL QVQLVQSGAEVKKPGSSVKVSCKASGTDF KLTYIHWVRQAPGQGLEWMGRVSPGSGNV KYNEKFKGRVTITADTSTSTAYMELSSLRSE DTAVYYCAGSYYSYDVLDYWGQGTTVTVS SGGGGSGGGGSGGGGSGGGGSDIQMTQSPS FLSASVGDRVTITCKASQNVGDRVAWYQQ KPGKAPKALIYSSSHRYKGVPSRFSGSGSGT EFTLTISSLQPEDFATYFCQQFKSYPLTFGQG TKLEIK SEQ ID NO: 105 VL DIQMTQSPSFLSASVGDRVTITCKASQNVGD RVAWYQQKPGKAPKALIYSSSHRYKGVPSR FSGSGSGTEFTLTISSLQPEDFATYFCQQFKS YPLTFGQGTKLEIK SEQ ID NO: 106 VH QVQLVQSGAEVKKPGSSVKVSCKASGTDF KLTYIHWVRQAPGQGLEWMGRVSPGSGNV KYNEKFKGRVTITADTSTSTAYMELSSLRSE DTAVYYCAGSYYSYDVLDYWGQGTTVTVS S A-H.12 SEQ ID NO: 107 VH+VL QVQLVQSGAEVKKPGSSVKVSCKASGTDF DKIYIHWVRQAPGQGLEWMGRVSAGSGNT KYNEKFKGRVTITADTSTSTAYMELSSLRSE DTAVYYCAGSYYSYDVLDYWGQGTTVTVS SGGGGSGGGGSGGGGSGGGGSDIQMTQSPS FLSASVGDRVTITCKASQNVGNRVAWYQQ KPGKAPKALIYSSSHRYKGVPSRFSGSGSGT EFTLTISSLQPEDFATYFCQQFKSYPLTFGQG TKLEIK SEQ ID NO: 108 VL DIQMTQSPSFLSASVGDRVTITCKASQNVGN RVAWYQQKPGKAPKALIYSSSHRYKGVPSR FSGSGSGTEFTLTISSLQPEDFATYFCQQFKS YPLTFGQGTKLEIK SEQ ID NO: 109 VH QVQLVQSGAEVKKPGSSVKVSCKASGTDF DKIYIHWVRQAPGQGLEWMGRVSAGSGNT KYNEKFKGRVTITADTSTSTAYMELSSLRSE DTAVYYCAGSYYSYDVLDYWGQGTTVTVS S A-H.13 SEQ ID NO: 110 VH+VL QVQLVQSGAEVKKPGSSVKVSCKASGTDF KLTYIHWVRQAPGQGLEWMGRIFPGSGNV KYNEKFKGRVTITADTSTSTAYMELSSLRSE DTAVYYCAGSYYSYDVLDYWGQGTTVTVS SGGGGSGGGGSGGGGSGGGGSDIQMTQSPS FLSASVGDRVTITCKASQNVDNRVAWYQQ KPGKAPKALIYSSSHRYKGVPSRFSGSGSGT EFTLTISSLQPEDFATYFCQQFKSYPLTFGQG TKLEIK SEQ ID NO: 111 VL DIQMTQSPSFLSASVGDRVTITCKASQNVDN RVAWYQQKPGKAPKALIYSSSHRYKGVPSR FSGSGSGTEFTLTISSLQPEDFATYFCQQFKS YPLTFGQGTKLEIK SEQ ID NO: 112 VH QVQLVQSGAEVKKPGSSVKVSCKASGTDF KLTYIHWVRQAPGQGLEWMGRIFPGSGNV KYNEKFKGRVTITADTSTSTAYMELSSLRSE DTAVYYCAGSYYSYDVLDYWGQGTTVTVS S A-H.14 SEQIDNO: 113 VH+VL QVQLVQSGAEVKKPGSSVKVSCKASGTDF DKIYIHW VRQAPGQGLEWMGRIS AGS GNT KYNEKFKGRVTITADTSTSTAYMELSSLRSE DTAVYYCAGSYYSYDVLDYWGQGTTVTVS SGGGGSGGGGSGGGGSGGGGSDIQMTQSPS FLSASVGDRVTITCKASQNVDDRVAWYQQ KPGKAPKALIYSSSHRYKGVPSRFSGSGSGT EFTLTISSLQPEDFATYFCQQFKSYPLTFGQG TKLEIK SEQIDNO: 114 VL DIQMTQSPSFLSASVGDRVTITCKASQNVDD RVAWYQQKPGKAPKALIYSSSHRYKGVPSR FSGSGSGTEFTLTISSLQPEDFATYFCQQFKS YPLTFGQGTKLEIK SEQIDNO: 115 VH QVQLVQSGAEVKKPGSSVKVSCKASGTDF DKIYIHWVRQAPGQGLEWMGRISAGSGNT KYNEKFKGRVTITADTSTSTAYMELSSLRSE DTAVYYCAGSYYSYDVLDYWGQGTTVTVS S A-H.15 SEQIDNO: 116 VH+VL QVQLVQSGAEVKKPGSSVKVSCKASGTDFR LTYIHWVRQAPGQGLEWMGRVSPGSGNTK YNEKFKGRVTITADTSTSTAYMELSSLRSED TAVYYCAGSYYSYDVLDYWGQGTTVTVSS GGGGSGGGGSGGGGSGGGGSDIQMTQSPSF LSASVGDRVTITCKASQNVDNKVAWHQQK PGKAPKALIYSSSHRYKGVPSRFSGSGSGTE FTLTISSLQPEDFATYFCQQFKSYPLTFGQGT KLEIK SEQIDNO: 117 VL DIQMTQSPSFLSASVGDRVTITCKASQNVDN KVAWHQQKPGKAPKALIYSSSHRYKGVPS RFSGSGSGTEFTLTISSLQPEDFATYFCQQFK SYPLTFGQGTKLEIK SEQIDNO: 118 VH QVQLVQSGAEVKKPGSSVKVSCKASGTDFR LTYIHWVRQAPGQGLEWMGRVSPGSGNTK YNEKFKGRVTITADTSTSTAYMELSSLRSED TAVYYCAGSYYSYDVLDYWGQGTTVTVSS A-H.16 SEQIDNO: 119 VH+VL QVQLVQSGAEVKKPGSSVKVSCKASGGTFR LTYIHWVRQAPGQGLEWMGRVYPGSGNTK YNEKFKGRVTITADTSTSTAYMELSSLRSED TAVYYCAGSYYSYDVLDYWGQGTTVTVSS GGGGSGGGGSGGGGSGGGGSDIQMTQSPSF LSASVGDRVTITCKASQNVDDRVAWYQQK PGKAPKALIYSSSHRYKGVPSRFSGSGSGTE FTLTISSLQPEDFATYFCQQFKSYPLTFGQGT KLEIK SEQ ID NO: 120 VL DIQMTQSPSFLSASVGDRVTITCKASQNVDD RVAWYQQKPGKAPKALIYSSSHRYKGVPSR FSGSGSGTEFTLTISSLQPEDFATYFCQQFKS YPLTFGQGTKLEIK SEQ ID NO: 121 VH QVQLVQSGAEVKKPGSSVKVSCKASGGTFR LTYIHWVRQAPGQGLEWMGRVYPGSGNTK YNEKFKGRVTITADTSTSTAYMELSSLRSED TAVYYCAGSYYSYDVLDYWGQGTTVTVSS A-H.17 SEQ ID NO: 122 VH+VL QVQLVQSGAEVKKPGSSVKVSCKASGTDFR LTYIHWVRQAPGQGLEWMGRIFPGSGNTK YNEKFKGRVTITADTSTSTAYMELSSLRSED TAVYYCAGSYYSYDVLDYWGQGTTVTVSS GGGGSGGGGSGGGGSGGGGSDIQMTQSPSF LSASVGDRVTITCKASQNVDDRVAWYQQK PGKAPKALIYSSSHRYKGVPSRFSGSGSGTE FTLTISSLQPEDFATYFCQQFKSYPLTFGQGT KLEIK SEQ ID NO: 123 VL DIQMTQSPSFLSASVGDRVTITCKASQNVDD RVAWYQQKPGKAPKALIYSSSHRYKGVPSR FSGSGSGTEFTLTISSLQPEDFATYFCQQFKS YPLTFGQGTKLEIK SEQ ID NO: 124 VH QVQLVQSGAEVKKPGSSVKVSCKASGTDFR LTYIHWVRQAPGQGLEWMGRIFPGSGNTK YNEKFKGRVTITADTSTSTAYMELSSLRSED TAVYYCAGSYYSYDVLDYWGQGTTVTVSS A-H.18 SEQ ID NO: 125 VH+VL QVQLVQSGAEVKKPGSSVKVSCKASGTDF KLTYIHWVRQAPGQGLEWMGRIFPGSGNV KYNEKFKGRVTITADTSTSTAYMELSSLRSE DTAVYYCAGSYYSYDVLDYWGQGTTVTVS SGGGGSGGGGSGGGGSGGGGSDIQMTQSPS FLSASVGDRVTITCKASQNVEDRVAWYQQ KPGKAPKALIYSSSHRYKGVPSRFSGSGSGT EFTLTISSLQPEDFATYFCQQFKSYPLTFGQG TKLEIK SEQ ID NO: 126 VL DIQMTQSPSFLSASVGDRVTITCKASQNVED RVAWYQQKPGKAPKALIYSSSHRYKGVPSR FSGSGSGTEFTLTISSLQPEDFATYFCQQFKS YPLTFGQGTKLEIK SEQ ID NO: 127 VH QVQLVQSGAEVKKPGSSVKVSCKASGTDF KLTYIHWVRQAPGQGLEWMGRIFPGSGNV KYNEKFKGRVTITADTSTSTAYMELSSLRSE DTAVYYCAGSYYSYDVLDYWGQGTTVTVS S A-H.19 SEQ ID NO: 128 VH+VL QVQLVQSGAEVKKPGSSVKVSCKASGGTFR LTYIHWVRQAPGQGLEWMGRISAGSGNVK YNEKFKGRVTITADTSTSTAYMELSSLRSED TAVYYCAGSYYSYDVLDYWGQGTTVTVSS GGGGSGGGGSGGGGSGGGGSDIQMTQSPSF LSASVGDRVTITCKASQNVGDRVAWYQQK PGKAPKALIYSSSHRYKGVPSRFSGSGSGTE FTLTISSLQPEDFATYFCQQFKSYPLTFGQGT KLEIK SEQ ID NO: 129 VL DIQMTQSPSFLSASVGDRVTITCKASQNVGD RVAWYQQKPGKAPKALIYSSSHRYKGVPSR FSGSGSGTEFTLTISSLQPEDFATYFCQQFKS YPLTFGQGTKLEIK SEQ ID NO: 130 VH QVQLVQSGAEVKKPGSSVKVSCKASGGTFR LTYIHWVRQAPGQGLEWMGRISAGSGNVK YNEKFKGRVTITADTSTSTAYMELSSLRSED TAVYYCAGSYYSYDVLDYWGQGTTVTVSS A-H.20 SEQ ID NO: 131 VH+VL QVQLVQSGAEVKKPGSSVKVSCKASGGTF DKTYIHWVRQAPGQGLEWMGRISAGSGNT KYNEKFKGRVTITADTSTSTAYMELSSLRSE DTAVYYCAGSYYSYDVLDYWGQGTTVTVS SGGGGSGGGGSGGGGSGGGGSDIQMTQSPS FLSASVGDRVTITCKASQNVDDRVAWYQQ KPGKAPKALIYSSSHRYKGVPSRFSGSGSGT EFTLTISSLQPEDFATYFCQQFKSYPLTFGQG TKLEIK SEQ ID NO: 132 VL DIQMTQSPSFLSASVGDRVTITCKASQNVDD RVAWYQQKPGKAPKALIYSSSHRYKGVPSR FSGSGSGTEFTLTISSLQPEDFATYFCQQFKS YPLTFGQGTKLEIK SEQ ID NO: 133 VH QVQLVQSGAEVKKPGSSVKVSCKASGGTF DKTYIHWVRQAPGQGLEWMGRISAGSGNT KYNEKFKGRVTITADTSTSTAYMELSSLRSE DTAVYYCAGSYYSYDVLDYWGQGTTVTVS S A-H.21 SEQ ID NO: 134 VH+VL QVQLVQSGAEVKKPGSSVKVSCKASGHDF DKFYIHWVRQAPGQGLEWMGRISAGSGNT KYNEKFKGRVTITADTSTSTAYMELSSLRSE DTAVYYCAGSYYSYDVLDYWGQGTTVTVS SGGGGSGGGGSGGGGSGGGGSDIQMTQSPS FLSASVGDRVTITCKASQNVDDRVAWYQQ KPGKAPKALIYSSSHRYKGVPSRFSGSGSGT EFTLTISSLQPEDFATYFCQQFKSYPLTFGQG TKLEIK SEQ ID NO: 135 VL DIQMTQSPSFLSASVGDRVTITCKASQNVDD RVAWYQQKPGKAPKALIYSSSHRYKGVPSR FSGSGSGTEFTLTISSLQPEDFATYFCQQFKS YPLTFGQGTKLEIK SEQ ID NO: 136 VH QVQLVQSGAEVKKPGSSVKVSCKASGHDF DKFYIHWVRQAPGQGLEWMGRISAGSGNT KYNEKFKGRVTITADTSTSTAYMELSSLRSE DTAVYYCAGSYYSYDVLDYWGQGTTVTVS S A-H.22 SEQ ID NO: 137 VH+VL QVQLVQSGAEVKKPGSSVKVSCKASGTDF KLTYIHWVRQAPGQGLEWMGRISAGSGNV KYNEKFKGRVTITADTSTSTAYMELSSLRSE DTAVYYCAGSYYSYDVLDYWGQGTTVTVS SGGGGSGGGGSGGGGSGGGGSDIQMTQSPS FLSASVGDRVTITCKASQNVDNKVAWHQQ KPGKAPKALIYSSSHRYKGVPSRFSGSGSGT EFTLTISSLQPEDFATYFCQQFKSYPLTFGQG TKLEIK SEQ ID NO: 138 VL DIQMTQSPSFLSASVGDRVTITCKASQNVDN KVAWHQQKPGKAPKALIYSSSHRYKGVPS RFSGSGSGTEFTLTISSLQPEDFATYFCQQFK SYPLTFGQGTKLEIK SEQ ID NO: 139 VH QVQLVQSGAEVKKPGSSVKVSCKASGTDF KLTYIHWVRQAPGQGLEWMGRISAGSGNV KYNEKFKGRVTITADTSTSTAYMELSSLRSE DTAVYYCAGSYYSYDVLDYWGQGTTVTVS S A-H.23 SEQ ID NO: 140 VH+VL QVQLVQSGAEVKKPGSSVKVSCKASGHDF RLTYIHWVRQAPGQGLEWMGRISAGSGNV KYNEKFKGRVTITADTSTSTAYMELSSLRSE DTAVYYCAGSYYSYDVLDYWGQGTTVTVS SGGGGSGGGGSGGGGSGGGGSDIQMTQSPS FLSASVGDRVTITCKASQNVADRVAWYQQ KPGKAPKALIYSSSHRYKGVPSRFSGSGSGT EFTLTISSLQPEDFATYFCQQFKSYPLTFGQG TKLEIK SEQ ID NO: 141 VL DIQMTQSPSFLSASVGDRVTITCKASQNVAD RVAWYQQKPGKAPKALIYSSSHRYKGVPSR FSGSGSGTEFTLTISSLQPEDFATYFCQQFKS YPLTFGQGTKLEIK SEQ ID NO: 142 VH QVQLVQSGAEVKKPGSSVKVSCKASGHDF RLTYIHWVRQAPGQGLEWMGRISAGSGNV KYNEKFKGRVTITADTSTSTAYMELSSLRSE DTAVYYCAGSYYSYDVLDYWGQGTTVTVS S A-H.24 SEQ ID NO: 143 VH+VL QVQLVQSGAEVKKPGSSVKVSCKASGHDF HLWYIHWVRQAPGQGLEWMGRVSAGSGN VKYNEKFKGRVTITADTSTSTAYMELSSLRS EDTAVYYCAGSYYSYDVLDYWGQGTTVT VSSGGGGSGGGGSGGGGSGGGGSDIQMTQ SPSFLSASVGDRVTITCKASQNVDNKVAWH QQKPGKAPKALIYSSSHRYKGVPSRFSGSGS GTEFTLTISSLQPEDFATYFCQQFKSYPLTFG QGTKLEIK SEQ ID NO: 144 VL DIQMTQSPSFLSASVGDRVTITCKASQNVDN KVAWHQQKPGKAPKALIYSSSHRYKGVPS RFSGSGSGTEFTLTISSLQPEDFATYFCQQFK SYPLTFGQGTKLEIK SEQ ID NO: 145 VH QVQLVQSGAEVKKPGSSVKVSCKASGHDF HLWYIHWVRQAPGQGLEWMGRVSAGSGN VKYNEKFKGRVTITADTSTSTAYMELSSLRS EDTAVYYCAGSYYSYDVLDYWGQGTTVT VSS A-H.25 SEQ ID NO: 146 VH+VL QVQLVQSGAEVKKPGSSVKVSCKASGHDF HLWYIHWVRQAPGQGLEWMGRVFAGSGN TKYNEKFKGRVTITADTSTSTAYMELSSLRS EDTAVYYCAGSYYSYDVLDYWGQGTTVT VSSGGGGSGGGGSGGGGSGGGGSDIQMTQ SPSFLSASVGDRVTITCKASQNVEDKVAWY QQKPGKAPKALIYSSSHRYKGVPSRFSGSGS GTEFTLTISSLQPEDFATYFCQQFKSYPLTFG QGTKLEIK SEQ ID NO: 147 VL DIQMTQSPSFLSASVGDRVTITCKASQNVED KVAWYQQKPGKAPKALIYSSSHRYKGVPS RFSGSGSGTEFTLTISSLQPEDFATYFCQQFK SYPLTFGQGTKLEIK SEQ ID NO: 148 VH QVQLVQSGAEVKKPGSSVKVSCKASGHDF HLWYIHWVRQAPGQGLEWMGRVFAGSGN TKYNEKFKGRVTITADTSTSTAYMELSSLRS EDTAVYYCAGSYYSYDVLDYWGQGTTVT VSS A-H.26 SEQ ID NO: 149 VH+VL QVQLVQSGAEVKKPGSSVKVSCKASGTDF KLTYIHWVRQAPGQGLEWMGRIFPGSGNT KYNEKFKGRVTITADTSTSTAYMELSSLRSE DTAVYYCAGSYYSYDVLDYWGQGTTVTVS SGGGGSGGGGSGGGGSGGGGSDIQMTQSPS FLSASVGDRVTITCKASQNVDDRVAWYQQ KPGKAPKALIYSSSHRYKGVPSRFSGSGSGT EFTLTISSLQPEDFATYFCQQFKSYPLTFGQG TKLEIK SEQ ID NO: 150 VL DIQMTQSPSFLSASVGDRVTITCKASQNVDD RVAWYQQKPGKAPKALIYSSSHRYKGVPSR FSGSGSGTEFTLTISSLQPEDFATYFCQQFKS YPLTFGQGTKLEIK SEQIDNO: 151 VH QVQLVQSGAEVKKPGSSVKVSCKASGTDF KLTYIHWVRQAPGQGLEWMGRIFPGSGNT KYNEKFKGRVTITADTSTSTAYMELSSLRSE DTAVYYCAGSYYSYDVLDYWGQGTTVTVS S A-H.27 SEQ ID NO: 153 VH+VL QVQLVQSGAEVKKPGSSVKVSCKASGTDF KLTYIHWVRQAPGQGLEWMGRVSAGSGN VKYNEKFKGRVTITADTSTSTAYMELSSLRS EDTAVYYCAGSYYSYDVLDYWGQGTTVT VSSGGGGSGGGGSGGGGSGGGGSDIQMTQ SPSFLSASVGDRVTITCKASQNVGNRVAWY QQKPGKAPKALIYSSSHRYKGVPSRFSGSGS GTEFTLTISSLQPEDFATYFCQQFKSYPLTFG QGTKLEIK SEQ ID NO: 154 VL DIQMTQSPSFLSASVGDRVTITCKASQNVGN RVAWYQQKPGKAPKALIYSSSHRYKGVPSR FSGSGSGTEFTLTISSLQPEDFATYFCQQFKS YPLTFGQGTKLEIK SEQ ID NO: 155 VH QVQLVQSGAEVKKPGSSVKVSCKASGTDF KLTYIHWVRQAPGQGLEWMGRVSAGSGN VKYNEKFKGRVTITADTSTSTAYMELSSLRS EDTAVYYCAGSYYSYDVLDYWGQGTTVT VSS A-H.28 SEQ ID NO: 156 VH+VL QVQLVQSGAEVKKPGSSVKVSCKASGTDF KLTYIHWVRQAPGQGLEWMGRISPGSGNT KYNEKFKGRVTITADTSTSTAYMELSSLRSE DTAVYYCAGSYYSYDVLDYWGQGTTVTVS SGGGGSGGGGSGGGGSGGGGSDIQMTQSPS FLSASVGDRVTITCKASQNVGDRVAWYQQ KPGKAPKALIYSSSHRYKGVPSRFSGSGSGT EFTLTISSLQPEDFATYFCQQFKSYPLTFGQG TKLEIK SEQ ID NO: 157 VL DIQMTQSPSFLSASVGDRVTITCKASQNVGD RVAWYQQKPGKAPKALIYSSSHRYKGVPSR FSGSGSGTEFTLTISSLQPEDFATYFCQQFKS YPLTFGQGTKLEIK SEQ ID NO: 158 V...

Claims

1. A composition comprising a multispecific molecule comprising:(i) a first domain comprising an antibody molecule or antigen binding domain that binds to a T cell receptor beta variable (TCRpV) region of a T cell receptor beta (TCRP) on a T cell in a T cell population,wherein the antibody molecule or antigen binding domain is a TCR agonist that binds to an outward facing region of the TCRpV region that is structurally conserved and sequence-wise variable; andwherein the first domain binds to human TCRpV5, human TCRpV6, human TCRpV12, or human TCRpV20; and(ii) a second domain that binds to a second target molecule, wherein the second domain comprises a cytokine, wherein:(a) the cytokine is a human IL-2 having a sequence with at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 2191, 2270, and 2280;(b) the cytokine is a human IL-12 having a sequence with at least 90% sequence identity to SEQ ID NO: 2290;(c) the cytokine is a human IL-15 having a sequence with at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 2170 and 2320; or(d) the cytokine is a human IL-21 having a sequence with at least 90% sequence identity to SEQ ID NO: 2193; andwherein the second target molecule is expressed by the same T cell expressing the TCRp comprising the TCRpV to which the first domain of the multispecific molecule binds,wherein when contacted to the T cell population, the multispecific molecule activates and / or expands the T cell.

2. The composition of claim 1, wherein the target cell is a cancer cell or a T cell.

3. The composition of claim 1 or 2, wherein the multispecific molecule comprises a firstpolypeptide chain and a second polypeptide chain;wherein the first polypeptide chain and the second polypeptide chain are separate chains and are not contiguously fused to each other;2019297451   16 Sep 2026wherein the first polypeptide chain comprises a first member of a dimerization module and the second polypeptide chain comprises a second member of the dimerization module,wherein the first polypeptide chain and the second polypeptide chain form a complex via association of the first member of the dimerization module and the second member of the dimerization module; andwherein the dimerization module comprises an immunoglobulin constant domain; wherein the first polypeptide chain comprises the first domain linked to the first member of the dimerization module, and the second polypeptide chain comprises the second domain that is linked to the second member of the dimerization module.

4. The composition of claim 3, wherein the first polypeptide chain comprises a firstportion of the first domain and the first portion of the first domain is linked to the first member of the dimerization module;wherein the multispecific molecule further comprises a third polypeptide chain, wherein the third polypeptide chain is a separate chain and is not contiguously fused to the first polypeptide chain and the second polypeptide chain; andwherein the third polypeptide chain comprises a second portion of the first domain, and the first portion of the first domain and the second portion of the first domain are assembled and form the first domain.

5. The composition of claim 3 or 4, wherein the first member of the dimerization moduleis a first Fc region, and the second member of the dimerization module is a second Fc region,wherein:(i) the first Fc region and the second Fc region comprise an Fc interface with one or more of: a knob-in-a hole, an electrostatic interaction, or a strand-exchange; or(ii) the first Fc region is an engineered Fc region comprising a knob and the second Fc region is an engineered Fc region comprising a hole, or the first Fc region is an engineered Fc region comprising a hole and the second Fc region is an engineered Fc region comprising a knob.

6. The composition of any one of claims 1-5, wherein:(i) the antibody molecule or the antigen binding domain that binds to a TCRpV region of a TCRP on a T cell in a T cell population comprises a scFv, a full-length antibody,2019297451   16 Sep 2026a Fab, a F(ab')2, an Fv, a single chain Fv, a half arm antibody, a diabody, a bivalent antibody, a monovalent antibody, or a bispecific antibody;(ii) the antibody molecule or the antigen binding domain that binds to a TCRpV region of a TCRp on a T cell in a T cell population comprises a scFv, a single domain antibody, a camelid antibody, or a Fab; or(iii) the antibody molecule or the antigen binding domain that binds to a TCRpV region of a TCRp on a T cell in a T cell population comprises a Fab.

7. The composition of any one of claims 1-6, wherein:(i) the first domain binds to human TCRpV6-5 or human TCRpV6-6;(ii) the first domain binds to human TCRpV5, human TCRpV6, human TCRpV12, or human TCRpV20; or(iii) the first domain binds to human TCRpV6.

8. The composition of any one of claims 1-7, wherein when contacted to the T cellpopulation, the multispecific molecule promotes T cells of the T cell population to kill cancer cells.

9. The composition of any one of claims 6-8, wherein the antibody molecule or the antigenbinding domain that binds to a TCRpV region of a TCRp on a T cell in a T cell population comprises:(A)(i) a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (HC CDR1), a HC CDR2, and a HC CDR3 comprising the HC CDR1 sequence, the HC CDR2 sequence, and the HC CDR3 sequence of SEQ ID NO: 142, respectively,wherein the HC CDR1 sequence, the HC CDR2 sequence, and the HC CDR3 sequence are determined according to the Kabat numbering scheme, the Chothia numbering scheme, or the ImMunoGeneTics Information System (IMGT); and(ii) a light chain variable region (VL) comprising a light chain complementarity determining region 1 (LC CDR1), a LC CDR2, and a LC CDR3 comprising the LC CDR1 sequence, the LC CDR2 sequence, and the LC CDR3 sequence of SEQ ID NO: 141, respectively,wherein the LC CDR1 sequence, the LC CDR2 sequence, and the LC CDR3 sequence are determined according to the Kabat numbering scheme, the Chothia numbering scheme, or the IMGT;2019297451   16 Sep 2026(B)(i) a VH comprising a HC CDR1, a HC CDR2, and a HC CDR3 comprising the HC CDR1 sequence, the HC CDR2 sequence, and the HC CDR3 sequence of SEQ ID NO: 155, respectively,wherein the HC CDR1 sequence, the HC CDR2 sequence, and the HC CDR3 sequence are determined according to the Kabat numbering scheme, the Chothia numbering scheme, or the IMGT; and(ii) a VL comprising a LC CDR1, a LC CDR2, and a LC CDR3 comprising the LC CDR1 sequence, the LC CDR2 sequence, and the LC CDR3 sequence of SEQ ID NO: 154, respectively,wherein the LC CDR1 sequence, the LC CDR2 sequence, and the LC CDR3 sequence are determined according to the Kabat numbering scheme, the Chothia numbering scheme, or the IMGT;(C)(i) a VH comprising a HC CDR1, a HC CDR2, and a HC CDR3 comprising the HC CDR1 sequence, the HC CDR2 sequence, and the HC CDR3 sequence of SEQ ID NO: 170, respectively,wherein the HC CDR1 sequence, the HC CDR2 sequence, and the HC CDR3 sequence are determined according to the Kabat numbering scheme, the Chothia numbering scheme, or the IMGT; and(ii) a VL comprising a LC CDR1, a LC CDR2, and a LC CDR3 comprising the LC CDR1 sequence, the LC CDR2 sequence, and the LC CDR3 sequence of SEQ ID NO: 169, respectively,wherein the LC CDR1 sequence, the LC CDR2 sequence, and the LC CDR3 sequence are determined according to the Kabat numbering scheme, the Chothia numbering scheme, or the IMGT;(D)(i) a VH comprising a HC CDR1, a HC CDR2, and a HC CDR3 comprising the HC CDR1 sequence, the HC CDR2 sequence, and the HC CDR3 sequence of SEQ ID NO: 185, respectively,wherein the HC CDR1 sequence, the HC CDR2 sequence, and the HC CDR3 sequence are determined according to the Kabat numbering scheme, the Chothia numbering scheme, or the IMGT; and(ii) a VL comprising a LC CDR1, a LC CDR2, and a LC CDR3 comprising the LC CDR1 sequence, the LC CDR2 sequence, and the LC CDR3 sequence of SEQ ID NO: 184, respectively,2019297451   16 Sep 2026wherein the LC CDR1 sequence, the LC CDR2 sequence, and the LC CDR3 sequence are determined according to the Kabat numbering scheme, the Chothia numbering scheme, or the IMGT; or(E)(i) a VH comprising a HC CDR1, a HC CDR2, and a HC CDR3 comprising the HC CDR1 sequence, the HC CDR2 sequence, and the HC CDR3 sequence of SEQ ID NO: 197, respectively,wherein the HC CDR1 sequence, the HC CDR2 sequence, and the HC CDR3 sequence are determined according to the Kabat numbering scheme, the Chothia numbering scheme, or the IMGT; and(ii) a VL comprising a LC CDR1, a LC CDR2, and a LC CDR3 comprising the LC CDR1 sequence, the LC CDR2 sequence, and the LC CDR3 sequence of SEQ ID NO: 196, respectively,wherein the LC CDR1 sequence, the LC CDR2 sequence, and the LC CDR3 sequence are determined according to the Kabat numbering scheme, the Chothia numbering scheme, or the IMGT.

10. The composition of claim 9, wherein:(i) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 142, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 141, wherein:(a) the VH comprises the HC CDR1, the HC CDR2, and the HC CDR3 comprising the HC CDR1 sequence, the HC CDR2 sequence, and the HC CDR3 sequence of SEQ ID NO: 142, respectively,wherein the HC CDR1 sequence, the HC CDR2 sequence, and the HC CDR3 sequence are determined according to the Kabat numbering scheme, the Chothia numbering scheme, or the IMGT; and(b) the VL comprises the LC CDR1, the LC CDR2, and the LC CDR3 comprising the LC CDR1 sequence, the LC CDR2 sequence, and the LC CDR3 sequence of SEQ ID NO: 141, respectively,wherein the LC CDR1 sequence, the LC CDR2 sequence, and the LC CDR3 sequence are determined according to the Kabat numbering scheme, the Chothia numbering scheme, or the IMGT;2019297451   16 Sep 2026(ii) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 155, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 154, wherein:(a) the VH comprises the HC CDR1, the HC CDR2, and the HC CDR3 comprising the HC CDR1 sequence, the HC CDR2 sequence, and the HC CDR3 sequence of SEQ ID NO: 155, respectively,wherein the HC CDR1 sequence, the HC CDR2 sequence, and the HC CDR3 sequence are determined according to the Kabat numbering scheme, the Chothia numbering scheme, or the IMGT; and(b) the VL comprises the LC CDR1, the LC CDR2, and the LC CDR3 comprising the LC CDR1 sequence, the LC CDR2 sequence, and the LC CDR3 sequence of SEQ ID NO: 154, respectively,wherein the LC CDR1 sequence, the LC CDR2 sequence, and the LC CDR3 sequence are determined according to the Kabat numbering scheme, the Chothia numbering scheme, or the IMGT;(iii)the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 170, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 169, wherein:(a) the VH comprises the HC CDR1, the HC CDR2, and the HC CDR3 comprising the HC CDR1 sequence, the HC CDR2 sequence, and the HC CDR3 sequence of SEQ ID NO: 170, respectively,wherein the HC CDR1 sequence, the HC CDR2 sequence, and the HC CDR3 sequence are determined according to the Kabat numbering scheme, the Chothia numbering scheme, or the IMGT; and(b) the VL comprises the LC CDR1, the LC CDR2, and the LC CDR3 comprising the LC CDR1 sequence, the LC CDR2 sequence, and the LC CDR3 sequence of SEQ ID NO: 169, respectively,wherein the LC CDR1 sequence, the LC CDR2 sequence, and the LC CDR3 sequence are determined according to the Kabat numbering scheme, the Chothia numbering scheme, or the IMGT;2019297451   16 Sep 2026(iv)the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 185, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 184, wherein:(a) the VH comprises the HC CDR1, the HC CDR2, and the HC CDR3 comprising the HC CDR1 sequence, the HC CDR2 sequence, and the HC CDR3 sequence of SEQ ID NO: 185, respectively,wherein the HC CDR1 sequence, the HC CDR2 sequence, and the HC CDR3 sequence are determined according to the Kabat numbering scheme, the Chothia numbering scheme, or the IMGT; and(b) the VL comprises the LC CDR1, the LC CDR2, and the LC CDR3 comprising the LC CDR1 sequence, the LC CDR2 sequence, and the LC CDR3 sequence of SEQ ID NO: 184, respectively,wherein the LC CDR1 sequence, the LC CDR2 sequence, and the LC CDR3 sequence are determined according to the Kabat numbering scheme, the Chothia numbering scheme, or the IMGT; or(v) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 197, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 196, wherein:(a) the VH comprises the HC CDR1, the HC CDR2, and the HC CDR3 comprising the HC CDR1 sequence, the HC CDR2 sequence, and the HC CDR3 sequence of SEQ ID NO: 197, respectively,wherein the HC CDR1 sequence, the HC CDR2 sequence, and the HC CDR3 sequence are determined according to the Kabat numbering scheme, the Chothia numbering scheme, or the IMGT; and(b) the VL comprises the LC CDR1, the LC CDR2, and the LC CDR3 comprising the LC CDR1 sequence, the LC CDR2 sequence, and the LC CDR3 sequence of SEQ ID NO: 196, respectively,wherein the LC CDR1 sequence, the LC CDR2 sequence, and the LC CDR3 sequence are determined according to the Kabat numbering scheme, the Chothia numbering scheme, or the IMGT.

11. The composition of claim 9 or 10, wherein the antibody molecule or the antigen binding domain that binds to a TCR0V region of a TCR0 on a T cell in a T cell population is a2019297451   16 Sep 2026single chain Fv (scFv) comprising an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 140, 153, 168, 183, or 195.

12. The composition of any one of claims 1-11, wherein:(i) the cytokine is IL-2 or a functional fragment thereof comprising the sequence of SEQ ID NO: 2191, the sequence of SEQ ID NO: 2270, or the sequence of SEQ ID NO: 2280;(ii) the cytokine is IL-12 or a functional fragment thereof comprising the sequence of SEQ ID NO: 2290;(iii) the cytokine is IL-15 or a functional fragment thereof comprising the sequence of SEQ ID NO: 2170 or the sequence of SEQ ID NO: 2320; or(iv) the cytokine is IL-21 or a functional fragment thereof comprising the sequence of SEQ ID NO: 2193.

13. The composition of any one of claims 1-12, wherein:(i) the cytokine comprises IL-15 or a functional fragment thereof linked to an IL15Ralpha dimerizing domain; or(ii) the cytokine comprises a human IL-15 having a sequence with at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 2170 and 2320, and wherein the cytokine further comprises the sequence according to SEQ ID NO: 2180 or a fragment thereof.

14. The composition of any one of claims 1-13, wherein the multispecific molecule further comprises a tumor-targeting moiety, and wherein:(i) the tumor-targeting moiety comprises an antibody molecule or an antigen binding domain that binds to a cancer antigen, a receptor or receptor fragment thereof that binds to a cancer antigen, a ligand or functional fragment thereof that binds to a cancer antigen, or any combination thereof; and / or(ii) the tumor-targeting moiety binds to a cancer antigen present on a cancer cell.

15. The composition of claim 14, wherein:(A)(i) the cancer antigen is a tumor antigen, a stromal antigen, or a hematological antigen; and / or(ii) the cancer antigen is selected from the group consisting of: BCMA, FcRH5, CD19, CD20, CD22, CD30, CD33, CD38, CD3, CD47, CD99, CD123, CLEC12, CD179A, SLAMF7, PDL1, ganglioside 2 (GD2), prostate stem cell antigen (PSCA), prostate specific membrane antigen (PSMA), prostate-specific antigen (PSA), carcinoembryonic antigen (CEA), Ron Kinase, c-Met, Immature2019297451   16 Sep 2026laminin receptor, TAG-72, BING-4, Calcium-activated chloride channel 2, Cyclin-B1, 9D7, Ep-CAM, EphA3, Her2 / neu, Telomerase, SAP-l, Survivin, NY-ESO-1 / LAGE-1, PRAME, SSX-2, Melan-A / MART-1, Gp100 / pmel17, Tyrosinase, MC1R, b-catenin, BRCA1 / 2, CDK4, CML66, Fibronectin, p53, Ras, TGF-B receptor, AFP, ETA, MAGE, CA-125, BAGE, GAGE, CDC27, actinin-4, TRP1 / gp75, TRP2, WT1, Epidermal growth factor receptor (EGFR), MART-2, MUC1, MUC2, MUM1, MUM2, MUM3, NA88-1, NPM, OA1, OGT, RCC, RU11, RU12, SAGE, TRG, TSTA, Folate receptor alpha, L1-CAM, CAIX, gpA33, GD3, GM2, VEGFR, an Integrin, a carbohydrate, IGF1R, TRAILR1, TRAILR2, RANKL, FAP, TGF-beta, hyaluronic acid, collagen, tenascin C, and tenascin W; and / or(B)(i) the cancer is a hematological cancer, a solid tumor, a metastatic cancer, a soft tissue tumor, or any combination thereof;(ii) the cancer is a solid tumor selected from the group consisting of pancreatic cancer, breast cancer, colorectal cancer, lung cancer, skin cancer, ovarian cancer, and liver cancer; or(iii) the cancer is a hematological cancer comprising a B-cell malignancy or T cell malignancy.

16. The composition of claim 14 or 15, wherein the tumor-targeting moiety binds to CD19, Her2 / neu, or CD123.

17. The composition of any one of claims 5-16, wherein:(1)(A)(i) the first Fc region and / or the second Fc region comprises a sequence with at least 90% identity to the sequence of SEQ ID NO: 41 or the sequence of SEQ ID NO: 42;(ii) the first Fc region and / or the second Fc region comprises a sequence with at least 90% identity to the following sequence: the sequence of SEQ ID NO: 3280 without the leader sequence of SEQ ID NO: 3288 or the sequence of SEQ ID NO: 3287 without the leader sequence of SEQ ID NO: 3288;(iii) the first Fc region comprises a sequence with at least 90% identity to the sequence of SEQ ID NO: 41 or the sequence of SEQ ID NO: 42, and the second Fc region comprises a sequence with at least 90% identity to the following sequence: the sequence of SEQ ID NO: 3280 without the leader sequence of SEQ ID NO: 3288 or the sequence of SEQ ID NO: 3287 without the leader sequence of SEQ ID NO: 3288; or2019297451   16 Sep 2026(iv) the first Fc region comprises a sequence with at least 90% identity to the following sequence: the sequence of SEQ ID NO: 3280 without the leader sequence of SEQ ID NO: 3288 or the sequence of SEQ ID NO: 3287 without the leader sequence of SEQ ID NO: 3288, and the second Fc region comprises a sequence with at least 90% identity to the sequence of SEQ ID NO: 41 or the sequence of SEQ ID NO: 42; and / or(B)(i) the first Fc region and / or the second Fc region comprise a mutation that decreases Fc receptor binding relative to an Fc region without the mutation; or(ii) the first Fc region and / or the second Fc region comprise a mutation that decreases Fc receptor binding relative to a Fc region without the mutation, the mutation that decreases Fc receptor binding is an N297A mutation according to EU Numbering in a heavy chain constant region or corresponds to the Ala at amino acid 180 of SEQ ID NO: 42 or the Ala at position 97 of SEQ ID NO: 3280 or SEQ ID NO: 3287; or(2)(i) the first Fc region comprises the sequence with at least 90% identity to the sequence of SEQ ID NO: 42, with an Ala at position 180 of SEQ ID NO: 42 that corresponds to N297A mutation according to EU Numbering; and(ii) the second Fc region comprises the sequence with at least 90% identity to the following sequence: the sequence of SEQ ID NO: 3280 without the leader sequence of SEQ ID NO: 3288 or the sequence of SEQ ID NO: 3287 without the leader sequence of SEQ ID NO: 3288, with an Ala at position 97 of SEQ ID NO: 3280 or SEQ ID NO: 3287 that corresponds to N297A mutation according to EU Numbering.

18. The composition of any one of claims 5-17, wherein:(1)(A)(i) the first Fc region comprises:(a) Y349C mutation according to EU Numbering,(b) T366S mutation according to EU Numbering,(c) L368A mutation according to EU Numbering, and(d) Y407V mutation according to EU Numbering; and(ii) the second Fc region comprises:(a) S354C mutation according to EU Numbering, and(b) T366W mutation according to EU Numbering; or(B)(i) the first Fc region comprises:2019297451   16 Sep 2026(a) S354C mutation according to EU Numbering, and(b) T366W mutation according to EU Numbering; and(ii) the second Fc region comprises:(a) Y349C mutation according to EU Numbering,(b) T366S mutation according to EU Numbering,(c) L368A mutation according to EU Numbering, and(d) Y407V mutation according to EU Numbering; or(2) the first Fc region comprises the sequence of SEQ ID NO: 42, and the second Fc region comprises the following sequence: the sequence of SEQ ID NO: 3280 without the leader sequence of SEQ ID NO: 3288 or the sequence of SEQ ID NO: 3287 without the leader sequence of SEQ ID NO: 3288, with the proviso that: (A)(i) the first Fc region comprises:(a) an Ala at position 180 of SEQ ID NO: 42 that corresponds to N297A mutation according to EU Numbering,(b) Y349C mutation according to EU Numbering,(c) T366S mutation according to EU Numbering,(d) L368A mutation according to EU Numbering, and(e) Y407V mutation according to EU Numbering; and(ii) the second Fc region comprises:(a) an Ala at position 97 of SEQ ID NO: 3280 or SEQ ID NO: 3287 that corresponds to N297A mutation according to EU Numbering,(b) S354C mutation according to EU Numbering, and(c) T366W mutation according to EU Numbering; or(B)(i) the first Fc region comprises:(a) an Ala at position 180 of SEQ ID NO: 42 that corresponds to N297A mutation according to EU Numbering,(b) S354C mutation according to EU Numbering, and(c) T366W mutation according to EU Numbering; and(ii) the second Fc region comprises:(a) an Ala at position 97 of SEQ ID NO: 3280 or SEQ ID NO: 3287 that corresponds to N297A mutation according to EU Numbering,(b) Y349C mutation according to EU Numbering,(c) T366S mutation according to EU Numbering,(d) L368A mutation according to EU Numbering, and2019297451   16 Sep 2026(e) Y407V mutation according to EU Numbering.

19. The composition of any one of claims 9-18, wherein the multispecific molecule further comprises a light chain constant region linked to the VL, andwherein the light chain constant region is a kappa light chain constant region or a lambda light chain constant region.

20. A recombinant polynucleotide comprising a sequence encoding the multispecific molecule of the composition of any one of claims 1-19.

21. A method of making the multispecific molecule of the composition of any one of claims 1-19 comprising: culturing a host cell comprising the recombinant polynucleotide of claim 20 or a vector comprising the recombinant polynucleotide under conditions suitable for gene expression and / or homo- or heterodimerization.

22. A pharmaceutical composition comprising the composition of any one of claims 1-19, and a pharmaceutically acceptable carrier, excipient, or diluent.

23. A method of treating cancer in a subject in need thereof comprising: administering a therapeutically effective amount of the composition of any one of claims 1-19 or the pharmaceutical composition of claim 22 to the subject, thereby treating the cancer in the subject, wherein the subject is human.

24. The method of claim 23, wherein:(i) the composition is administered to the subject in combination with an immune checkpoint inhibitor; or(ii) the composition is administered to the subject in combination with an immune checkpoint inhibitor, wherein:(a) the immune checkpoint inhibitor is a PD-1 inhibitor or a PD-L1 inhibitor;(b) the immune checkpoint inhibitor is a PD-1 inhibitor selected from the group consisting of Nivolumab, Pembrolizumab, Pidilizumab, AMP 514, immunoadhesin, and AMP-224; or(c) the immune checkpoint inhibitor is a PD-L1 inhibitor selected from the group consisting of MPDL3280A, MEDI-4736, MSB-0010718C, MSB0010718C, and YW243.55.S70.

25. A method of treating a solid cancer in a human subject in need thereof comprising: administering a therapeutically effective amount of the composition of any one of2019297451   16 Sep 2026claims 1-19 or the pharmaceutical composition of claim 22 to the human subject, thereby treating the solid cancer in the human subject,wherein the first domain binds to a human T cell receptor beta chain variable (TCRPV) region of a human TCR0 of a human TCRp subfamily member expressed by a subset of T cells of the human subject;wherein the first domain binds to human TCRPV5, human TCRPV6, human TCRPV12, or human TCRPV20;wherein the second domain comprises a cytokine that binds to a second target molecule expressed by T cells of the human subject;wherein:(i)(a) the cytokine is a human IL-2 having a sequence with at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 2191, 2270, and 2280, or(b) the cytokine is a human IL-2 having a sequence with at least 95% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 2191, 2270, and 2280;(ii)(a) the cytokine is a human IL-12 having a sequence with at least 90% sequence identity to SEQ ID NO: 2290, or(b) the cytokine is a human IL-12 having a sequence with at least 95% sequence identity to SEQ ID NO: 2290;(iii)(A)(a) the cytokine is a human IL-15 having a sequence with at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 2170 and 2320, or(b) the cytokine is a human IL-15 having a sequence with at least 95% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 2170 and 2320; or(B)(a) the cytokine is a human IL-15 having a sequence with at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 2170 and 2320, and the cytokine further comprises an IL15Ralpha dimerizing domain, or(b) the cytokine is a human IL-15 having a sequence with at least 95% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 2170 and 2320, and the cytokine further comprises an IL15Ralpha dimerizing domain; or2019297451   16 Sep 2026(iv)(a) the cytokine is a human IL-21 having a sequence with at least 90% sequence identity to SEQ ID NO: 2193, or(b) the cytokine is a human IL-21 having a sequence with at least 95% sequence identity to SEQ ID NO: 2193;wherein binding of the first domain to the TCRpV region and binding of the second domain to the second target molecule promote the subset of T cells to kill cancer cells.

26. The method of claim 25, wherein: (i) the first domain binds to human TCRPV6; or (ii) the human TCRP subfamily member comprises a human TCRpV region that is TRBV6-5.

27. A method of expanding and / or activating T cells in a T cell population comprising: contacting the T cell population with an effective amount of the composition of any one of claims 1-19, thereby expanding and / or activating the T cells in the T cell population, wherein the T cells express a T cell receptor (TCR) comprising the T cell receptor beta (TCRp);wherein the expansion is selective expansion of a subset of T cells that express a TCR comprising a TCRp that comprises a TCRpV region subfamily member to which the first domain binds in the T cell population; andwherein the T cell expansion and / or activation occurs in vivo or ex vivo.

28. Use of the composition of any one of claims 1-19 or the pharmaceutical composition of claim 22 in the manufacture of a medicament for treating cancer in a subject in need thereof, wherein the subject is human.

29. The method of claim 23 or 24 or the use of claim 28, wherein:(i) the cancer is a solid tumor, a hematological cancer, a metastatic cancer, a soft tissue tumor, or a combination thereof;(ii) the cancer is a solid tumor selected from the group consisting of melanoma, pancreatic cancer, breast cancer, colorectal cancer, lung cancer, skin cancer, ovarian cancer, and liver cancer; or(iii) the cancer is a hematological cancer comprising a B-cell malignancy or T cell malignancy.

30. Use of the composition of any one of claims 1-19 or the pharmaceutical composition of claim 22 in the manufacture of a medicament for treating a solid cancer in a human subject in need thereof,2019297451   16 Sep 2026wherein the first domain binds to a human T cell receptor beta chain variable (TCRpV) region of a human TCRp of a human TCRp subfamily member expressed by a subset of T cells of the human subject;wherein the first domain binds to human TCRPV5, human TCRpV6, human TCRPV12, or human TCRPV20;wherein the second domain comprises a cytokine that binds to a second target molecule expressed by T cells of the human subject;wherein:(i)(a)  the cytokine is a human IL-2 having a sequence with at least 90%sequence identity to a sequence selected from the group consisting ofSEQ ID NOs: 2191, 2270, and 2280, or(b) the cytokine is a human IL-2 having a sequence with at least 95%sequence identity to a sequence selected from the group consisting ofSEQ ID NOs: 2191, 2270, and 2280;(ii)(a) the cytokine is a human IL-12 having a sequence with at least 90% sequence identity to SEQ ID NO: 2290, or(b) the cytokine is a human IL-12 having a sequence with at least 95% sequence identity to SEQ ID NO: 2290;(iii)(A)(a) the cytokine is a human IL-15 having a sequence with at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 2170 and 2320, or(b) the cytokine is a human IL-15 having a sequence with at least 95% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 2170 and 2320; or(B)(a) the cytokine is a human IL-15 having a sequence with at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 2170 and 2320, and the cytokine further comprises an IL15Ralpha dimerizing domain, or(b) the cytokine is a human IL-15 having a sequence with at least 95% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 2170 and 2320, and the cytokine further comprises an IL15Ralpha dimerizing domain; or(iv)(a) the cytokine is a human IL-21 having a sequence with at least 90% sequence identity to SEQ ID NO: 2193, or2019297451   16 Sep 2026(b) the cytokine is a human IL-21 having a sequence with at least 95% sequence identity to SEQ ID NO: 2193;wherein binding of the first domain to the TCR^V region and binding of the second domain to the second target molecule promote the subset of T cells to kill cancer cells.

Images